id	sid	tid	token	lemma	pos
cord-002240-38aabxh1	1	1	key	key	NN
cord-002240-38aabxh1	1	2	:	:	:
cord-002240-38aabxh1	2	1	cord-002240	cord-002240	NNP
cord-002240-38aabxh1	2	2	-	-	HYPH
cord-002240-38aabxh1	2	3	38aabxh1	38aabxh1	JJ
cord-002240-38aabxh1	2	4	authors	author	NNS
cord-002240-38aabxh1	2	5	:	:	:
cord-002240-38aabxh1	2	6	Prina	Prina	NNP
cord-002240-38aabxh1	2	7	,	,	,
cord-002240-38aabxh1	2	8	Elena	Elena	NNP
cord-002240-38aabxh1	2	9	;	;	:
cord-002240-38aabxh1	2	10	Ceccato	Ceccato	NNP
cord-002240-38aabxh1	2	11	,	,	,
cord-002240-38aabxh1	2	12	Adrian	Adrian	NNP
cord-002240-38aabxh1	2	13	;	;	:
cord-002240-38aabxh1	2	14	Torres	Torres	NNP
cord-002240-38aabxh1	2	15	,	,	,
cord-002240-38aabxh1	2	16	Antoni	Antoni	NNP
cord-002240-38aabxh1	2	17	title	title	NN
cord-002240-38aabxh1	2	18	:	:	:
cord-002240-38aabxh1	2	19	New	new	JJ
cord-002240-38aabxh1	2	20	aspects	aspect	NNS
cord-002240-38aabxh1	2	21	in	in	IN
cord-002240-38aabxh1	2	22	the	the	DT
cord-002240-38aabxh1	2	23	management	management	NN
cord-002240-38aabxh1	2	24	of	of	IN
cord-002240-38aabxh1	2	25	pneumonia	pneumonia	NN
cord-002240-38aabxh1	2	26	date	date	NN
cord-002240-38aabxh1	2	27	:	:	:
cord-002240-38aabxh1	2	28	2016	2016	CD
cord-002240-38aabxh1	2	29	-	-	SYM
cord-002240-38aabxh1	2	30	10	10	CD
cord-002240-38aabxh1	2	31	-	-	HYPH
cord-002240-38aabxh1	2	32	01	01	CD
cord-002240-38aabxh1	2	33	journal	journal	NN
cord-002240-38aabxh1	2	34	:	:	:
cord-002240-38aabxh1	3	1	Crit	Crit	NNP
cord-002240-38aabxh1	3	2	Care	Care	NNP
cord-002240-38aabxh1	3	3	DOI	doi	NN
cord-002240-38aabxh1	3	4	:	:	:
cord-002240-38aabxh1	3	5	10.1186	10.1186	CD
cord-002240-38aabxh1	3	6	/	/	SYM
cord-002240-38aabxh1	3	7	s13054	s13054	NN
cord-002240-38aabxh1	3	8	-	-	HYPH
cord-002240-38aabxh1	3	9	016	016	CD
cord-002240-38aabxh1	3	10	-	-	HYPH
cord-002240-38aabxh1	3	11	1442-y	1442-y	CD
cord-002240-38aabxh1	4	1	sha	sha	NNP
cord-002240-38aabxh1	4	2	:	:	:
cord-002240-38aabxh1	4	3	f04ed0b001f814e08e669ede76e3a5879eb11630	f04ed0b001f814e08e669ede76e3a5879eb11630	NNP
cord-002240-38aabxh1	4	4	doc_id	doc_id	CD
cord-002240-38aabxh1	4	5	:	:	:
cord-002240-38aabxh1	4	6	2240	2240	CD
cord-002240-38aabxh1	4	7	cord_uid	cord_uid	NNS
cord-002240-38aabxh1	4	8	:	:	:
cord-002240-38aabxh1	5	1	38aabxh1	38aabxh1	NNP
cord-002240-38aabxh1	6	1	Despite	despite	IN
cord-002240-38aabxh1	6	2	improvements	improvement	NNS
cord-002240-38aabxh1	6	3	in	in	IN
cord-002240-38aabxh1	6	4	the	the	DT
cord-002240-38aabxh1	6	5	management	management	NN
cord-002240-38aabxh1	6	6	of	of	IN
cord-002240-38aabxh1	6	7	community	community	NN
cord-002240-38aabxh1	6	8	-	-	HYPH
cord-002240-38aabxh1	6	9	acquired	acquire	VBN
cord-002240-38aabxh1	6	10	pneumonia	pneumonia	NN
cord-002240-38aabxh1	6	11	(	(	-LRB-
cord-002240-38aabxh1	6	12	CAP	CAP	NNP
cord-002240-38aabxh1	6	13	)	)	-RRB-
cord-002240-38aabxh1	6	14	,	,	,
cord-002240-38aabxh1	6	15	morbidity	morbidity	NN
cord-002240-38aabxh1	6	16	and	and	CC
cord-002240-38aabxh1	6	17	mortality	mortality	NN
cord-002240-38aabxh1	6	18	are	be	VBP
cord-002240-38aabxh1	6	19	still	still	RB
cord-002240-38aabxh1	6	20	high	high	JJ
cord-002240-38aabxh1	6	21	,	,	,
cord-002240-38aabxh1	6	22	especially	especially	RB
cord-002240-38aabxh1	6	23	in	in	IN
cord-002240-38aabxh1	6	24	patients	patient	NNS
cord-002240-38aabxh1	6	25	with	with	IN
cord-002240-38aabxh1	6	26	more	more	RBR
cord-002240-38aabxh1	6	27	severe	severe	JJ
cord-002240-38aabxh1	6	28	disease	disease	NN
cord-002240-38aabxh1	6	29	.	.	.
cord-002240-38aabxh1	7	1	Early	early	JJ
cord-002240-38aabxh1	7	2	and	and	CC
cord-002240-38aabxh1	7	3	appropriate	appropriate	JJ
cord-002240-38aabxh1	7	4	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	7	5	remain	remain	VBP
cord-002240-38aabxh1	7	6	the	the	DT
cord-002240-38aabxh1	7	7	cornerstone	cornerstone	NN
cord-002240-38aabxh1	7	8	in	in	IN
cord-002240-38aabxh1	7	9	the	the	DT
cord-002240-38aabxh1	7	10	treatment	treatment	NN
cord-002240-38aabxh1	7	11	of	of	IN
cord-002240-38aabxh1	7	12	CAP	CAP	NNP
cord-002240-38aabxh1	7	13	.	.	.
cord-002240-38aabxh1	8	1	However	however	RB
cord-002240-38aabxh1	8	2	,	,	,
cord-002240-38aabxh1	8	3	two	two	CD
cord-002240-38aabxh1	8	4	aspects	aspect	NNS
cord-002240-38aabxh1	8	5	seem	seem	VBP
cord-002240-38aabxh1	8	6	to	to	TO
cord-002240-38aabxh1	8	7	contribute	contribute	VB
cord-002240-38aabxh1	8	8	to	to	IN
cord-002240-38aabxh1	8	9	a	a	DT
cord-002240-38aabxh1	8	10	worse	bad	JJR
cord-002240-38aabxh1	8	11	outcome	outcome	NN
cord-002240-38aabxh1	8	12	:	:	:
cord-002240-38aabxh1	8	13	an	an	DT
cord-002240-38aabxh1	8	14	uncontrolled	uncontrolled	JJ
cord-002240-38aabxh1	8	15	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	8	16	reaction	reaction	NN
cord-002240-38aabxh1	8	17	and	and	CC
cord-002240-38aabxh1	8	18	an	an	DT
cord-002240-38aabxh1	8	19	inadequate	inadequate	JJ
cord-002240-38aabxh1	8	20	immune	immune	JJ
cord-002240-38aabxh1	8	21	response	response	NN
cord-002240-38aabxh1	8	22	.	.	.
cord-002240-38aabxh1	9	1	Adjuvant	adjuvant	JJ
cord-002240-38aabxh1	9	2	treatments	treatment	NNS
cord-002240-38aabxh1	9	3	,	,	,
cord-002240-38aabxh1	9	4	such	such	JJ
cord-002240-38aabxh1	9	5	as	as	IN
cord-002240-38aabxh1	9	6	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	9	7	and	and	CC
cord-002240-38aabxh1	9	8	intravenous	intravenous	JJ
cord-002240-38aabxh1	9	9	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	9	10	,	,	,
cord-002240-38aabxh1	9	11	have	have	VBP
cord-002240-38aabxh1	9	12	been	be	VBN
cord-002240-38aabxh1	9	13	proposed	propose	VBN
cord-002240-38aabxh1	9	14	to	to	TO
cord-002240-38aabxh1	9	15	counterbalance	counterbalance	VB
cord-002240-38aabxh1	9	16	these	these	DT
cord-002240-38aabxh1	9	17	effects	effect	NNS
cord-002240-38aabxh1	9	18	.	.	.
cord-002240-38aabxh1	10	1	The	the	DT
cord-002240-38aabxh1	10	2	use	use	NN
cord-002240-38aabxh1	10	3	of	of	IN
cord-002240-38aabxh1	10	4	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	10	5	in	in	IN
cord-002240-38aabxh1	10	6	patients	patient	NNS
cord-002240-38aabxh1	10	7	with	with	IN
cord-002240-38aabxh1	10	8	severe	severe	JJ
cord-002240-38aabxh1	10	9	CAP	cap	NN
cord-002240-38aabxh1	10	10	and	and	CC
cord-002240-38aabxh1	10	11	a	a	DT
cord-002240-38aabxh1	10	12	strong	strong	JJ
cord-002240-38aabxh1	10	13	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	10	14	reaction	reaction	NN
cord-002240-38aabxh1	10	15	can	can	MD
cord-002240-38aabxh1	10	16	reduce	reduce	VB
cord-002240-38aabxh1	10	17	the	the	DT
cord-002240-38aabxh1	10	18	time	time	NN
cord-002240-38aabxh1	10	19	to	to	IN
cord-002240-38aabxh1	10	20	clinical	clinical	JJ
cord-002240-38aabxh1	10	21	stability	stability	NN
cord-002240-38aabxh1	10	22	,	,	,
cord-002240-38aabxh1	10	23	the	the	DT
cord-002240-38aabxh1	10	24	risk	risk	NN
cord-002240-38aabxh1	10	25	of	of	IN
cord-002240-38aabxh1	10	26	treatment	treatment	NN
cord-002240-38aabxh1	10	27	failure	failure	NN
cord-002240-38aabxh1	10	28	,	,	,
cord-002240-38aabxh1	10	29	and	and	CC
cord-002240-38aabxh1	10	30	the	the	DT
cord-002240-38aabxh1	10	31	risk	risk	NN
cord-002240-38aabxh1	10	32	of	of	IN
cord-002240-38aabxh1	10	33	progression	progression	NN
cord-002240-38aabxh1	10	34	to	to	IN
cord-002240-38aabxh1	10	35	acute	acute	JJ
cord-002240-38aabxh1	10	36	respiratory	respiratory	JJ
cord-002240-38aabxh1	10	37	distress	distress	NN
cord-002240-38aabxh1	10	38	syndrome	syndrome	NN
cord-002240-38aabxh1	10	39	.	.	.
cord-002240-38aabxh1	11	1	The	the	DT
cord-002240-38aabxh1	11	2	administration	administration	NN
cord-002240-38aabxh1	11	3	of	of	IN
cord-002240-38aabxh1	11	4	intravenous	intravenous	JJ
cord-002240-38aabxh1	11	5	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	11	6	seems	seem	VBZ
cord-002240-38aabxh1	11	7	to	to	TO
cord-002240-38aabxh1	11	8	reinforce	reinforce	VB
cord-002240-38aabxh1	11	9	the	the	DT
cord-002240-38aabxh1	11	10	immune	immune	JJ
cord-002240-38aabxh1	11	11	response	response	NN
cord-002240-38aabxh1	11	12	to	to	IN
cord-002240-38aabxh1	11	13	the	the	DT
cord-002240-38aabxh1	11	14	infection	infection	NN
cord-002240-38aabxh1	11	15	in	in	IN
cord-002240-38aabxh1	11	16	particular	particular	JJ
cord-002240-38aabxh1	11	17	in	in	IN
cord-002240-38aabxh1	11	18	patients	patient	NNS
cord-002240-38aabxh1	11	19	with	with	IN
cord-002240-38aabxh1	11	20	inadequate	inadequate	JJ
cord-002240-38aabxh1	11	21	levels	level	NNS
cord-002240-38aabxh1	11	22	of	of	IN
cord-002240-38aabxh1	11	23	antibodies	antibody	NNS
cord-002240-38aabxh1	11	24	and	and	CC
cord-002240-38aabxh1	11	25	when	when	WRB
cord-002240-38aabxh1	11	26	an	an	DT
cord-002240-38aabxh1	11	27	enriched	enriched	JJ
cord-002240-38aabxh1	11	28	IgM	igm	NN
cord-002240-38aabxh1	11	29	preparation	preparation	NN
cord-002240-38aabxh1	11	30	has	have	VBZ
cord-002240-38aabxh1	11	31	been	be	VBN
cord-002240-38aabxh1	11	32	used	use	VBN
cord-002240-38aabxh1	11	33	;	;	:
cord-002240-38aabxh1	11	34	however	however	RB
cord-002240-38aabxh1	11	35	,	,	,
cord-002240-38aabxh1	11	36	more	more	JJR
cord-002240-38aabxh1	11	37	studies	study	NNS
cord-002240-38aabxh1	11	38	are	be	VBP
cord-002240-38aabxh1	11	39	needed	need	VBN
cord-002240-38aabxh1	11	40	to	to	TO
cord-002240-38aabxh1	11	41	determinate	determinate	VB
cord-002240-38aabxh1	11	42	their	-PRON-	PRP$
cord-002240-38aabxh1	11	43	impact	impact	NN
cord-002240-38aabxh1	11	44	on	on	IN
cord-002240-38aabxh1	11	45	outcome	outcome	NN
cord-002240-38aabxh1	11	46	and	and	CC
cord-002240-38aabxh1	11	47	to	to	TO
cord-002240-38aabxh1	11	48	define	define	VB
cord-002240-38aabxh1	11	49	the	the	DT
cord-002240-38aabxh1	11	50	population	population	NN
cord-002240-38aabxh1	11	51	that	that	WDT
cord-002240-38aabxh1	11	52	will	will	MD
cord-002240-38aabxh1	11	53	receive	receive	VB
cord-002240-38aabxh1	11	54	more	more	JJR
cord-002240-38aabxh1	11	55	benefit	benefit	NN
cord-002240-38aabxh1	11	56	.	.	.
cord-002240-38aabxh1	12	1	Despite	despite	IN
cord-002240-38aabxh1	12	2	the	the	DT
cord-002240-38aabxh1	12	3	use	use	NN
cord-002240-38aabxh1	12	4	of	of	IN
cord-002240-38aabxh1	12	5	early	early	JJ
cord-002240-38aabxh1	12	6	and	and	CC
cord-002240-38aabxh1	12	7	appropriate	appropriate	JJ
cord-002240-38aabxh1	12	8	antibiotic	antibiotic	JJ
cord-002240-38aabxh1	12	9	treatment	treatment	NN
cord-002240-38aabxh1	12	10	,	,	,
cord-002240-38aabxh1	12	11	mortality	mortality	NN
cord-002240-38aabxh1	12	12	related	relate	VBN
cord-002240-38aabxh1	12	13	to	to	IN
cord-002240-38aabxh1	12	14	community	community	NN
cord-002240-38aabxh1	12	15	-	-	HYPH
cord-002240-38aabxh1	12	16	acquired	acquire	VBN
cord-002240-38aabxh1	12	17	pneumonia	pneumonia	NN
cord-002240-38aabxh1	12	18	(	(	-LRB-
cord-002240-38aabxh1	12	19	CAP	CAP	NNP
cord-002240-38aabxh1	12	20	)	)	-RRB-
cord-002240-38aabxh1	12	21	is	be	VBZ
cord-002240-38aabxh1	12	22	still	still	RB
cord-002240-38aabxh1	12	23	high	high	JJ
cord-002240-38aabxh1	12	24	[	[	-LRB-
cord-002240-38aabxh1	12	25	1	1	CD
cord-002240-38aabxh1	12	26	]	]	-RRB-
cord-002240-38aabxh1	12	27	,	,	,
cord-002240-38aabxh1	12	28	especially	especially	RB
cord-002240-38aabxh1	12	29	in	in	IN
cord-002240-38aabxh1	12	30	patients	patient	NNS
cord-002240-38aabxh1	12	31	with	with	IN
cord-002240-38aabxh1	12	32	severe	severe	JJ
cord-002240-38aabxh1	12	33	disease	disease	NN
cord-002240-38aabxh1	12	34	.	.	.
cord-002240-38aabxh1	13	1	Previous	previous	JJ
cord-002240-38aabxh1	13	2	studies	study	NNS
cord-002240-38aabxh1	13	3	have	have	VBP
cord-002240-38aabxh1	13	4	shown	show	VBN
cord-002240-38aabxh1	13	5	that	that	IN
cord-002240-38aabxh1	13	6	approximately	approximately	RB
cord-002240-38aabxh1	13	7	18	18	CD
cord-002240-38aabxh1	13	8	%	%	NN
cord-002240-38aabxh1	13	9	of	of	IN
cord-002240-38aabxh1	13	10	patients	patient	NNS
cord-002240-38aabxh1	13	11	hospitalized	hospitalize	VBN
cord-002240-38aabxh1	13	12	for	for	IN
cord-002240-38aabxh1	13	13	CAP	CAP	NNP
cord-002240-38aabxh1	13	14	matched	match	VBD
cord-002240-38aabxh1	13	15	the	the	DT
cord-002240-38aabxh1	13	16	criteria	criterion	NNS
cord-002240-38aabxh1	13	17	for	for	IN
cord-002240-38aabxh1	13	18	severe	severe	JJ
cord-002240-38aabxh1	13	19	CAP	cap	NN
cord-002240-38aabxh1	13	20	.	.	.
cord-002240-38aabxh1	14	1	These	these	DT
cord-002240-38aabxh1	14	2	patients	patient	NNS
cord-002240-38aabxh1	14	3	more	more	RBR
cord-002240-38aabxh1	14	4	frequently	frequently	RB
cord-002240-38aabxh1	14	5	present	present	JJ
cord-002240-38aabxh1	14	6	with	with	IN
cord-002240-38aabxh1	14	7	septic	septic	JJ
cord-002240-38aabxh1	14	8	shock	shock	NN
cord-002240-38aabxh1	14	9	and	and	CC
cord-002240-38aabxh1	14	10	need	need	NN
cord-002240-38aabxh1	14	11	for	for	IN
cord-002240-38aabxh1	14	12	*	*	NFP
cord-002240-38aabxh1	14	13	Correspondence	correspondence	NN
cord-002240-38aabxh1	14	14	:	:	:
cord-002240-38aabxh1	14	15	ATORRES@clinic.ub.es	atorres@clinic.ub.es	NN
cord-002240-38aabxh1	14	16	1	1	CD
cord-002240-38aabxh1	14	17	Servei	Servei	NNP
cord-002240-38aabxh1	14	18	de	de	NNP
cord-002240-38aabxh1	14	19	Pneumologia	Pneumologia	NNP
cord-002240-38aabxh1	14	20	,	,	,
cord-002240-38aabxh1	14	21	Institut	Institut	NNP
cord-002240-38aabxh1	14	22	del	del	NNP
cord-002240-38aabxh1	14	23	Torax	Torax	NNP
cord-002240-38aabxh1	14	24	,	,	,
cord-002240-38aabxh1	14	25	Hospital	Hospital	NNP
cord-002240-38aabxh1	14	26	Clinic	Clinic	NNP
cord-002240-38aabxh1	14	27	,	,	,
cord-002240-38aabxh1	14	28	IDIBAPS	IDIBAPS	NNP
cord-002240-38aabxh1	14	29	,	,	,
cord-002240-38aabxh1	14	30	Universitat	Universitat	NNP
cord-002240-38aabxh1	14	31	de	de	NNP
cord-002240-38aabxh1	14	32	Barcelona	Barcelona	NNP
cord-002240-38aabxh1	14	33	,	,	,
cord-002240-38aabxh1	14	34	Barcelona	Barcelona	NNP
cord-002240-38aabxh1	14	35	,	,	,
cord-002240-38aabxh1	14	36	Spain	Spain	NNP
cord-002240-38aabxh1	14	37	2	2	CD
cord-002240-38aabxh1	14	38	Centro	Centro	NNP
cord-002240-38aabxh1	14	39	de	de	NNP
cord-002240-38aabxh1	14	40	Investigación	Investigación	NNP
cord-002240-38aabxh1	14	41	Biomedica	Biomedica	NNP
cord-002240-38aabxh1	14	42	En	En	NNP
cord-002240-38aabxh1	14	43	Red	Red	NNP
cord-002240-38aabxh1	14	44	-	-	HYPH
cord-002240-38aabxh1	14	45	Enfermedades	Enfermedades	NNP
cord-002240-38aabxh1	14	46	Respiratorias	Respiratorias	NNP
cord-002240-38aabxh1	14	47	(	(	-LRB-
cord-002240-38aabxh1	14	48	CibeRes	CibeRes	NNP
cord-002240-38aabxh1	14	49	,	,	,
cord-002240-38aabxh1	14	50	CB06/06/0028	CB06/06/0028	NNP
cord-002240-38aabxh1	14	51	)	)	-RRB-
cord-002240-38aabxh1	14	52	,	,	,
cord-002240-38aabxh1	14	53	Barcelona	Barcelona	NNP
cord-002240-38aabxh1	14	54	,	,	,
cord-002240-38aabxh1	14	55	Spain	Spain	NNP
cord-002240-38aabxh1	14	56	Full	full	JJ
cord-002240-38aabxh1	14	57	list	list	NN
cord-002240-38aabxh1	14	58	of	of	IN
cord-002240-38aabxh1	14	59	author	author	NN
cord-002240-38aabxh1	14	60	information	information	NN
cord-002240-38aabxh1	14	61	is	be	VBZ
cord-002240-38aabxh1	14	62	available	available	JJ
cord-002240-38aabxh1	14	63	at	at	IN
cord-002240-38aabxh1	14	64	the	the	DT
cord-002240-38aabxh1	14	65	end	end	NN
cord-002240-38aabxh1	14	66	of	of	IN
cord-002240-38aabxh1	14	67	the	the	DT
cord-002240-38aabxh1	14	68	article	article	NN
cord-002240-38aabxh1	14	69	mechanical	mechanical	JJ
cord-002240-38aabxh1	14	70	ventilation	ventilation	NN
cord-002240-38aabxh1	14	71	,	,	,
cord-002240-38aabxh1	14	72	with	with	IN
cord-002240-38aabxh1	14	73	a	a	DT
cord-002240-38aabxh1	14	74	mortality	mortality	NN
cord-002240-38aabxh1	14	75	of	of	IN
cord-002240-38aabxh1	14	76	approximately	approximately	RB
cord-002240-38aabxh1	14	77	29	29	CD
cord-002240-38aabxh1	14	78	%	%	NN
cord-002240-38aabxh1	14	79	[	[	-LRB-
cord-002240-38aabxh1	14	80	2	2	CD
cord-002240-38aabxh1	14	81	]	]	-RRB-
cord-002240-38aabxh1	14	82	.	.	.
cord-002240-38aabxh1	15	1	In	in	IN
cord-002240-38aabxh1	15	2	addition	addition	NN
cord-002240-38aabxh1	15	3	to	to	IN
cord-002240-38aabxh1	15	4	the	the	DT
cord-002240-38aabxh1	15	5	infection	infection	NN
cord-002240-38aabxh1	15	6	,	,	,
cord-002240-38aabxh1	15	7	septic	septic	JJ
cord-002240-38aabxh1	15	8	shock	shock	NN
cord-002240-38aabxh1	15	9	is	be	VBZ
cord-002240-38aabxh1	15	10	generally	generally	RB
cord-002240-38aabxh1	15	11	thought	think	VBN
cord-002240-38aabxh1	15	12	to	to	TO
cord-002240-38aabxh1	15	13	be	be	VB
cord-002240-38aabxh1	15	14	caused	cause	VBN
cord-002240-38aabxh1	15	15	by	by	IN
cord-002240-38aabxh1	15	16	an	an	DT
cord-002240-38aabxh1	15	17	excessive	excessive	JJ
cord-002240-38aabxh1	15	18	or	or	CC
cord-002240-38aabxh1	15	19	uncontrolled	uncontrolled	JJ
cord-002240-38aabxh1	15	20	pro	pro	JJ
cord-002240-38aabxh1	15	21	-	-	JJ
cord-002240-38aabxh1	15	22	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	15	23	response	response	NN
cord-002240-38aabxh1	15	24	[	[	-LRB-
cord-002240-38aabxh1	15	25	3	3	CD
cord-002240-38aabxh1	15	26	]	]	-RRB-
cord-002240-38aabxh1	15	27	.	.	.
cord-002240-38aabxh1	16	1	Pneumonia	pneumonia	NN
cord-002240-38aabxh1	16	2	is	be	VBZ
cord-002240-38aabxh1	16	3	a	a	DT
cord-002240-38aabxh1	16	4	complex	complex	JJ
cord-002240-38aabxh1	16	5	disease	disease	NN
cord-002240-38aabxh1	16	6	caused	cause	VBN
cord-002240-38aabxh1	16	7	by	by	IN
cord-002240-38aabxh1	16	8	the	the	DT
cord-002240-38aabxh1	16	9	action	action	NN
cord-002240-38aabxh1	16	10	of	of	IN
cord-002240-38aabxh1	16	11	pathogens	pathogen	NNS
cord-002240-38aabxh1	16	12	and	and	CC
cord-002240-38aabxh1	16	13	the	the	DT
cord-002240-38aabxh1	16	14	local	local	JJ
cord-002240-38aabxh1	16	15	and	and	CC
cord-002240-38aabxh1	16	16	systemic	systemic	JJ
cord-002240-38aabxh1	16	17	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	16	18	responses	response	NNS
cord-002240-38aabxh1	16	19	of	of	IN
cord-002240-38aabxh1	16	20	the	the	DT
cord-002240-38aabxh1	16	21	patient	patient	NN
cord-002240-38aabxh1	16	22	.	.	.
cord-002240-38aabxh1	17	1	A	a	DT
cord-002240-38aabxh1	17	2	stronger	strong	JJR
cord-002240-38aabxh1	17	3	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	17	4	response	response	NN
cord-002240-38aabxh1	17	5	has	have	VBZ
cord-002240-38aabxh1	17	6	been	be	VBN
cord-002240-38aabxh1	17	7	shown	show	VBN
cord-002240-38aabxh1	17	8	to	to	TO
cord-002240-38aabxh1	17	9	be	be	VB
cord-002240-38aabxh1	17	10	associated	associate	VBN
cord-002240-38aabxh1	17	11	with	with	IN
cord-002240-38aabxh1	17	12	treatment	treatment	NN
cord-002240-38aabxh1	17	13	failure	failure	NN
cord-002240-38aabxh1	17	14	and	and	CC
cord-002240-38aabxh1	17	15	mortality	mortality	NN
cord-002240-38aabxh1	17	16	[	[	-LRB-
cord-002240-38aabxh1	17	17	4	4	CD
cord-002240-38aabxh1	17	18	]	]	-RRB-
cord-002240-38aabxh1	17	19	.	.	.
cord-002240-38aabxh1	18	1	In	in	IN
cord-002240-38aabxh1	18	2	particular	particular	JJ
cord-002240-38aabxh1	18	3	,	,	,
cord-002240-38aabxh1	18	4	high	high	JJ
cord-002240-38aabxh1	18	5	levels	level	NNS
cord-002240-38aabxh1	18	6	of	of	IN
cord-002240-38aabxh1	18	7	interleukin	interleukin	NN
cord-002240-38aabxh1	18	8	(	(	-LRB-
cord-002240-38aabxh1	18	9	IL)-6	IL)-6	NNP
cord-002240-38aabxh1	18	10	,	,	,
cord-002240-38aabxh1	18	11	IL-8	IL-8	NNP
cord-002240-38aabxh1	18	12	,	,	,
cord-002240-38aabxh1	18	13	and	and	CC
cord-002240-38aabxh1	18	14	IL-10	IL-10	NNP
cord-002240-38aabxh1	18	15	have	have	VBP
cord-002240-38aabxh1	18	16	been	be	VBN
cord-002240-38aabxh1	18	17	detected	detect	VBN
cord-002240-38aabxh1	18	18	in	in	IN
cord-002240-38aabxh1	18	19	patients	patient	NNS
cord-002240-38aabxh1	18	20	with	with	IN
cord-002240-38aabxh1	18	21	severe	severe	JJ
cord-002240-38aabxh1	18	22	pneumonia	pneumonia	NN
cord-002240-38aabxh1	18	23	and	and	CC
cord-002240-38aabxh1	18	24	excess	excess	JJ
cord-002240-38aabxh1	18	25	IL-6	IL-6	NNP
cord-002240-38aabxh1	18	26	and	and	CC
cord-002240-38aabxh1	18	27	IL-10	IL-10	NNP
cord-002240-38aabxh1	18	28	was	be	VBD
cord-002240-38aabxh1	18	29	associated	associate	VBN
cord-002240-38aabxh1	18	30	with	with	IN
cord-002240-38aabxh1	18	31	increased	increase	VBN
cord-002240-38aabxh1	18	32	mortality	mortality	NN
cord-002240-38aabxh1	18	33	(	(	-LRB-
cord-002240-38aabxh1	18	34	from	from	IN
cord-002240-38aabxh1	18	35	4.8	4.8	CD
cord-002240-38aabxh1	18	36	to	to	IN
cord-002240-38aabxh1	18	37	11.4	11.4	CD
cord-002240-38aabxh1	18	38	%	%	NN
cord-002240-38aabxh1	18	39	)	)	-RRB-
cord-002240-38aabxh1	18	40	[	[	-LRB-
cord-002240-38aabxh1	18	41	5	5	CD
cord-002240-38aabxh1	18	42	,	,	,
cord-002240-38aabxh1	18	43	6	6	CD
cord-002240-38aabxh1	18	44	]	]	-RRB-
cord-002240-38aabxh1	18	45	.	.	.
cord-002240-38aabxh1	19	1	Moreover	moreover	RB
cord-002240-38aabxh1	19	2	,	,	,
cord-002240-38aabxh1	19	3	in	in	IN
cord-002240-38aabxh1	19	4	some	some	DT
cord-002240-38aabxh1	19	5	patients	patient	NNS
cord-002240-38aabxh1	19	6	with	with	IN
cord-002240-38aabxh1	19	7	CAP	cap	NN
cord-002240-38aabxh1	19	8	,	,	,
cord-002240-38aabxh1	19	9	excessive	excessive	JJ
cord-002240-38aabxh1	19	10	levels	level	NNS
cord-002240-38aabxh1	19	11	of	of	IN
cord-002240-38aabxh1	19	12	cytokines	cytokine	NNS
cord-002240-38aabxh1	19	13	can	can	MD
cord-002240-38aabxh1	19	14	be	be	VB
cord-002240-38aabxh1	19	15	released	release	VBN
cord-002240-38aabxh1	19	16	(	(	-LRB-
cord-002240-38aabxh1	19	17	called	call	VBN
cord-002240-38aabxh1	19	18	the	the	DT
cord-002240-38aabxh1	19	19	Jarisch	Jarisch	NNP
cord-002240-38aabxh1	19	20	-	-	HYPH
cord-002240-38aabxh1	19	21	Herxheimerlike	Herxheimerlike	NNP
cord-002240-38aabxh1	19	22	reaction	reaction	NN
cord-002240-38aabxh1	19	23	)	)	-RRB-
cord-002240-38aabxh1	19	24	after	after	IN
cord-002240-38aabxh1	19	25	the	the	DT
cord-002240-38aabxh1	19	26	initiation	initiation	NN
cord-002240-38aabxh1	19	27	of	of	IN
cord-002240-38aabxh1	19	28	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	19	29	,	,	,
cord-002240-38aabxh1	19	30	causing	cause	VBG
cord-002240-38aabxh1	19	31	damage	damage	NN
cord-002240-38aabxh1	19	32	similar	similar	JJ
cord-002240-38aabxh1	19	33	to	to	IN
cord-002240-38aabxh1	19	34	other	other	JJ
cord-002240-38aabxh1	19	35	infections	infection	NNS
cord-002240-38aabxh1	19	36	characterized	characterize	VBN
cord-002240-38aabxh1	19	37	by	by	IN
cord-002240-38aabxh1	19	38	high	high	JJ
cord-002240-38aabxh1	19	39	bacterial	bacterial	JJ
cord-002240-38aabxh1	19	40	load	load	NN
cord-002240-38aabxh1	19	41	(	(	-LRB-
cord-002240-38aabxh1	19	42	e.g.	e.g.	RB
cord-002240-38aabxh1	19	43	,	,	,
cord-002240-38aabxh1	19	44	meningococcal	meningococcal	JJ
cord-002240-38aabxh1	19	45	meningitis	meningitis	NN
cord-002240-38aabxh1	19	46	)	)	-RRB-
cord-002240-38aabxh1	19	47	[	[	-LRB-
cord-002240-38aabxh1	19	48	7	7	CD
cord-002240-38aabxh1	19	49	,	,	,
cord-002240-38aabxh1	19	50	8	8	CD
cord-002240-38aabxh1	19	51	]	]	-RRB-
cord-002240-38aabxh1	19	52	.	.	.
cord-002240-38aabxh1	20	1	Another	another	DT
cord-002240-38aabxh1	20	2	aspect	aspect	NN
cord-002240-38aabxh1	20	3	regarding	regard	VBG
cord-002240-38aabxh1	20	4	the	the	DT
cord-002240-38aabxh1	20	5	immune	immune	JJ
cord-002240-38aabxh1	20	6	response	response	NN
cord-002240-38aabxh1	20	7	to	to	IN
cord-002240-38aabxh1	20	8	the	the	DT
cord-002240-38aabxh1	20	9	infection	infection	NN
cord-002240-38aabxh1	20	10	is	be	VBZ
cord-002240-38aabxh1	20	11	that	that	IN
cord-002240-38aabxh1	20	12	low	low	JJ
cord-002240-38aabxh1	20	13	levels	level	NNS
cord-002240-38aabxh1	20	14	of	of	IN
cord-002240-38aabxh1	20	15	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	20	16	are	be	VBP
cord-002240-38aabxh1	20	17	found	find	VBN
cord-002240-38aabxh1	20	18	,	,	,
cord-002240-38aabxh1	20	19	particularly	particularly	RB
cord-002240-38aabxh1	20	20	in	in	IN
cord-002240-38aabxh1	20	21	patients	patient	NNS
cord-002240-38aabxh1	20	22	with	with	IN
cord-002240-38aabxh1	20	23	recurrent	recurrent	JJ
cord-002240-38aabxh1	20	24	episodes	episode	NNS
cord-002240-38aabxh1	20	25	of	of	IN
cord-002240-38aabxh1	20	26	pneumonia	pneumonia	NN
cord-002240-38aabxh1	20	27	,	,	,
cord-002240-38aabxh1	20	28	and	and	CC
cord-002240-38aabxh1	20	29	may	may	MD
cord-002240-38aabxh1	20	30	be	be	VB
cord-002240-38aabxh1	20	31	responsible	responsible	JJ
cord-002240-38aabxh1	20	32	for	for	IN
cord-002240-38aabxh1	20	33	the	the	DT
cord-002240-38aabxh1	20	34	predisposition	predisposition	NN
cord-002240-38aabxh1	20	35	to	to	IN
cord-002240-38aabxh1	20	36	recurrent	recurrent	JJ
cord-002240-38aabxh1	20	37	infections	infection	NNS
cord-002240-38aabxh1	20	38	and	and	CC
cord-002240-38aabxh1	20	39	worse	bad	JJR
cord-002240-38aabxh1	20	40	outcome	outcome	NN
cord-002240-38aabxh1	20	41	[	[	-LRB-
cord-002240-38aabxh1	20	42	9	9	CD
cord-002240-38aabxh1	20	43	]	]	-RRB-
cord-002240-38aabxh1	20	44	.	.	.
cord-002240-38aabxh1	21	1	Considering	consider	VBG
cord-002240-38aabxh1	21	2	that	that	IN
cord-002240-38aabxh1	21	3	pathogens	pathogen	NNS
cord-002240-38aabxh1	21	4	resistant	resistant	JJ
cord-002240-38aabxh1	21	5	to	to	IN
cord-002240-38aabxh1	21	6	the	the	DT
cord-002240-38aabxh1	21	7	empiric	empiric	JJ
cord-002240-38aabxh1	21	8	antibiotic	antibiotic	JJ
cord-002240-38aabxh1	21	9	treatment	treatment	NN
cord-002240-38aabxh1	21	10	are	be	VBP
cord-002240-38aabxh1	21	11	not	not	RB
cord-002240-38aabxh1	21	12	a	a	DT
cord-002240-38aabxh1	21	13	common	common	JJ
cord-002240-38aabxh1	21	14	cause	cause	NN
cord-002240-38aabxh1	21	15	of	of	IN
cord-002240-38aabxh1	21	16	CAP	cap	NN
cord-002240-38aabxh1	21	17	,	,	,
cord-002240-38aabxh1	21	18	two	two	CD
cord-002240-38aabxh1	21	19	aspects	aspect	NNS
cord-002240-38aabxh1	21	20	seem	seem	VBP
cord-002240-38aabxh1	21	21	to	to	TO
cord-002240-38aabxh1	21	22	contribute	contribute	VB
cord-002240-38aabxh1	21	23	to	to	IN
cord-002240-38aabxh1	21	24	a	a	DT
cord-002240-38aabxh1	21	25	worse	bad	JJR
cord-002240-38aabxh1	21	26	outcome	outcome	NN
cord-002240-38aabxh1	21	27	:	:	:
cord-002240-38aabxh1	21	28	an	an	DT
cord-002240-38aabxh1	21	29	uncontrolled	uncontrolled	JJ
cord-002240-38aabxh1	21	30	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	21	31	reaction	reaction	NN
cord-002240-38aabxh1	21	32	and	and	CC
cord-002240-38aabxh1	21	33	an	an	DT
cord-002240-38aabxh1	21	34	inadequate	inadequate	JJ
cord-002240-38aabxh1	21	35	immune	immune	JJ
cord-002240-38aabxh1	21	36	response	response	NN
cord-002240-38aabxh1	21	37	.	.	.
cord-002240-38aabxh1	22	1	Adjuvant	adjuvant	JJ
cord-002240-38aabxh1	22	2	treatments	treatment	NNS
cord-002240-38aabxh1	22	3	,	,	,
cord-002240-38aabxh1	22	4	such	such	JJ
cord-002240-38aabxh1	22	5	as	as	IN
cord-002240-38aabxh1	22	6	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	22	7	and	and	CC
cord-002240-38aabxh1	22	8	intravenous	intravenous	JJ
cord-002240-38aabxh1	22	9	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	22	10	,	,	,
cord-002240-38aabxh1	22	11	have	have	VBP
cord-002240-38aabxh1	22	12	been	be	VBN
cord-002240-38aabxh1	22	13	proposed	propose	VBN
cord-002240-38aabxh1	22	14	to	to	TO
cord-002240-38aabxh1	22	15	counterbalance	counterbalance	VB
cord-002240-38aabxh1	22	16	these	these	DT
cord-002240-38aabxh1	22	17	effects	effect	NNS
cord-002240-38aabxh1	22	18	.	.	.
cord-002240-38aabxh1	23	1	Glucocorticosteroid	Glucocorticosteroid	NNP
cord-002240-38aabxh1	23	2	drugs	drug	NNS
cord-002240-38aabxh1	23	3	reproduce	reproduce	VBP
cord-002240-38aabxh1	23	4	effects	effect	NNS
cord-002240-38aabxh1	23	5	similar	similar	JJ
cord-002240-38aabxh1	23	6	to	to	IN
cord-002240-38aabxh1	23	7	endogenous	endogenous	JJ
cord-002240-38aabxh1	23	8	cortisol	cortisol	NN
cord-002240-38aabxh1	23	9	:	:	:
cord-002240-38aabxh1	23	10	they	-PRON-	PRP
cord-002240-38aabxh1	23	11	have	have	VBP
cord-002240-38aabxh1	23	12	anti	anti	JJ
cord-002240-38aabxh1	23	13	-	-	JJ
cord-002240-38aabxh1	23	14	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	23	15	activity	activity	NN
cord-002240-38aabxh1	23	16	by	by	IN
cord-002240-38aabxh1	23	17	switching	switch	VBG
cord-002240-38aabxh1	23	18	genes	gene	NNS
cord-002240-38aabxh1	23	19	on	on	IN
cord-002240-38aabxh1	23	20	and	and	CC
cord-002240-38aabxh1	23	21	off	off	RB
cord-002240-38aabxh1	23	22	,	,	,
cord-002240-38aabxh1	23	23	resulting	result	VBG
cord-002240-38aabxh1	23	24	in	in	IN
cord-002240-38aabxh1	23	25	a	a	DT
cord-002240-38aabxh1	23	26	reduction	reduction	NN
cord-002240-38aabxh1	23	27	of	of	IN
cord-002240-38aabxh1	23	28	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	23	29	cytokines	cytokine	NNS
cord-002240-38aabxh1	23	30	and	and	CC
cord-002240-38aabxh1	23	31	chemokines	chemokine	NNS
cord-002240-38aabxh1	23	32	.	.	.
cord-002240-38aabxh1	24	1	Corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	24	2	have	have	VBP
cord-002240-38aabxh1	24	3	an	an	DT
cord-002240-38aabxh1	24	4	effect	effect	NN
cord-002240-38aabxh1	24	5	on	on	IN
cord-002240-38aabxh1	24	6	structural	structural	JJ
cord-002240-38aabxh1	24	7	cells	cell	NNS
cord-002240-38aabxh1	24	8	of	of	IN
cord-002240-38aabxh1	24	9	the	the	DT
cord-002240-38aabxh1	24	10	respiratory	respiratory	JJ
cord-002240-38aabxh1	24	11	tract	tract	NN
cord-002240-38aabxh1	24	12	:	:	:
cord-002240-38aabxh1	24	13	they	-PRON-	PRP
cord-002240-38aabxh1	24	14	act	act	VBP
cord-002240-38aabxh1	24	15	on	on	IN
cord-002240-38aabxh1	24	16	epithelial	epithelial	JJ
cord-002240-38aabxh1	24	17	cells	cell	NNS
cord-002240-38aabxh1	24	18	by	by	IN
cord-002240-38aabxh1	24	19	inhibiting	inhibit	VBG
cord-002240-38aabxh1	24	20	transcription	transcription	NN
cord-002240-38aabxh1	24	21	factors	factor	NNS
cord-002240-38aabxh1	24	22	such	such	JJ
cord-002240-38aabxh1	24	23	as	as	IN
cord-002240-38aabxh1	24	24	NF	NF	NNP
cord-002240-38aabxh1	24	25	-	-	HYPH
cord-002240-38aabxh1	24	26	kB	kB	NNP
cord-002240-38aabxh1	24	27	,	,	,
cord-002240-38aabxh1	24	28	on	on	IN
cord-002240-38aabxh1	24	29	mucous	mucous	JJ
cord-002240-38aabxh1	24	30	glands	gland	NNS
cord-002240-38aabxh1	24	31	by	by	IN
cord-002240-38aabxh1	24	32	decreasing	decrease	VBG
cord-002240-38aabxh1	24	33	mucus	mucus	NN
cord-002240-38aabxh1	24	34	secretion	secretion	NN
cord-002240-38aabxh1	24	35	,	,	,
cord-002240-38aabxh1	24	36	and	and	CC
cord-002240-38aabxh1	24	37	on	on	IN
cord-002240-38aabxh1	24	38	smooth	smooth	JJ
cord-002240-38aabxh1	24	39	muscle	muscle	NN
cord-002240-38aabxh1	24	40	cells	cell	NNS
cord-002240-38aabxh1	24	41	by	by	IN
cord-002240-38aabxh1	24	42	increasing	increase	VBG
cord-002240-38aabxh1	24	43	β2	β2	NN
cord-002240-38aabxh1	24	44	receptors	receptor	NNS
cord-002240-38aabxh1	24	45	[	[	-LRB-
cord-002240-38aabxh1	24	46	11	11	CD
cord-002240-38aabxh1	24	47	]	]	-RRB-
cord-002240-38aabxh1	24	48	.	.	.
cord-002240-38aabxh1	25	1	Another	another	DT
cord-002240-38aabxh1	25	2	aspect	aspect	NN
cord-002240-38aabxh1	25	3	that	that	WDT
cord-002240-38aabxh1	25	4	may	may	MD
cord-002240-38aabxh1	25	5	contribute	contribute	VB
cord-002240-38aabxh1	25	6	to	to	IN
cord-002240-38aabxh1	25	7	the	the	DT
cord-002240-38aabxh1	25	8	beneficial	beneficial	JJ
cord-002240-38aabxh1	25	9	effect	effect	NN
cord-002240-38aabxh1	25	10	of	of	IN
cord-002240-38aabxh1	25	11	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	25	12	treatment	treatment	NN
cord-002240-38aabxh1	25	13	is	be	VBZ
cord-002240-38aabxh1	25	14	related	relate	VBN
cord-002240-38aabxh1	25	15	to	to	IN
cord-002240-38aabxh1	25	16	the	the	DT
cord-002240-38aabxh1	25	17	presence	presence	NN
cord-002240-38aabxh1	25	18	of	of	IN
cord-002240-38aabxh1	25	19	adrenal	adrenal	JJ
cord-002240-38aabxh1	25	20	insufficiency	insufficiency	NN
cord-002240-38aabxh1	25	21	or	or	CC
cord-002240-38aabxh1	25	22	inadequate	inadequate	JJ
cord-002240-38aabxh1	25	23	adrenal	adrenal	JJ
cord-002240-38aabxh1	25	24	function	function	NN
cord-002240-38aabxh1	25	25	in	in	IN
cord-002240-38aabxh1	25	26	some	some	DT
cord-002240-38aabxh1	25	27	cases	case	NNS
cord-002240-38aabxh1	25	28	of	of	IN
cord-002240-38aabxh1	25	29	severe	severe	JJ
cord-002240-38aabxh1	25	30	CAP	cap	NN
cord-002240-38aabxh1	25	31	[	[	-LRB-
cord-002240-38aabxh1	25	32	12	12	CD
cord-002240-38aabxh1	25	33	]	]	-RRB-
cord-002240-38aabxh1	25	34	.	.	.
cord-002240-38aabxh1	26	1	In	in	IN
cord-002240-38aabxh1	26	2	an	an	DT
cord-002240-38aabxh1	26	3	animal	animal	NN
cord-002240-38aabxh1	26	4	model	model	NN
cord-002240-38aabxh1	26	5	of	of	IN
cord-002240-38aabxh1	26	6	mechanically	mechanically	RB
cord-002240-38aabxh1	26	7	ventilated	ventilate	VBN
cord-002240-38aabxh1	26	8	piglets	piglet	NNS
cord-002240-38aabxh1	26	9	with	with	IN
cord-002240-38aabxh1	26	10	pneumonia	pneumonia	NN
cord-002240-38aabxh1	26	11	due	due	IN
cord-002240-38aabxh1	26	12	to	to	IN
cord-002240-38aabxh1	26	13	Pseudomonas	Pseudomonas	NNP
cord-002240-38aabxh1	26	14	aeruginosa	aeruginosa	NN
cord-002240-38aabxh1	26	15	,	,	,
cord-002240-38aabxh1	26	16	we	-PRON-	PRP
cord-002240-38aabxh1	26	17	demonstrated	demonstrate	VBD
cord-002240-38aabxh1	26	18	the	the	DT
cord-002240-38aabxh1	26	19	presence	presence	NN
cord-002240-38aabxh1	26	20	of	of	IN
cord-002240-38aabxh1	26	21	lower	low	JJR
cord-002240-38aabxh1	26	22	bacterial	bacterial	JJ
cord-002240-38aabxh1	26	23	burden	burden	NN
cord-002240-38aabxh1	26	24	in	in	IN
cord-002240-38aabxh1	26	25	the	the	DT
cord-002240-38aabxh1	26	26	lungs	lung	NNS
cord-002240-38aabxh1	26	27	and	and	CC
cord-002240-38aabxh1	26	28	less	less	RBR
cord-002240-38aabxh1	26	29	severe	severe	JJ
cord-002240-38aabxh1	26	30	histological	histological	JJ
cord-002240-38aabxh1	26	31	pneumonia	pneumonia	NN
cord-002240-38aabxh1	26	32	in	in	IN
cord-002240-38aabxh1	26	33	the	the	DT
cord-002240-38aabxh1	26	34	group	group	NN
cord-002240-38aabxh1	26	35	treated	treat	VBN
cord-002240-38aabxh1	26	36	with	with	IN
cord-002240-38aabxh1	26	37	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	26	38	plus	plus	CC
cord-002240-38aabxh1	26	39	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	26	40	in	in	IN
cord-002240-38aabxh1	26	41	comparison	comparison	NN
cord-002240-38aabxh1	26	42	with	with	IN
cord-002240-38aabxh1	26	43	the	the	DT
cord-002240-38aabxh1	26	44	group	group	NN
cord-002240-38aabxh1	26	45	treated	treat	VBN
cord-002240-38aabxh1	26	46	with	with	IN
cord-002240-38aabxh1	26	47	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	26	48	plus	plus	CC
cord-002240-38aabxh1	26	49	placebo	placebo	NN
cord-002240-38aabxh1	26	50	,	,	,
cord-002240-38aabxh1	26	51	suggesting	suggest	VBG
cord-002240-38aabxh1	26	52	a	a	DT
cord-002240-38aabxh1	26	53	potential	potential	JJ
cord-002240-38aabxh1	26	54	beneficial	beneficial	JJ
cord-002240-38aabxh1	26	55	effect	effect	NN
cord-002240-38aabxh1	26	56	of	of	IN
cord-002240-38aabxh1	26	57	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	26	58	on	on	IN
cord-002240-38aabxh1	26	59	bacterial	bacterial	JJ
cord-002240-38aabxh1	26	60	burden	burden	NN
cord-002240-38aabxh1	26	61	and	and	CC
cord-002240-38aabxh1	26	62	lung	lung	NN
cord-002240-38aabxh1	26	63	tissue	tissue	NN
cord-002240-38aabxh1	26	64	severity	severity	NN
cord-002240-38aabxh1	26	65	,	,	,
cord-002240-38aabxh1	26	66	in	in	IN
cord-002240-38aabxh1	26	67	addition	addition	NN
cord-002240-38aabxh1	26	68	to	to	IN
cord-002240-38aabxh1	26	69	the	the	DT
cord-002240-38aabxh1	26	70	systemic	systemic	JJ
cord-002240-38aabxh1	26	71	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	26	72	response	response	NN
cord-002240-38aabxh1	26	73	[	[	-LRB-
cord-002240-38aabxh1	26	74	13	13	CD
cord-002240-38aabxh1	26	75	]	]	-RRB-
cord-002240-38aabxh1	26	76	.	.	.
cord-002240-38aabxh1	27	1	In	in	IN
cord-002240-38aabxh1	27	2	acute	acute	JJ
cord-002240-38aabxh1	27	3	respiratory	respiratory	JJ
cord-002240-38aabxh1	27	4	distress	distress	NN
cord-002240-38aabxh1	27	5	syndrome	syndrome	NN
cord-002240-38aabxh1	27	6	(	(	-LRB-
cord-002240-38aabxh1	27	7	ARDS	ARDS	NNP
cord-002240-38aabxh1	27	8	)	)	-RRB-
cord-002240-38aabxh1	27	9	,	,	,
cord-002240-38aabxh1	27	10	the	the	DT
cord-002240-38aabxh1	27	11	presence	presence	NN
cord-002240-38aabxh1	27	12	of	of	IN
cord-002240-38aabxh1	27	13	high	high	JJ
cord-002240-38aabxh1	27	14	levels	level	NNS
cord-002240-38aabxh1	27	15	of	of	IN
cord-002240-38aabxh1	27	16	cytokines	cytokine	NNS
cord-002240-38aabxh1	27	17	is	be	VBZ
cord-002240-38aabxh1	27	18	associated	associate	VBN
cord-002240-38aabxh1	27	19	with	with	IN
cord-002240-38aabxh1	27	20	a	a	DT
cord-002240-38aabxh1	27	21	higher	high	JJR
cord-002240-38aabxh1	27	22	risk	risk	NN
cord-002240-38aabxh1	27	23	of	of	IN
cord-002240-38aabxh1	27	24	nosocomial	nosocomial	JJ
cord-002240-38aabxh1	27	25	infection	infection	NN
cord-002240-38aabxh1	27	26	because	because	IN
cord-002240-38aabxh1	27	27	the	the	DT
cord-002240-38aabxh1	27	28	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	27	29	biomarkers	biomarker	NNS
cord-002240-38aabxh1	27	30	appear	appear	VBP
cord-002240-38aabxh1	27	31	to	to	TO
cord-002240-38aabxh1	27	32	favor	favor	VB
cord-002240-38aabxh1	27	33	bacterial	bacterial	JJ
cord-002240-38aabxh1	27	34	growth	growth	NN
cord-002240-38aabxh1	27	35	.	.	.
cord-002240-38aabxh1	28	1	Meduri	Meduri	NNP
cord-002240-38aabxh1	28	2	et	et	NNP
cord-002240-38aabxh1	28	3	al	al	NNP
cord-002240-38aabxh1	28	4	.	.	.
cord-002240-38aabxh1	29	1	[	[	-LRB-
cord-002240-38aabxh1	29	2	14	14	CD
cord-002240-38aabxh1	29	3	]	]	-RRB-
cord-002240-38aabxh1	29	4	,	,	,
cord-002240-38aabxh1	29	5	in	in	IN
cord-002240-38aabxh1	29	6	an	an	DT
cord-002240-38aabxh1	29	7	in	in	FW
cord-002240-38aabxh1	29	8	vitro	vitro	FW
cord-002240-38aabxh1	29	9	study	study	NN
cord-002240-38aabxh1	29	10	,	,	,
cord-002240-38aabxh1	29	11	showed	show	VBD
cord-002240-38aabxh1	29	12	that	that	IN
cord-002240-38aabxh1	29	13	the	the	DT
cord-002240-38aabxh1	29	14	addition	addition	NN
cord-002240-38aabxh1	29	15	of	of	IN
cord-002240-38aabxh1	29	16	methylprednisone	methylprednisone	NN
cord-002240-38aabxh1	29	17	to	to	TO
cord-002240-38aabxh1	29	18	monocytes	monocyte	NNS
cord-002240-38aabxh1	29	19	stimulated	stimulate	VBN
cord-002240-38aabxh1	29	20	by	by	IN
cord-002240-38aabxh1	29	21	lipopolysaccharide	lipopolysaccharide	NN
cord-002240-38aabxh1	29	22	can	can	MD
cord-002240-38aabxh1	29	23	increase	increase	VB
cord-002240-38aabxh1	29	24	the	the	DT
cord-002240-38aabxh1	29	25	ability	ability	NN
cord-002240-38aabxh1	29	26	to	to	TO
cord-002240-38aabxh1	29	27	suppress	suppress	VB
cord-002240-38aabxh1	29	28	bacterial	bacterial	JJ
cord-002240-38aabxh1	29	29	replication	replication	NN
cord-002240-38aabxh1	29	30	.	.	.
cord-002240-38aabxh1	30	1	The	the	DT
cord-002240-38aabxh1	30	2	main	main	JJ
cord-002240-38aabxh1	30	3	studies	study	NNS
cord-002240-38aabxh1	30	4	on	on	IN
cord-002240-38aabxh1	30	5	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	30	6	in	in	IN
cord-002240-38aabxh1	30	7	pneumonia	pneumonia	NN
cord-002240-38aabxh1	30	8	are	be	VBP
cord-002240-38aabxh1	30	9	summarized	summarize	VBN
cord-002240-38aabxh1	30	10	in	in	IN
cord-002240-38aabxh1	30	11	Table	Table	NNP
cord-002240-38aabxh1	30	12	1	1	CD
cord-002240-38aabxh1	30	13	[	[	-LRB-
cord-002240-38aabxh1	30	14	15	15	CD
cord-002240-38aabxh1	30	15	]	]	-RRB-
cord-002240-38aabxh1	30	16	[	[	-LRB-
cord-002240-38aabxh1	30	17	16	16	CD
cord-002240-38aabxh1	30	18	]	]	-RRB-
cord-002240-38aabxh1	30	19	[	[	-LRB-
cord-002240-38aabxh1	30	20	17	17	CD
cord-002240-38aabxh1	30	21	]	]	-RRB-
cord-002240-38aabxh1	31	1	[	[	-LRB-
cord-002240-38aabxh1	31	2	18	18	CD
cord-002240-38aabxh1	31	3	]	]	-RRB-
cord-002240-38aabxh1	31	4	[	[	-LRB-
cord-002240-38aabxh1	31	5	19	19	CD
cord-002240-38aabxh1	31	6	]	]	-RRB-
cord-002240-38aabxh1	31	7	[	[	-LRB-
cord-002240-38aabxh1	31	8	20	20	CD
cord-002240-38aabxh1	31	9	]	]	-RRB-
cord-002240-38aabxh1	31	10	[	[	-LRB-
cord-002240-38aabxh1	31	11	21	21	CD
cord-002240-38aabxh1	31	12	]	]	-RRB-
cord-002240-38aabxh1	32	1	[	[	-LRB-
cord-002240-38aabxh1	32	2	22	22	CD
cord-002240-38aabxh1	32	3	]	]	-RRB-
cord-002240-38aabxh1	32	4	[	[	-LRB-
cord-002240-38aabxh1	32	5	23	23	CD
cord-002240-38aabxh1	32	6	]	]	-RRB-
cord-002240-38aabxh1	33	1	[	[	-LRB-
cord-002240-38aabxh1	33	2	24	24	CD
cord-002240-38aabxh1	33	3	]	]	-RRB-
cord-002240-38aabxh1	33	4	[	[	-LRB-
cord-002240-38aabxh1	33	5	25	25	CD
cord-002240-38aabxh1	33	6	]	]	-RRB-
cord-002240-38aabxh1	33	7	[	[	-LRB-
cord-002240-38aabxh1	33	8	26	26	CD
cord-002240-38aabxh1	33	9	]	]	-RRB-
cord-002240-38aabxh1	33	10	.	.	.
cord-002240-38aabxh1	34	1	Several	several	JJ
cord-002240-38aabxh1	34	2	studies	study	NNS
cord-002240-38aabxh1	34	3	have	have	VBP
cord-002240-38aabxh1	34	4	evaluated	evaluate	VBN
cord-002240-38aabxh1	34	5	the	the	DT
cord-002240-38aabxh1	34	6	effects	effect	NNS
cord-002240-38aabxh1	34	7	of	of	IN
cord-002240-38aabxh1	34	8	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	34	9	in	in	IN
cord-002240-38aabxh1	34	10	CAP	CAP	NNP
cord-002240-38aabxh1	34	11	.	.	.
cord-002240-38aabxh1	35	1	The	the	DT
cord-002240-38aabxh1	35	2	first	first	JJ
cord-002240-38aabxh1	35	3	studies	study	NNS
cord-002240-38aabxh1	35	4	and	and	CC
cord-002240-38aabxh1	35	5	meta	meta	NNP
cord-002240-38aabxh1	35	6	-	-	HYPH
cord-002240-38aabxh1	35	7	analyses	analysis	NNS
cord-002240-38aabxh1	35	8	included	include	VBD
cord-002240-38aabxh1	35	9	a	a	DT
cord-002240-38aabxh1	35	10	heterogeneous	heterogeneous	JJ
cord-002240-38aabxh1	35	11	population	population	NN
cord-002240-38aabxh1	35	12	evaluating	evaluate	VBG
cord-002240-38aabxh1	35	13	different	different	JJ
cord-002240-38aabxh1	35	14	outcomes	outcome	NNS
cord-002240-38aabxh1	35	15	,	,	,
cord-002240-38aabxh1	35	16	resulting	result	VBG
cord-002240-38aabxh1	35	17	in	in	IN
cord-002240-38aabxh1	35	18	controversial	controversial	JJ
cord-002240-38aabxh1	35	19	data	datum	NNS
cord-002240-38aabxh1	35	20	.	.	.
cord-002240-38aabxh1	36	1	A	a	DT
cord-002240-38aabxh1	36	2	Cochrane	Cochrane	NNP
cord-002240-38aabxh1	36	3	meta	meta	NN
cord-002240-38aabxh1	36	4	-	-	HYPH
cord-002240-38aabxh1	36	5	analysis	analysis	NN
cord-002240-38aabxh1	36	6	[	[	-LRB-
cord-002240-38aabxh1	36	7	19	19	CD
cord-002240-38aabxh1	36	8	]	]	-RRB-
cord-002240-38aabxh1	36	9	selected	select	VBN
cord-002240-38aabxh1	36	10	six	six	CD
cord-002240-38aabxh1	36	11	randomized	randomize	VBN
cord-002240-38aabxh1	36	12	controlled	control	VBN
cord-002240-38aabxh1	36	13	trails	trail	NNS
cord-002240-38aabxh1	36	14	(	(	-LRB-
cord-002240-38aabxh1	36	15	RCTs	RCTs	NNP
cord-002240-38aabxh1	36	16	)	)	-RRB-
cord-002240-38aabxh1	36	17	of	of	IN
cord-002240-38aabxh1	36	18	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	36	19	in	in	IN
cord-002240-38aabxh1	36	20	pneumonia	pneumonia	NN
cord-002240-38aabxh1	36	21	including	include	VBG
cord-002240-38aabxh1	36	22	a	a	DT
cord-002240-38aabxh1	36	23	total	total	NN
cord-002240-38aabxh1	36	24	of	of	IN
cord-002240-38aabxh1	36	25	437	437	CD
cord-002240-38aabxh1	36	26	participants	participant	NNS
cord-002240-38aabxh1	36	27	.	.	.
cord-002240-38aabxh1	37	1	The	the	DT
cord-002240-38aabxh1	37	2	use	use	NN
cord-002240-38aabxh1	37	3	of	of	IN
cord-002240-38aabxh1	37	4	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	37	5	accelerated	accelerate	VBD
cord-002240-38aabxh1	37	6	the	the	DT
cord-002240-38aabxh1	37	7	resolution	resolution	NN
cord-002240-38aabxh1	37	8	of	of	IN
cord-002240-38aabxh1	37	9	symptoms	symptom	NNS
cord-002240-38aabxh1	37	10	and	and	CC
cord-002240-38aabxh1	37	11	time	time	NN
cord-002240-38aabxh1	37	12	to	to	IN
cord-002240-38aabxh1	37	13	clinical	clinical	JJ
cord-002240-38aabxh1	37	14	stability	stability	NN
cord-002240-38aabxh1	37	15	(	(	-LRB-
cord-002240-38aabxh1	37	16	defined	define	VBN
cord-002240-38aabxh1	37	17	as	as	IN
cord-002240-38aabxh1	37	18	improvement	improvement	NN
cord-002240-38aabxh1	37	19	in	in	IN
cord-002240-38aabxh1	37	20	chest	chest	NN
cord-002240-38aabxh1	37	21	X	x	NN
cord-002240-38aabxh1	37	22	-	-	NN
cord-002240-38aabxh1	37	23	ray	ray	NN
cord-002240-38aabxh1	37	24	and	and	CC
cord-002240-38aabxh1	37	25	normalization	normalization	NN
cord-002240-38aabxh1	37	26	of	of	IN
cord-002240-38aabxh1	37	27	temperature	temperature	NN
cord-002240-38aabxh1	37	28	,	,	,
cord-002240-38aabxh1	37	29	respiratory	respiratory	JJ
cord-002240-38aabxh1	37	30	rate	rate	NN
cord-002240-38aabxh1	37	31	,	,	,
cord-002240-38aabxh1	37	32	and	and	CC
cord-002240-38aabxh1	37	33	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	37	34	markers	marker	NNS
cord-002240-38aabxh1	37	35	)	)	-RRB-
cord-002240-38aabxh1	37	36	.	.	.
cord-002240-38aabxh1	38	1	Corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	38	2	provided	provide	VBD
cord-002240-38aabxh1	38	3	no	no	DT
cord-002240-38aabxh1	38	4	benefit	benefit	NN
cord-002240-38aabxh1	38	5	in	in	IN
cord-002240-38aabxh1	38	6	terms	term	NNS
cord-002240-38aabxh1	38	7	of	of	IN
cord-002240-38aabxh1	38	8	mortality	mortality	NN
cord-002240-38aabxh1	38	9	and	and	CC
cord-002240-38aabxh1	38	10	the	the	DT
cord-002240-38aabxh1	38	11	authors	author	NNS
cord-002240-38aabxh1	38	12	concluded	conclude	VBD
cord-002240-38aabxh1	38	13	that	that	IN
cord-002240-38aabxh1	38	14	it	-PRON-	PRP
cord-002240-38aabxh1	38	15	was	be	VBD
cord-002240-38aabxh1	38	16	not	not	RB
cord-002240-38aabxh1	38	17	possible	possible	JJ
cord-002240-38aabxh1	38	18	to	to	TO
cord-002240-38aabxh1	38	19	make	make	VB
cord-002240-38aabxh1	38	20	any	any	DT
cord-002240-38aabxh1	38	21	definitive	definitive	JJ
cord-002240-38aabxh1	38	22	recommendations	recommendation	NNS
cord-002240-38aabxh1	38	23	because	because	IN
cord-002240-38aabxh1	38	24	the	the	DT
cord-002240-38aabxh1	38	25	studies	study	NNS
cord-002240-38aabxh1	38	26	analyzed	analyze	VBN
cord-002240-38aabxh1	38	27	in	in	IN
cord-002240-38aabxh1	38	28	the	the	DT
cord-002240-38aabxh1	38	29	meta	meta	NNP
cord-002240-38aabxh1	38	30	-	-	HYPH
cord-002240-38aabxh1	38	31	analysis	analysis	NN
cord-002240-38aabxh1	38	32	did	do	VBD
cord-002240-38aabxh1	38	33	not	not	RB
cord-002240-38aabxh1	38	34	provide	provide	VB
cord-002240-38aabxh1	38	35	strong	strong	JJ
cord-002240-38aabxh1	38	36	evidence	evidence	NN
cord-002240-38aabxh1	38	37	.	.	.
cord-002240-38aabxh1	39	1	Another	another	DT
cord-002240-38aabxh1	39	2	meta	meta	JJ
cord-002240-38aabxh1	39	3	-	-	HYPH
cord-002240-38aabxh1	39	4	analysis	analysis	NN
cord-002240-38aabxh1	39	5	[	[	-LRB-
cord-002240-38aabxh1	39	6	20	20	CD
cord-002240-38aabxh1	39	7	]	]	-RRB-
cord-002240-38aabxh1	39	8	including	include	VBG
cord-002240-38aabxh1	39	9	nine	nine	CD
cord-002240-38aabxh1	39	10	RCTs	rct	NNS
cord-002240-38aabxh1	39	11	with	with	IN
cord-002240-38aabxh1	39	12	a	a	DT
cord-002240-38aabxh1	39	13	total	total	NN
cord-002240-38aabxh1	39	14	of	of	IN
cord-002240-38aabxh1	39	15	1001	1001	CD
cord-002240-38aabxh1	39	16	patients	patient	NNS
cord-002240-38aabxh1	39	17	showed	show	VBD
cord-002240-38aabxh1	39	18	that	that	IN
cord-002240-38aabxh1	39	19	the	the	DT
cord-002240-38aabxh1	39	20	use	use	NN
cord-002240-38aabxh1	39	21	of	of	IN
cord-002240-38aabxh1	39	22	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	39	23	was	be	VBD
cord-002240-38aabxh1	39	24	not	not	RB
cord-002240-38aabxh1	39	25	associated	associate	VBN
cord-002240-38aabxh1	39	26	with	with	IN
cord-002240-38aabxh1	39	27	significantly	significantly	RB
cord-002240-38aabxh1	39	28	lower	low	JJR
cord-002240-38aabxh1	39	29	mortality	mortality	NN
cord-002240-38aabxh1	39	30	considering	consider	VBG
cord-002240-38aabxh1	39	31	all	all	PDT
cord-002240-38aabxh1	39	32	the	the	DT
cord-002240-38aabxh1	39	33	patients	patient	NNS
cord-002240-38aabxh1	39	34	(	(	-LRB-
cord-002240-38aabxh1	39	35	odds	odd	NNS
cord-002240-38aabxh1	39	36	ratio	ratio	NN
cord-002240-38aabxh1	39	37	(	(	-LRB-
cord-002240-38aabxh1	39	38	OR	or	CC
cord-002240-38aabxh1	40	1	)	)	-RRB-
cord-002240-38aabxh1	40	2	0.62	0.62	CD
cord-002240-38aabxh1	40	3	,	,	,
cord-002240-38aabxh1	40	4	95	95	CD
cord-002240-38aabxh1	40	5	%	%	NN
cord-002240-38aabxh1	40	6	confidence	confidence	NN
cord-002240-38aabxh1	40	7	interval	interval	NN
cord-002240-38aabxh1	40	8	(	(	-LRB-
cord-002240-38aabxh1	40	9	CI	CI	NNP
cord-002240-38aabxh1	40	10	)	)	-RRB-
cord-002240-38aabxh1	40	11	0.37	0.37	CD
cord-002240-38aabxh1	40	12	-	-	SYM
cord-002240-38aabxh1	40	13	1.04	1.04	CD
cord-002240-38aabxh1	40	14	;	;	:
cord-002240-38aabxh1	40	15	p	p	NN
cord-002240-38aabxh1	40	16	=	=	SYM
cord-002240-38aabxh1	40	17	0.07	0.07	CD
cord-002240-38aabxh1	40	18	)	)	-RRB-
cord-002240-38aabxh1	40	19	.	.	.
cord-002240-38aabxh1	41	1	However	however	RB
cord-002240-38aabxh1	41	2	,	,	,
cord-002240-38aabxh1	41	3	a	a	DT
cord-002240-38aabxh1	41	4	survival	survival	NN
cord-002240-38aabxh1	41	5	benefit	benefit	NN
cord-002240-38aabxh1	41	6	was	be	VBD
cord-002240-38aabxh1	41	7	detected	detect	VBN
cord-002240-38aabxh1	41	8	in	in	IN
cord-002240-38aabxh1	41	9	the	the	DT
cord-002240-38aabxh1	41	10	subgroup	subgroup	NN
cord-002240-38aabxh1	41	11	of	of	IN
cord-002240-38aabxh1	41	12	patients	patient	NNS
cord-002240-38aabxh1	41	13	with	with	IN
cord-002240-38aabxh1	41	14	severe	severe	JJ
cord-002240-38aabxh1	41	15	CAP	cap	NN
cord-002240-38aabxh1	41	16	(	(	-LRB-
cord-002240-38aabxh1	41	17	OR	or	CC
cord-002240-38aabxh1	41	18	0.26	0.26	CD
cord-002240-38aabxh1	41	19	,	,	,
cord-002240-38aabxh1	41	20	95	95	CD
cord-002240-38aabxh1	41	21	%	%	NN
cord-002240-38aabxh1	41	22	CI	CI	NNP
cord-002240-38aabxh1	41	23	0.11	0.11	CD
cord-002240-38aabxh1	41	24	-	-	HYPH
cord-002240-38aabxh1	41	25	0.64	0.64	CD
cord-002240-38aabxh1	41	26	;	;	:
cord-002240-38aabxh1	41	27	p	p	NN
cord-002240-38aabxh1	41	28	=	=	SYM
cord-002240-38aabxh1	41	29	0.003	0.003	CD
cord-002240-38aabxh1	41	30	)	)	-RRB-
cord-002240-38aabxh1	41	31	and	and	CC
cord-002240-38aabxh1	41	32	among	among	IN
cord-002240-38aabxh1	41	33	patients	patient	NNS
cord-002240-38aabxh1	41	34	receiving	receive	VBG
cord-002240-38aabxh1	41	35	more	more	RBR
cord-002240-38aabxh1	41	36	prolonged	prolong	VBN
cord-002240-38aabxh1	41	37	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	41	38	treatment	treatment	NN
cord-002240-38aabxh1	41	39	(	(	-LRB-
cord-002240-38aabxh1	41	40	OR	or	CC
cord-002240-38aabxh1	42	1	0.51	0.51	CD
cord-002240-38aabxh1	43	1	,	,	,
cord-002240-38aabxh1	43	2	95	95	CD
cord-002240-38aabxh1	43	3	%	%	NN
cord-002240-38aabxh1	43	4	CI	CI	NNP
cord-002240-38aabxh1	43	5	0.26	0.26	CD
cord-002240-38aabxh1	43	6	-	-	HYPH
cord-002240-38aabxh1	43	7	0.97	0.97	CD
cord-002240-38aabxh1	43	8	;	;	:
cord-002240-38aabxh1	43	9	p	p	NN
cord-002240-38aabxh1	43	10	=	=	SYM
cord-002240-38aabxh1	43	11	0.04	0.04	CD
cord-002240-38aabxh1	43	12	)	)	-RRB-
cord-002240-38aabxh1	43	13	.	.	.
cord-002240-38aabxh1	44	1	Prolonged	prolonged	JJ
cord-002240-38aabxh1	44	2	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	44	3	treatment	treatment	NN
cord-002240-38aabxh1	44	4	was	be	VBD
cord-002240-38aabxh1	44	5	defined	define	VBN
cord-002240-38aabxh1	44	6	as	as	IN
cord-002240-38aabxh1	44	7	more	more	JJR
cord-002240-38aabxh1	44	8	than	than	IN
cord-002240-38aabxh1	44	9	5	5	CD
cord-002240-38aabxh1	44	10	days	day	NNS
cord-002240-38aabxh1	44	11	of	of	IN
cord-002240-38aabxh1	44	12	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	44	13	treatment	treatment	NN
cord-002240-38aabxh1	44	14	and	and	CC
cord-002240-38aabxh1	44	15	a	a	DT
cord-002240-38aabxh1	44	16	maximum	maximum	NN
cord-002240-38aabxh1	44	17	of	of	IN
cord-002240-38aabxh1	44	18	9	9	CD
cord-002240-38aabxh1	44	19	days	day	NNS
cord-002240-38aabxh1	44	20	.	.	.
cord-002240-38aabxh1	45	1	In	in	IN
cord-002240-38aabxh1	45	2	terms	term	NNS
cord-002240-38aabxh1	45	3	of	of	IN
cord-002240-38aabxh1	45	4	adverse	adverse	JJ
cord-002240-38aabxh1	45	5	effects	effect	NNS
cord-002240-38aabxh1	45	6	,	,	,
cord-002240-38aabxh1	45	7	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	45	8	increased	increase	VBD
cord-002240-38aabxh1	45	9	the	the	DT
cord-002240-38aabxh1	45	10	risk	risk	NN
cord-002240-38aabxh1	45	11	of	of	IN
cord-002240-38aabxh1	45	12	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	45	13	(	(	-LRB-
cord-002240-38aabxh1	45	14	OR	or	CC
cord-002240-38aabxh1	45	15	2.64	2.64	CD
cord-002240-38aabxh1	45	16	,	,	,
cord-002240-38aabxh1	45	17	95	95	CD
cord-002240-38aabxh1	45	18	%	%	NN
cord-002240-38aabxh1	45	19	CI	CI	NNP
cord-002240-38aabxh1	45	20	1.68	1.68	CD
cord-002240-38aabxh1	45	21	-	-	HYPH
cord-002240-38aabxh1	45	22	4.15	4.15	CD
cord-002240-38aabxh1	45	23	;	;	:
cord-002240-38aabxh1	45	24	p	p	NN
cord-002240-38aabxh1	45	25	<	<	XX
cord-002240-38aabxh1	45	26	0.001	0.001	CD
cord-002240-38aabxh1	45	27	)	)	-RRB-
cord-002240-38aabxh1	45	28	but	but	CC
cord-002240-38aabxh1	45	29	did	do	VBD
cord-002240-38aabxh1	45	30	not	not	RB
cord-002240-38aabxh1	45	31	increase	increase	VB
cord-002240-38aabxh1	45	32	the	the	DT
cord-002240-38aabxh1	45	33	risk	risk	NN
cord-002240-38aabxh1	45	34	of	of	IN
cord-002240-38aabxh1	45	35	superinfection	superinfection	NN
cord-002240-38aabxh1	45	36	(	(	-LRB-
cord-002240-38aabxh1	45	37	OR	or	CC
cord-002240-38aabxh1	45	38	1.36	1.36	CD
cord-002240-38aabxh1	45	39	,	,	,
cord-002240-38aabxh1	45	40	95	95	CD
cord-002240-38aabxh1	45	41	%	%	NN
cord-002240-38aabxh1	45	42	CI	CI	NNP
cord-002240-38aabxh1	45	43	0.65	0.65	CD
cord-002240-38aabxh1	45	44	-	-	HYPH
cord-002240-38aabxh1	45	45	2.84	2.84	CD
cord-002240-38aabxh1	45	46	;	;	:
cord-002240-38aabxh1	45	47	p	p	NN
cord-002240-38aabxh1	45	48	=	=	SYM
cord-002240-38aabxh1	45	49	0.41	0.41	CD
cord-002240-38aabxh1	45	50	)	)	-RRB-
cord-002240-38aabxh1	45	51	or	or	CC
cord-002240-38aabxh1	45	52	gastroduodenal	gastroduodenal	JJ
cord-002240-38aabxh1	45	53	bleeding	bleeding	NN
cord-002240-38aabxh1	45	54	(	(	-LRB-
cord-002240-38aabxh1	45	55	OR	or	CC
cord-002240-38aabxh1	45	56	1.67	1.67	CD
cord-002240-38aabxh1	46	1	,	,	,
cord-002240-38aabxh1	46	2	95	95	CD
cord-002240-38aabxh1	46	3	%	%	NN
cord-002240-38aabxh1	46	4	CI	CI	NNP
cord-002240-38aabxh1	46	5	0.41	0.41	CD
cord-002240-38aabxh1	46	6	-	-	HYPH
cord-002240-38aabxh1	46	7	6.80	6.80	CD
cord-002240-38aabxh1	46	8	;	;	:
cord-002240-38aabxh1	46	9	p	p	NN
cord-002240-38aabxh1	46	10	=	=	SYM
cord-002240-38aabxh1	46	11	0.47	0.47	CD
cord-002240-38aabxh1	46	12	)	)	-RRB-
cord-002240-38aabxh1	46	13	.	.	.
cord-002240-38aabxh1	47	1	In	in	IN
cord-002240-38aabxh1	47	2	conclusion	conclusion	NN
cord-002240-38aabxh1	47	3	,	,	,
cord-002240-38aabxh1	47	4	these	these	DT
cord-002240-38aabxh1	47	5	studies	study	NNS
cord-002240-38aabxh1	47	6	were	be	VBD
cord-002240-38aabxh1	47	7	not	not	RB
cord-002240-38aabxh1	47	8	able	able	JJ
cord-002240-38aabxh1	47	9	to	to	TO
cord-002240-38aabxh1	47	10	provide	provide	VB
cord-002240-38aabxh1	47	11	definitive	definitive	JJ
cord-002240-38aabxh1	47	12	results	result	NNS
cord-002240-38aabxh1	47	13	regarding	regard	VBG
cord-002240-38aabxh1	47	14	the	the	DT
cord-002240-38aabxh1	47	15	use	use	NN
cord-002240-38aabxh1	47	16	of	of	IN
cord-002240-38aabxh1	47	17	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	47	18	in	in	IN
cord-002240-38aabxh1	47	19	CAP	CAP	NNP
cord-002240-38aabxh1	47	20	.	.	.
cord-002240-38aabxh1	48	1	The	the	DT
cord-002240-38aabxh1	48	2	main	main	JJ
cord-002240-38aabxh1	48	3	limitations	limitation	NNS
cord-002240-38aabxh1	48	4	regarded	regard	VBD
cord-002240-38aabxh1	48	5	the	the	DT
cord-002240-38aabxh1	48	6	inclusion	inclusion	NN
cord-002240-38aabxh1	48	7	of	of	IN
cord-002240-38aabxh1	48	8	a	a	DT
cord-002240-38aabxh1	48	9	heterogeneous	heterogeneous	JJ
cord-002240-38aabxh1	48	10	population	population	NN
cord-002240-38aabxh1	48	11	in	in	IN
cord-002240-38aabxh1	48	12	terms	term	NNS
cord-002240-38aabxh1	48	13	of	of	IN
cord-002240-38aabxh1	48	14	severity	severity	NN
cord-002240-38aabxh1	48	15	(	(	-LRB-
cord-002240-38aabxh1	48	16	from	from	IN
cord-002240-38aabxh1	48	17	mild	mild	JJ
cord-002240-38aabxh1	48	18	to	to	IN
cord-002240-38aabxh1	48	19	severe	severe	JJ
cord-002240-38aabxh1	48	20	)	)	-RRB-
cord-002240-38aabxh1	48	21	and	and	CC
cord-002240-38aabxh1	48	22	level	level	NN
cord-002240-38aabxh1	48	23	of	of	IN
cord-002240-38aabxh1	48	24	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	48	25	response	response	NN
cord-002240-38aabxh1	48	26	(	(	-LRB-
cord-002240-38aabxh1	48	27	e.g.	e.g.	RB
cord-002240-38aabxh1	48	28	,	,	,
cord-002240-38aabxh1	48	29	defined	define	VBN
cord-002240-38aabxh1	48	30	by	by	IN
cord-002240-38aabxh1	48	31	the	the	DT
cord-002240-38aabxh1	48	32	level	level	NN
cord-002240-38aabxh1	48	33	of	of	IN
cord-002240-38aabxh1	48	34	C	c	NN
cord-002240-38aabxh1	48	35	-	-	HYPH
cord-002240-38aabxh1	48	36	reactive	reactive	JJ
cord-002240-38aabxh1	48	37	protein	protein	NN
cord-002240-38aabxh1	48	38	(	(	-LRB-
cord-002240-38aabxh1	48	39	CRP	CRP	NNP
cord-002240-38aabxh1	48	40	)	)	-RRB-
cord-002240-38aabxh1	48	41	)	)	-RRB-
cord-002240-38aabxh1	48	42	and	and	CC
cord-002240-38aabxh1	48	43	the	the	DT
cord-002240-38aabxh1	48	44	use	use	NN
cord-002240-38aabxh1	48	45	,	,	,
cord-002240-38aabxh1	48	46	in	in	IN
cord-002240-38aabxh1	48	47	some	some	DT
cord-002240-38aabxh1	48	48	cases	case	NNS
cord-002240-38aabxh1	48	49	,	,	,
cord-002240-38aabxh1	48	50	of	of	IN
cord-002240-38aabxh1	48	51	inadequate	inadequate	JJ
cord-002240-38aabxh1	48	52	dosage	dosage	NN
cord-002240-38aabxh1	48	53	of	of	IN
cord-002240-38aabxh1	48	54	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	48	55	(	(	-LRB-
cord-002240-38aabxh1	48	56	low	low	JJ
cord-002240-38aabxh1	48	57	or	or	CC
cord-002240-38aabxh1	48	58	excessively	excessively	RB
cord-002240-38aabxh1	48	59	high	high	JJ
cord-002240-38aabxh1	48	60	)	)	-RRB-
cord-002240-38aabxh1	48	61	.	.	.
cord-002240-38aabxh1	49	1	Two	two	CD
cord-002240-38aabxh1	49	2	recent	recent	JJ
cord-002240-38aabxh1	49	3	multicenter	multicenter	JJ
cord-002240-38aabxh1	49	4	RCTs	rct	NNS
cord-002240-38aabxh1	49	5	have	have	VBP
cord-002240-38aabxh1	49	6	been	be	VBN
cord-002240-38aabxh1	49	7	published	publish	VBN
cord-002240-38aabxh1	49	8	regarding	regard	VBG
cord-002240-38aabxh1	49	9	the	the	DT
cord-002240-38aabxh1	49	10	use	use	NN
cord-002240-38aabxh1	49	11	of	of	IN
cord-002240-38aabxh1	49	12	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	49	13	in	in	IN
cord-002240-38aabxh1	49	14	CAP	CAP	NNP
cord-002240-38aabxh1	49	15	.	.	.
cord-002240-38aabxh1	50	1	In	in	IN
cord-002240-38aabxh1	50	2	a	a	DT
cord-002240-38aabxh1	50	3	multicenter	multicenter	JJ
cord-002240-38aabxh1	50	4	,	,	,
cord-002240-38aabxh1	50	5	double	double	JJ
cord-002240-38aabxh1	50	6	-	-	HYPH
cord-002240-38aabxh1	50	7	blind	blind	JJ
cord-002240-38aabxh1	50	8	,	,	,
cord-002240-38aabxh1	50	9	randomized	randomized	JJ
cord-002240-38aabxh1	50	10	,	,	,
cord-002240-38aabxh1	50	11	placebocontrolled	placebocontrolled	JJ
cord-002240-38aabxh1	50	12	trial	trial	NN
cord-002240-38aabxh1	50	13	[	[	-LRB-
cord-002240-38aabxh1	50	14	24	24	CD
cord-002240-38aabxh1	50	15	]	]	-RRB-
cord-002240-38aabxh1	50	16	,	,	,
cord-002240-38aabxh1	50	17	a	a	DT
cord-002240-38aabxh1	50	18	total	total	NN
cord-002240-38aabxh1	50	19	of	of	IN
cord-002240-38aabxh1	50	20	785	785	CD
cord-002240-38aabxh1	50	21	patients	patient	NNS
cord-002240-38aabxh1	50	22	with	with	IN
cord-002240-38aabxh1	50	23	CAP	CAP	NNP
cord-002240-38aabxh1	50	24	were	be	VBD
cord-002240-38aabxh1	50	25	randomized	randomize	VBN
cord-002240-38aabxh1	50	26	to	to	TO
cord-002240-38aabxh1	50	27	receive	receive	VB
cord-002240-38aabxh1	50	28	oral	oral	JJ
cord-002240-38aabxh1	50	29	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	50	30	(	(	-LRB-
cord-002240-38aabxh1	50	31	50	50	CD
cord-002240-38aabxh1	50	32	mg	mg	NN
cord-002240-38aabxh1	50	33	of	of	IN
cord-002240-38aabxh1	50	34	prednisone	prednisone	NNP
cord-002240-38aabxh1	50	35	for	for	IN
cord-002240-38aabxh1	50	36	7	7	CD
cord-002240-38aabxh1	50	37	days	day	NNS
cord-002240-38aabxh1	50	38	)	)	-RRB-
cord-002240-38aabxh1	50	39	or	or	CC
cord-002240-38aabxh1	50	40	placebo	placebo	NN
cord-002240-38aabxh1	50	41	as	as	IN
cord-002240-38aabxh1	50	42	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	50	43	treatment	treatment	NN
cord-002240-38aabxh1	50	44	.	.	.
cord-002240-38aabxh1	51	1	The	the	DT
cord-002240-38aabxh1	51	2	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	51	3	group	group	NN
cord-002240-38aabxh1	51	4	reported	report	VBD
cord-002240-38aabxh1	51	5	a	a	DT
cord-002240-38aabxh1	51	6	shorter	short	JJR
cord-002240-38aabxh1	51	7	time	time	NN
cord-002240-38aabxh1	51	8	to	to	TO
cord-002240-38aabxh1	51	9	reach	reach	VB
cord-002240-38aabxh1	51	10	clinical	clinical	JJ
cord-002240-38aabxh1	51	11	stability	stability	NN
cord-002240-38aabxh1	51	12	in	in	IN
cord-002240-38aabxh1	51	13	comparison	comparison	NN
cord-002240-38aabxh1	51	14	with	with	IN
cord-002240-38aabxh1	51	15	the	the	DT
cord-002240-38aabxh1	51	16	placebo	placebo	NN
cord-002240-38aabxh1	51	17	group	group	NN
cord-002240-38aabxh1	51	18	(	(	-LRB-
cord-002240-38aabxh1	51	19	3	3	CD
cord-002240-38aabxh1	51	20	days	day	NNS
cord-002240-38aabxh1	51	21	versus	versus	IN
cord-002240-38aabxh1	51	22	4.4	4.4	CD
cord-002240-38aabxh1	51	23	days	day	NNS
cord-002240-38aabxh1	51	24	)	)	-RRB-
cord-002240-38aabxh1	51	25	.	.	.
cord-002240-38aabxh1	52	1	In	in	IN
cord-002240-38aabxh1	52	2	the	the	DT
cord-002240-38aabxh1	52	3	study	study	NN
cord-002240-38aabxh1	52	4	,	,	,
cord-002240-38aabxh1	52	5	the	the	DT
cord-002240-38aabxh1	52	6	time	time	NN
cord-002240-38aabxh1	52	7	to	to	IN
cord-002240-38aabxh1	52	8	clinical	clinical	JJ
cord-002240-38aabxh1	52	9	stability	stability	NN
cord-002240-38aabxh1	52	10	was	be	VBD
cord-002240-38aabxh1	52	11	defined	define	VBN
cord-002240-38aabxh1	52	12	as	as	IN
cord-002240-38aabxh1	52	13	the	the	DT
cord-002240-38aabxh1	52	14	days	day	NNS
cord-002240-38aabxh1	52	15	until	until	IN
cord-002240-38aabxh1	52	16	reaching	reach	VBG
cord-002240-38aabxh1	52	17	stable	stable	JJ
cord-002240-38aabxh1	52	18	vital	vital	JJ
cord-002240-38aabxh1	52	19	signs	sign	NNS
cord-002240-38aabxh1	52	20	for	for	IN
cord-002240-38aabxh1	52	21	24	24	CD
cord-002240-38aabxh1	52	22	h	h	NN
cord-002240-38aabxh1	52	23	or	or	CC
cord-002240-38aabxh1	52	24	longer	long	RBR
cord-002240-38aabxh1	52	25	(	(	-LRB-
cord-002240-38aabxh1	52	26	including	include	VBG
cord-002240-38aabxh1	52	27	normalization	normalization	NN
cord-002240-38aabxh1	52	28	of	of	IN
cord-002240-38aabxh1	52	29	temperature	temperature	NN
cord-002240-38aabxh1	52	30	,	,	,
cord-002240-38aabxh1	52	31	heart	heart	NN
cord-002240-38aabxh1	52	32	rate	rate	NN
cord-002240-38aabxh1	52	33	,	,	,
cord-002240-38aabxh1	52	34	spontaneous	spontaneous	JJ
cord-002240-38aabxh1	52	35	respiratory	respiratory	JJ
cord-002240-38aabxh1	52	36	rate	rate	NN
cord-002240-38aabxh1	52	37	,	,	,
cord-002240-38aabxh1	52	38	systolic	systolic	JJ
cord-002240-38aabxh1	52	39	blood	blood	NN
cord-002240-38aabxh1	52	40	pressure	pressure	NN
cord-002240-38aabxh1	52	41	,	,	,
cord-002240-38aabxh1	52	42	mental	mental	JJ
cord-002240-38aabxh1	52	43	status	status	NN
cord-002240-38aabxh1	52	44	,	,	,
cord-002240-38aabxh1	52	45	ability	ability	NN
cord-002240-38aabxh1	52	46	for	for	IN
cord-002240-38aabxh1	52	47	oral	oral	JJ
cord-002240-38aabxh1	52	48	intake	intake	NN
cord-002240-38aabxh1	52	49	,	,	,
cord-002240-38aabxh1	52	50	and	and	CC
cord-002240-38aabxh1	52	51	adequate	adequate	JJ
cord-002240-38aabxh1	52	52	oxygenation	oxygenation	NN
cord-002240-38aabxh1	52	53	on	on	IN
cord-002240-38aabxh1	52	54	room	room	NN
cord-002240-38aabxh1	52	55	air	air	NN
cord-002240-38aabxh1	52	56	)	)	-RRB-
cord-002240-38aabxh1	52	57	.	.	.
cord-002240-38aabxh1	53	1	The	the	DT
cord-002240-38aabxh1	53	2	complications	complication	NNS
cord-002240-38aabxh1	53	3	related	relate	VBN
cord-002240-38aabxh1	53	4	to	to	IN
cord-002240-38aabxh1	53	5	pneumonia	pneumonia	NN
cord-002240-38aabxh1	53	6	were	be	VBD
cord-002240-38aabxh1	53	7	not	not	RB
cord-002240-38aabxh1	53	8	significantly	significantly	RB
cord-002240-38aabxh1	53	9	different	different	JJ
cord-002240-38aabxh1	53	10	in	in	IN
cord-002240-38aabxh1	53	11	the	the	DT
cord-002240-38aabxh1	53	12	groups	group	NNS
cord-002240-38aabxh1	53	13	whereas	whereas	IN
cord-002240-38aabxh1	53	14	the	the	DT
cord-002240-38aabxh1	53	15	prednisone	prednisone	NNP
cord-002240-38aabxh1	53	16	group	group	NN
cord-002240-38aabxh1	53	17	more	more	RBR
cord-002240-38aabxh1	53	18	frequently	frequently	RB
cord-002240-38aabxh1	53	19	presented	present	VBN
cord-002240-38aabxh1	53	20	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	53	21	needing	need	VBG
cord-002240-38aabxh1	53	22	insulin	insulin	NN
cord-002240-38aabxh1	53	23	treatment	treatment	NN
cord-002240-38aabxh1	53	24	(	(	-LRB-
cord-002240-38aabxh1	53	25	19	19	CD
cord-002240-38aabxh1	53	26	versus	versus	IN
cord-002240-38aabxh1	53	27	11	11	CD
cord-002240-38aabxh1	53	28	%	%	NN
cord-002240-38aabxh1	53	29	;	;	,
cord-002240-38aabxh1	53	30	OR	or	CC
cord-002240-38aabxh1	53	31	1.96	1.96	CD
cord-002240-38aabxh1	53	32	;	;	.
cord-002240-38aabxh1	54	1	95	95	CD
cord-002240-38aabxh1	54	2	%	%	NN
cord-002240-38aabxh1	54	3	CI	CI	NNP
cord-002240-38aabxh1	54	4	1.31	1.31	CD
cord-002240-38aabxh1	54	5	-	-	SYM
cord-002240-38aabxh1	54	6	2.93	2.93	CD
cord-002240-38aabxh1	54	7	;	;	:
cord-002240-38aabxh1	54	8	p	p	NN
cord-002240-38aabxh1	54	9	=	=	SYM
cord-002240-38aabxh1	54	10	0.001	0.001	CD
cord-002240-38aabxh1	54	11	)	)	-RRB-
cord-002240-38aabxh1	54	12	.	.	.
cord-002240-38aabxh1	55	1	However	however	RB
cord-002240-38aabxh1	55	2	,	,	,
cord-002240-38aabxh1	55	3	other	other	JJ
cord-002240-38aabxh1	55	4	adverse	adverse	JJ
cord-002240-38aabxh1	55	5	events	event	NNS
cord-002240-38aabxh1	55	6	typically	typically	RB
cord-002240-38aabxh1	55	7	associated	associate	VBN
cord-002240-38aabxh1	55	8	with	with	IN
cord-002240-38aabxh1	55	9	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	55	10	use	use	NN
cord-002240-38aabxh1	55	11	(	(	-LRB-
cord-002240-38aabxh1	55	12	such	such	JJ
cord-002240-38aabxh1	55	13	as	as	IN
cord-002240-38aabxh1	55	14	gastrointestinal	gastrointestinal	JJ
cord-002240-38aabxh1	55	15	bleeding	bleeding	NN
cord-002240-38aabxh1	55	16	,	,	,
cord-002240-38aabxh1	55	17	nosocomial	nosocomial	JJ
cord-002240-38aabxh1	55	18	infections	infection	NNS
cord-002240-38aabxh1	55	19	)	)	-RRB-
cord-002240-38aabxh1	55	20	were	be	VBD
cord-002240-38aabxh1	55	21	rare	rare	JJ
cord-002240-38aabxh1	55	22	and	and	CC
cord-002240-38aabxh1	55	23	similar	similar	JJ
cord-002240-38aabxh1	55	24	in	in	IN
cord-002240-38aabxh1	55	25	both	both	DT
cord-002240-38aabxh1	55	26	groups	group	NNS
cord-002240-38aabxh1	55	27	.	.	.
cord-002240-38aabxh1	56	1	The	the	DT
cord-002240-38aabxh1	56	2	mortality	mortality	NN
cord-002240-38aabxh1	56	3	rate	rate	NN
cord-002240-38aabxh1	56	4	,	,	,
cord-002240-38aabxh1	56	5	considered	consider	VBN
cord-002240-38aabxh1	56	6	as	as	IN
cord-002240-38aabxh1	56	7	a	a	DT
cord-002240-38aabxh1	56	8	secondary	secondary	JJ
cord-002240-38aabxh1	56	9	outcome	outcome	NN
cord-002240-38aabxh1	56	10	in	in	IN
cord-002240-38aabxh1	56	11	the	the	DT
cord-002240-38aabxh1	56	12	study	study	NN
cord-002240-38aabxh1	56	13	,	,	,
cord-002240-38aabxh1	56	14	was	be	VBD
cord-002240-38aabxh1	56	15	not	not	RB
cord-002240-38aabxh1	56	16	different	different	JJ
cord-002240-38aabxh1	56	17	in	in	IN
cord-002240-38aabxh1	56	18	the	the	DT
cord-002240-38aabxh1	56	19	two	two	CD
cord-002240-38aabxh1	56	20	groups	group	NNS
cord-002240-38aabxh1	57	1	(	(	-LRB-
cord-002240-38aabxh1	57	2	n	n	NN
cord-002240-38aabxh1	57	3	=	=	SYM
cord-002240-38aabxh1	57	4	16	16	CD
cord-002240-38aabxh1	57	5	(	(	-LRB-
cord-002240-38aabxh1	57	6	4	4	CD
cord-002240-38aabxh1	57	7	%	%	NN
cord-002240-38aabxh1	57	8	)	)	-RRB-
cord-002240-38aabxh1	57	9	in	in	IN
cord-002240-38aabxh1	57	10	the	the	DT
cord-002240-38aabxh1	57	11	prednisone	prednisone	NNP
cord-002240-38aabxh1	57	12	group	group	NNP
cord-002240-38aabxh1	57	13	versus	versus	IN
cord-002240-38aabxh1	57	14	n	n	NNP
cord-002240-38aabxh1	57	15	=	=	SYM
cord-002240-38aabxh1	57	16	13	13	CD
cord-002240-38aabxh1	57	17	(	(	-LRB-
cord-002240-38aabxh1	57	18	3	3	CD
cord-002240-38aabxh1	57	19	%	%	NN
cord-002240-38aabxh1	57	20	)	)	-RRB-
cord-002240-38aabxh1	57	21	in	in	IN
cord-002240-38aabxh1	57	22	the	the	DT
cord-002240-38aabxh1	57	23	placebo	placebo	NN
cord-002240-38aabxh1	57	24	group	group	NN
cord-002240-38aabxh1	57	25	;	;	:
cord-002240-38aabxh1	57	26	p	p	NN
cord-002240-38aabxh1	57	27	=	=	SYM
cord-002240-38aabxh1	57	28	0.57	0.57	CD
cord-002240-38aabxh1	57	29	)	)	-RRB-
cord-002240-38aabxh1	57	30	.	.	.
cord-002240-38aabxh1	58	1	This	this	DT
cord-002240-38aabxh1	58	2	study	study	NN
cord-002240-38aabxh1	58	3	presented	present	VBD
cord-002240-38aabxh1	58	4	some	some	DT
cord-002240-38aabxh1	58	5	limitations	limitation	NNS
cord-002240-38aabxh1	58	6	,	,	,
cord-002240-38aabxh1	58	7	in	in	IN
cord-002240-38aabxh1	58	8	particular	particular	JJ
cord-002240-38aabxh1	58	9	the	the	DT
cord-002240-38aabxh1	58	10	use	use	NN
cord-002240-38aabxh1	58	11	of	of	IN
cord-002240-38aabxh1	58	12	a	a	DT
cord-002240-38aabxh1	58	13	weak	weak	JJ
cord-002240-38aabxh1	58	14	outcome	outcome	NN
cord-002240-38aabxh1	58	15	such	such	JJ
cord-002240-38aabxh1	58	16	as	as	IN
cord-002240-38aabxh1	58	17	clinical	clinical	JJ
cord-002240-38aabxh1	58	18	stability	stability	NN
cord-002240-38aabxh1	58	19	,	,	,
cord-002240-38aabxh1	58	20	which	which	WDT
cord-002240-38aabxh1	58	21	included	include	VBD
cord-002240-38aabxh1	58	22	some	some	DT
cord-002240-38aabxh1	58	23	items	item	NNS
cord-002240-38aabxh1	58	24	such	such	JJ
cord-002240-38aabxh1	58	25	as	as	IN
cord-002240-38aabxh1	58	26	temperature	temperature	NN
cord-002240-38aabxh1	58	27	that	that	WDT
cord-002240-38aabxh1	58	28	could	could	MD
cord-002240-38aabxh1	58	29	be	be	VB
cord-002240-38aabxh1	58	30	influenced	influence	VBN
cord-002240-38aabxh1	58	31	by	by	IN
cord-002240-38aabxh1	58	32	the	the	DT
cord-002240-38aabxh1	58	33	use	use	NN
cord-002240-38aabxh1	58	34	of	of	IN
cord-002240-38aabxh1	58	35	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	58	36	.	.	.
cord-002240-38aabxh1	59	1	Moreover	moreover	RB
cord-002240-38aabxh1	59	2	,	,	,
cord-002240-38aabxh1	59	3	the	the	DT
cord-002240-38aabxh1	59	4	majority	majority	NN
cord-002240-38aabxh1	59	5	of	of	IN
cord-002240-38aabxh1	59	6	patients	patient	NNS
cord-002240-38aabxh1	59	7	had	have	VBD
cord-002240-38aabxh1	59	8	a	a	DT
cord-002240-38aabxh1	59	9	mild	mild	JJ
cord-002240-38aabxh1	59	10	disease	disease	NN
cord-002240-38aabxh1	59	11	presentation	presentation	NN
cord-002240-38aabxh1	59	12	,	,	,
cord-002240-38aabxh1	59	13	thereby	thereby	RB
cord-002240-38aabxh1	59	14	decreasing	decrease	VBG
cord-002240-38aabxh1	59	15	result	result	NN
cord-002240-38aabxh1	59	16	validation	validation	NN
cord-002240-38aabxh1	59	17	for	for	IN
cord-002240-38aabxh1	59	18	the	the	DT
cord-002240-38aabxh1	59	19	most	most	RBS
cord-002240-38aabxh1	59	20	severe	severe	JJ
cord-002240-38aabxh1	59	21	diseases	disease	NNS
cord-002240-38aabxh1	59	22	.	.	.
cord-002240-38aabxh1	60	1	We	-PRON-	PRP
cord-002240-38aabxh1	60	2	recently	recently	RB
cord-002240-38aabxh1	60	3	published	publish	VBD
cord-002240-38aabxh1	60	4	a	a	DT
cord-002240-38aabxh1	60	5	multicentre	multicentre	NN
cord-002240-38aabxh1	60	6	RCT	RCT	NNP
cord-002240-38aabxh1	60	7	[	[	-LRB-
cord-002240-38aabxh1	60	8	23	23	CD
cord-002240-38aabxh1	60	9	]	]	-RRB-
cord-002240-38aabxh1	60	10	where	where	WRB
cord-002240-38aabxh1	60	11	we	-PRON-	PRP
cord-002240-38aabxh1	60	12	compared	compare	VBD
cord-002240-38aabxh1	60	13	patients	patient	NNS
cord-002240-38aabxh1	60	14	with	with	IN
cord-002240-38aabxh1	60	15	severe	severe	JJ
cord-002240-38aabxh1	60	16	CAP	cap	NN
cord-002240-38aabxh1	60	17	and	and	CC
cord-002240-38aabxh1	60	18	strong	strong	JJ
cord-002240-38aabxh1	60	19	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	60	20	response	response	NN
cord-002240-38aabxh1	60	21	(	(	-LRB-
cord-002240-38aabxh1	60	22	defined	define	VBN
cord-002240-38aabxh1	60	23	by	by	IN
cord-002240-38aabxh1	60	24	a	a	DT
cord-002240-38aabxh1	60	25	CRP	crp	NN
cord-002240-38aabxh1	60	26	>	>	SYM
cord-002240-38aabxh1	60	27	150	150	CD
cord-002240-38aabxh1	60	28	mg	mg	NNP
cord-002240-38aabxh1	60	29	/	/	SYM
cord-002240-38aabxh1	60	30	L	L	NNP
cord-002240-38aabxh1	60	31	)	)	-RRB-
cord-002240-38aabxh1	60	32	treated	treat	VBN
cord-002240-38aabxh1	60	33	with	with	IN
cord-002240-38aabxh1	60	34	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	60	35	plus	plus	CC
cord-002240-38aabxh1	60	36	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	60	37	versus	versus	IN
cord-002240-38aabxh1	60	38	placebo	placebo	NN
cord-002240-38aabxh1	60	39	plus	plus	CC
cord-002240-38aabxh1	60	40	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	60	41	.	.	.
cord-002240-38aabxh1	61	1	We	-PRON-	PRP
cord-002240-38aabxh1	61	2	used	use	VBD
cord-002240-38aabxh1	61	3	intravenous	intravenous	JJ
cord-002240-38aabxh1	61	4	methylprednisolone	methylprednisolone	NN
cord-002240-38aabxh1	61	5	at	at	IN
cord-002240-38aabxh1	61	6	a	a	DT
cord-002240-38aabxh1	61	7	dose	dose	NN
cord-002240-38aabxh1	61	8	of	of	IN
cord-002240-38aabxh1	61	9	0.5	0.5	CD
cord-002240-38aabxh1	61	10	/	/	SYM
cord-002240-38aabxh1	61	11	mg	mg	NNP
cord-002240-38aabxh1	61	12	/	/	SYM
cord-002240-38aabxh1	61	13	kg	kg	NNP
cord-002240-38aabxh1	61	14	every	every	DT
cord-002240-38aabxh1	61	15	12	12	CD
cord-002240-38aabxh1	61	16	h	h	NN
cord-002240-38aabxh1	61	17	for	for	IN
cord-002240-38aabxh1	61	18	5	5	CD
cord-002240-38aabxh1	61	19	days	day	NNS
cord-002240-38aabxh1	61	20	.	.	.
cord-002240-38aabxh1	62	1	We	-PRON-	PRP
cord-002240-38aabxh1	62	2	included	include	VBD
cord-002240-38aabxh1	62	3	only	only	RB
cord-002240-38aabxh1	62	4	patients	patient	NNS
cord-002240-38aabxh1	62	5	with	with	IN
cord-002240-38aabxh1	62	6	severe	severe	JJ
cord-002240-38aabxh1	62	7	CAP	cap	NN
cord-002240-38aabxh1	62	8	,	,	,
cord-002240-38aabxh1	62	9	defined	define	VBN
cord-002240-38aabxh1	62	10	according	accord	VBG
cord-002240-38aabxh1	62	11	to	to	IN
cord-002240-38aabxh1	62	12	the	the	DT
cord-002240-38aabxh1	62	13	modified	modify	VBN
cord-002240-38aabxh1	62	14	American	American	NNP
cord-002240-38aabxh1	62	15	Thoracic	Thoracic	NNP
cord-002240-38aabxh1	62	16	Society	Society	NNP
cord-002240-38aabxh1	62	17	criteria	criterion	NNS
cord-002240-38aabxh1	62	18	or	or	CC
cord-002240-38aabxh1	62	19	by	by	IN
cord-002240-38aabxh1	62	20	a	a	DT
cord-002240-38aabxh1	62	21	Pneumonia	Pneumonia	NNP
cord-002240-38aabxh1	62	22	Severity	Severity	NNP
cord-002240-38aabxh1	62	23	Index	Index	NNP
cord-002240-38aabxh1	62	24	risk	risk	NN
cord-002240-38aabxh1	62	25	class	class	NN
cord-002240-38aabxh1	62	26	V	v	NN
cord-002240-38aabxh1	62	27	[	[	-LRB-
cord-002240-38aabxh1	62	28	27	27	CD
cord-002240-38aabxh1	62	29	]	]	-RRB-
cord-002240-38aabxh1	62	30	.	.	.
cord-002240-38aabxh1	63	1	The	the	DT
cord-002240-38aabxh1	63	2	patients	patient	NNS
cord-002240-38aabxh1	63	3	receiving	receive	VBG
cord-002240-38aabxh1	63	4	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	63	5	had	have	VBD
cord-002240-38aabxh1	63	6	significantly	significantly	RB
cord-002240-38aabxh1	63	7	lower	low	JJR
cord-002240-38aabxh1	63	8	treatment	treatment	NN
cord-002240-38aabxh1	63	9	failure	failure	NN
cord-002240-38aabxh1	63	10	in	in	IN
cord-002240-38aabxh1	63	11	comparison	comparison	NN
cord-002240-38aabxh1	63	12	with	with	IN
cord-002240-38aabxh1	63	13	the	the	DT
cord-002240-38aabxh1	63	14	placebo	placebo	NN
cord-002240-38aabxh1	63	15	group	group	NN
cord-002240-38aabxh1	63	16	(	(	-LRB-
cord-002240-38aabxh1	63	17	13	13	CD
cord-002240-38aabxh1	63	18	versus	versus	IN
cord-002240-38aabxh1	63	19	31	31	CD
cord-002240-38aabxh1	63	20	%	%	NN
cord-002240-38aabxh1	63	21	,	,	,
cord-002240-38aabxh1	63	22	respectively	respectively	RB
cord-002240-38aabxh1	63	23	;	;	:
cord-002240-38aabxh1	63	24	p	p	NN
cord-002240-38aabxh1	63	25	=	=	SYM
cord-002240-38aabxh1	63	26	0.02	0.02	CD
cord-002240-38aabxh1	63	27	)	)	-RRB-
cord-002240-38aabxh1	63	28	.	.	.
cord-002240-38aabxh1	64	1	This	this	DT
cord-002240-38aabxh1	64	2	difference	difference	NN
cord-002240-38aabxh1	64	3	was	be	VBD
cord-002240-38aabxh1	64	4	due	due	JJ
cord-002240-38aabxh1	64	5	to	to	IN
cord-002240-38aabxh1	64	6	late	late	JJ
cord-002240-38aabxh1	64	7	treatment	treatment	NN
cord-002240-38aabxh1	64	8	failure	failure	NN
cord-002240-38aabxh1	64	9	(	(	-LRB-
cord-002240-38aabxh1	64	10	developing	develop	VBG
cord-002240-38aabxh1	64	11	between	between	IN
cord-002240-38aabxh1	64	12	72	72	CD
cord-002240-38aabxh1	64	13	and	and	CC
cord-002240-38aabxh1	64	14	120	120	CD
cord-002240-38aabxh1	64	15	h	h	NN
cord-002240-38aabxh1	64	16	after	after	IN
cord-002240-38aabxh1	64	17	treatment	treatment	NN
cord-002240-38aabxh1	64	18	initiation	initiation	NN
cord-002240-38aabxh1	64	19	)	)	-RRB-
cord-002240-38aabxh1	64	20	and	and	CC
cord-002240-38aabxh1	64	21	,	,	,
cord-002240-38aabxh1	64	22	in	in	IN
cord-002240-38aabxh1	64	23	particular	particular	JJ
cord-002240-38aabxh1	64	24	,	,	,
cord-002240-38aabxh1	64	25	patients	patient	NNS
cord-002240-38aabxh1	64	26	in	in	IN
cord-002240-38aabxh1	64	27	the	the	DT
cord-002240-38aabxh1	64	28	corticosteroid	corticosteroid	NNP
cord-002240-38aabxh1	64	29	group	group	NN
cord-002240-38aabxh1	64	30	showed	show	VBD
cord-002240-38aabxh1	64	31	a	a	DT
cord-002240-38aabxh1	64	32	more	more	RBR
cord-002240-38aabxh1	64	33	evident	evident	JJ
cord-002240-38aabxh1	64	34	effect	effect	NN
cord-002240-38aabxh1	64	35	on	on	IN
cord-002240-38aabxh1	64	36	the	the	DT
cord-002240-38aabxh1	64	37	reduction	reduction	NN
cord-002240-38aabxh1	64	38	of	of	IN
cord-002240-38aabxh1	64	39	radiological	radiological	JJ
cord-002240-38aabxh1	64	40	 	 	_SP
cord-002240-38aabxh1	64	41	Late	late	JJ
cord-002240-38aabxh1	64	42	failure	failure	NN
cord-002240-38aabxh1	64	43	(	(	-LRB-
cord-002240-38aabxh1	64	44	>	>	XX
cord-002240-38aabxh1	65	1	72	72	CD
cord-002240-38aabxh1	65	2	h	h	NN
cord-002240-38aabxh1	65	3	after	after	IN
cord-002240-38aabxh1	65	4	admission	admission	NN
cord-002240-38aabxh1	65	5	)	)	-RRB-
cord-002240-38aabxh1	65	6	was	be	VBD
cord-002240-38aabxh1	65	7	more	more	RBR
cord-002240-38aabxh1	65	8	common	common	JJ
cord-002240-38aabxh1	65	9	in	in	IN
cord-002240-38aabxh1	65	10	the	the	DT
cord-002240-38aabxh1	65	11	prednisolone	prednisolone	NNP
cord-002240-38aabxh1	65	12	group	group	NN
cord-002240-38aabxh1	65	13	than	than	IN
cord-002240-38aabxh1	65	14	in	in	IN
cord-002240-38aabxh1	65	15	the	the	DT
cord-002240-38aabxh1	65	16	placebo	placebo	NN
cord-002240-38aabxh1	65	17	group	group	NN
cord-002240-38aabxh1	65	18	(	(	-LRB-
cord-002240-38aabxh1	65	19	19.2	19.2	CD
cord-002240-38aabxh1	65	20	versus	versus	IN
cord-002240-38aabxh1	65	21	6.4	6.4	CD
cord-002240-38aabxh1	65	22	%	%	NN
cord-002240-38aabxh1	65	23	,	,	,
cord-002240-38aabxh1	65	24	respectively	respectively	RB
cord-002240-38aabxh1	65	25	;	;	:
cord-002240-38aabxh1	65	26	p	p	NN
cord-002240-38aabxh1	65	27	=	=	SYM
cord-002240-38aabxh1	65	28	0.04	0.04	CD
cord-002240-38aabxh1	65	29	)	)	-RRB-
cord-002240-38aabxh1	65	30	.	.	.
cord-002240-38aabxh1	66	1	Meijvis	Meijvis	NNP
cord-002240-38aabxh1	66	2	et	et	NNP
cord-002240-38aabxh1	66	3	al	al	NNP
cord-002240-38aabxh1	66	4	.	.	.
cord-002240-38aabxh1	67	1	2011	2011	CD
cord-002240-38aabxh1	68	1	[	[	-LRB-
cord-002240-38aabxh1	68	2	18	18	CD
cord-002240-38aabxh1	68	3	]	]	-RRB-
cord-002240-38aabxh1	68	4	Bicenter	Bicenter	NNP
cord-002240-38aabxh1	68	5	RCT	RCT	NNP
cord-002240-38aabxh1	68	6	in	in	IN
cord-002240-38aabxh1	68	7	Netherlands	Netherlands	NNP
cord-002240-38aabxh1	68	8	Reduction	Reduction	NNP
cord-002240-38aabxh1	68	9	in	in	IN
cord-002240-38aabxh1	68	10	length	length	NN
cord-002240-38aabxh1	68	11	of	of	IN
cord-002240-38aabxh1	68	12	stay	stay	NN
cord-002240-38aabxh1	68	13	in	in	IN
cord-002240-38aabxh1	68	14	dexamethasone	dexamethasone	NN
cord-002240-38aabxh1	68	15	group	group	NN
cord-002240-38aabxh1	68	16	compared	compare	VBN
cord-002240-38aabxh1	68	17	with	with	IN
cord-002240-38aabxh1	68	18	the	the	DT
cord-002240-38aabxh1	68	19	placebo	placebo	NN
cord-002240-38aabxh1	68	20	group	group	NN
cord-002240-38aabxh1	68	21	(	(	-LRB-
cord-002240-38aabxh1	68	22	6.5	6.5	CD
cord-002240-38aabxh1	68	23	versus	versus	IN
cord-002240-38aabxh1	68	24	7.5	7.5	CD
cord-002240-38aabxh1	68	25	days	day	NNS
cord-002240-38aabxh1	68	26	,	,	,
cord-002240-38aabxh1	68	27	respectively	respectively	RB
cord-002240-38aabxh1	68	28	;	;	:
cord-002240-38aabxh1	68	29	p	p	NN
cord-002240-38aabxh1	68	30	=	=	SYM
cord-002240-38aabxh1	68	31	0.048	0.048	CD
cord-002240-38aabxh1	68	32	)	)	-RRB-
cord-002240-38aabxh1	69	1	Dexamethasone	dexamethasone	NN
cord-002240-38aabxh1	69	2	versus	versus	IN
cord-002240-38aabxh1	69	3	placebo	placebo	NN
cord-002240-38aabxh1	69	4	Patients	patient	NNS
cord-002240-38aabxh1	69	5	with	with	IN
cord-002240-38aabxh1	69	6	CAP	CAP	NNP
cord-002240-38aabxh1	69	7	Chen	Chen	NNP
cord-002240-38aabxh1	69	8	et	et	FW
cord-002240-38aabxh1	69	9	al	al	NNP
cord-002240-38aabxh1	69	10	.	.	.
cord-002240-38aabxh1	70	1	2011	2011	CD
cord-002240-38aabxh1	71	1	[	[	-LRB-
cord-002240-38aabxh1	71	2	19	19	CD
cord-002240-38aabxh1	71	3	]	]	-RRB-
cord-002240-38aabxh1	71	4	Meta	Meta	NNP
cord-002240-38aabxh1	71	5	-	-	HYPH
cord-002240-38aabxh1	71	6	analysis	analysis	NN
cord-002240-38aabxh1	71	7	Accelerated	accelerate	VBD
cord-002240-38aabxh1	71	8	the	the	DT
cord-002240-38aabxh1	71	9	resolution	resolution	NN
cord-002240-38aabxh1	71	10	of	of	IN
cord-002240-38aabxh1	71	11	symptoms	symptom	NNS
cord-002240-38aabxh1	71	12	or	or	CC
cord-002240-38aabxh1	71	13	time	time	NN
cord-002240-38aabxh1	71	14	to	to	IN
cord-002240-38aabxh1	71	15	clinical	clinical	JJ
cord-002240-38aabxh1	71	16	stability	stability	NN
cord-002240-38aabxh1	71	17	and	and	CC
cord-002240-38aabxh1	71	18	decreased	decrease	VBD
cord-002240-38aabxh1	71	19	the	the	DT
cord-002240-38aabxh1	71	20	rate	rate	NN
cord-002240-38aabxh1	71	21	of	of	IN
cord-002240-38aabxh1	71	22	relapse	relapse	NN
cord-002240-38aabxh1	71	23	of	of	IN
cord-002240-38aabxh1	71	24	the	the	DT
cord-002240-38aabxh1	71	25	disease	disease	NN
cord-002240-38aabxh1	71	26	Patients	patient	NNS
cord-002240-38aabxh1	71	27	with	with	IN
cord-002240-38aabxh1	71	28	pneumonia	pneumonia	NN
cord-002240-38aabxh1	71	29	Nie	Nie	NNP
cord-002240-38aabxh1	71	30	et	et	NNP
cord-002240-38aabxh1	71	31	al	al	NNP
cord-002240-38aabxh1	71	32	.	.	.
cord-002240-38aabxh1	72	1	2012	2012	CD
cord-002240-38aabxh1	72	2	[	[	-LRB-
cord-002240-38aabxh1	72	3	20	20	CD
cord-002240-38aabxh1	72	4	]	]	-RRB-
cord-002240-38aabxh1	73	1	Meta	Meta	NNP
cord-002240-38aabxh1	73	2	-	-	HYPH
cord-002240-38aabxh1	73	3	analysis	analysis	NN
cord-002240-38aabxh1	73	4	Corticosteroids	Corticosteroids	NNPS
cord-002240-38aabxh1	73	5	did	do	VBD
cord-002240-38aabxh1	73	6	not	not	RB
cord-002240-38aabxh1	73	7	significantly	significantly	RB
cord-002240-38aabxh1	73	8	reduce	reduce	VB
cord-002240-38aabxh1	73	9	mortality	mortality	NN
cord-002240-38aabxh1	73	10	in	in	IN
cord-002240-38aabxh1	73	11	the	the	DT
cord-002240-38aabxh1	73	12	general	general	JJ
cord-002240-38aabxh1	73	13	population	population	NN
cord-002240-38aabxh1	73	14	(	(	-LRB-
cord-002240-38aabxh1	73	15	The	the	DT
cord-002240-38aabxh1	73	16	association	association	NN
cord-002240-38aabxh1	73	17	between	between	IN
cord-002240-38aabxh1	73	18	treatment	treatment	NN
cord-002240-38aabxh1	73	19	failure	failure	NN
cord-002240-38aabxh1	73	20	,	,	,
cord-002240-38aabxh1	73	21	with	with	IN
cord-002240-38aabxh1	73	22	radiographic	radiographic	JJ
cord-002240-38aabxh1	73	23	progression	progression	NN
cord-002240-38aabxh1	73	24	as	as	IN
cord-002240-38aabxh1	73	25	a	a	DT
cord-002240-38aabxh1	73	26	criterion	criterion	NN
cord-002240-38aabxh1	73	27	,	,	,
cord-002240-38aabxh1	73	28	and	and	CC
cord-002240-38aabxh1	73	29	mortality	mortality	NN
cord-002240-38aabxh1	73	30	has	have	VBZ
cord-002240-38aabxh1	73	31	been	be	VBN
cord-002240-38aabxh1	73	32	shown	show	VBN
cord-002240-38aabxh1	73	33	by	by	IN
cord-002240-38aabxh1	73	34	Menendez	Menendez	NNP
cord-002240-38aabxh1	73	35	et	et	NNP
cord-002240-38aabxh1	73	36	al	al	NNP
cord-002240-38aabxh1	73	37	.	.	.
cord-002240-38aabxh1	74	1	[	[	-LRB-
cord-002240-38aabxh1	74	2	5	5	CD
cord-002240-38aabxh1	74	3	]	]	-RRB-
cord-002240-38aabxh1	74	4	.	.	.
cord-002240-38aabxh1	75	1	The	the	DT
cord-002240-38aabxh1	75	2	protective	protective	JJ
cord-002240-38aabxh1	75	3	effect	effect	NN
cord-002240-38aabxh1	75	4	of	of	IN
cord-002240-38aabxh1	75	5	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	75	6	on	on	IN
cord-002240-38aabxh1	75	7	radiographic	radiographic	JJ
cord-002240-38aabxh1	75	8	progression	progression	NN
cord-002240-38aabxh1	75	9	could	could	MD
cord-002240-38aabxh1	75	10	be	be	VB
cord-002240-38aabxh1	75	11	interpreted	interpret	VBN
cord-002240-38aabxh1	75	12	as	as	IN
cord-002240-38aabxh1	75	13	an	an	DT
cord-002240-38aabxh1	75	14	effect	effect	NN
cord-002240-38aabxh1	75	15	preventing	prevent	VBG
cord-002240-38aabxh1	75	16	the	the	DT
cord-002240-38aabxh1	75	17	development	development	NN
cord-002240-38aabxh1	75	18	of	of	IN
cord-002240-38aabxh1	75	19	ARDS	ARDS	NNP
cord-002240-38aabxh1	75	20	or	or	CC
cord-002240-38aabxh1	75	21	blocking	block	VBG
cord-002240-38aabxh1	75	22	the	the	DT
cord-002240-38aabxh1	75	23	Jarisch	Jarisch	NNP
cord-002240-38aabxh1	75	24	-	-	HYPH
cord-002240-38aabxh1	75	25	Herxheimer	Herxheimer	NNP
cord-002240-38aabxh1	75	26	-	-	HYPH
cord-002240-38aabxh1	75	27	like	like	JJ
cord-002240-38aabxh1	75	28	reaction	reaction	NN
cord-002240-38aabxh1	75	29	[	[	-LRB-
cord-002240-38aabxh1	75	30	8	8	CD
cord-002240-38aabxh1	75	31	]	]	-RRB-
cord-002240-38aabxh1	75	32	.	.	.
cord-002240-38aabxh1	76	1	No	no	DT
cord-002240-38aabxh1	76	2	significant	significant	JJ
cord-002240-38aabxh1	76	3	difference	difference	NN
cord-002240-38aabxh1	76	4	was	be	VBD
cord-002240-38aabxh1	76	5	observed	observe	VBN
cord-002240-38aabxh1	76	6	in	in	IN
cord-002240-38aabxh1	76	7	mortality	mortality	NN
cord-002240-38aabxh1	76	8	between	between	IN
cord-002240-38aabxh1	76	9	the	the	DT
cord-002240-38aabxh1	76	10	two	two	CD
cord-002240-38aabxh1	76	11	groups	group	NNS
cord-002240-38aabxh1	76	12	(	(	-LRB-
cord-002240-38aabxh1	76	13	10	10	CD
cord-002240-38aabxh1	76	14	%	%	NN
cord-002240-38aabxh1	76	15	in	in	IN
cord-002240-38aabxh1	76	16	the	the	DT
cord-002240-38aabxh1	76	17	methylprednisolone	methylprednisolone	NNP
cord-002240-38aabxh1	76	18	arm	arm	NN
cord-002240-38aabxh1	76	19	versus	versus	IN
cord-002240-38aabxh1	76	20	15	15	CD
cord-002240-38aabxh1	76	21	%	%	NN
cord-002240-38aabxh1	76	22	in	in	IN
cord-002240-38aabxh1	76	23	the	the	DT
cord-002240-38aabxh1	76	24	placebo	placebo	NN
cord-002240-38aabxh1	76	25	arm	arm	NN
cord-002240-38aabxh1	76	26	;	;	:
cord-002240-38aabxh1	76	27	p	p	NN
cord-002240-38aabxh1	76	28	=	=	SYM
cord-002240-38aabxh1	76	29	0.37	0.37	CD
cord-002240-38aabxh1	76	30	)	)	-RRB-
cord-002240-38aabxh1	76	31	;	;	:
cord-002240-38aabxh1	76	32	however	however	RB
cord-002240-38aabxh1	76	33	,	,	,
cord-002240-38aabxh1	76	34	the	the	DT
cord-002240-38aabxh1	76	35	study	study	NN
cord-002240-38aabxh1	76	36	was	be	VBD
cord-002240-38aabxh1	76	37	not	not	RB
cord-002240-38aabxh1	76	38	powered	power	VBN
cord-002240-38aabxh1	76	39	for	for	IN
cord-002240-38aabxh1	76	40	mortality	mortality	NN
cord-002240-38aabxh1	76	41	as	as	IN
cord-002240-38aabxh1	76	42	this	this	DT
cord-002240-38aabxh1	76	43	was	be	VBD
cord-002240-38aabxh1	76	44	not	not	RB
cord-002240-38aabxh1	76	45	the	the	DT
cord-002240-38aabxh1	76	46	primary	primary	JJ
cord-002240-38aabxh1	76	47	outcome	outcome	NN
cord-002240-38aabxh1	76	48	.	.	.
cord-002240-38aabxh1	77	1	Importantly	importantly	RB
cord-002240-38aabxh1	77	2	,	,	,
cord-002240-38aabxh1	77	3	we	-PRON-	PRP
cord-002240-38aabxh1	77	4	detected	detect	VBD
cord-002240-38aabxh1	77	5	no	no	DT
cord-002240-38aabxh1	77	6	significant	significant	JJ
cord-002240-38aabxh1	77	7	side	side	NN
cord-002240-38aabxh1	77	8	effects	effect	NNS
cord-002240-38aabxh1	77	9	in	in	IN
cord-002240-38aabxh1	77	10	patients	patient	NNS
cord-002240-38aabxh1	77	11	receiving	receive	VBG
cord-002240-38aabxh1	77	12	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	77	13	.	.	.
cord-002240-38aabxh1	78	1	The	the	DT
cord-002240-38aabxh1	78	2	strength	strength	NN
cord-002240-38aabxh1	78	3	of	of	IN
cord-002240-38aabxh1	78	4	this	this	DT
cord-002240-38aabxh1	78	5	study	study	NN
cord-002240-38aabxh1	78	6	is	be	VBZ
cord-002240-38aabxh1	78	7	the	the	DT
cord-002240-38aabxh1	78	8	homogeneous	homogeneous	JJ
cord-002240-38aabxh1	78	9	population	population	NN
cord-002240-38aabxh1	78	10	with	with	IN
cord-002240-38aabxh1	78	11	severe	severe	JJ
cord-002240-38aabxh1	78	12	CAP	cap	NN
cord-002240-38aabxh1	78	13	and	and	CC
cord-002240-38aabxh1	78	14	a	a	DT
cord-002240-38aabxh1	78	15	strong	strong	JJ
cord-002240-38aabxh1	78	16	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	78	17	response	response	NN
cord-002240-38aabxh1	78	18	and	and	CC
cord-002240-38aabxh1	78	19	the	the	DT
cord-002240-38aabxh1	78	20	use	use	NN
cord-002240-38aabxh1	78	21	of	of	IN
cord-002240-38aabxh1	78	22	an	an	DT
cord-002240-38aabxh1	78	23	outcome	outcome	NN
cord-002240-38aabxh1	78	24	(	(	-LRB-
cord-002240-38aabxh1	78	25	treatment	treatment	NN
cord-002240-38aabxh1	78	26	failure	failure	NN
cord-002240-38aabxh1	78	27	)	)	-RRB-
cord-002240-38aabxh1	78	28	closely	closely	RB
cord-002240-38aabxh1	78	29	associated	associate	VBN
cord-002240-38aabxh1	78	30	with	with	IN
cord-002240-38aabxh1	78	31	mortality	mortality	NN
cord-002240-38aabxh1	78	32	[	[	-LRB-
cord-002240-38aabxh1	78	33	5	5	CD
cord-002240-38aabxh1	78	34	]	]	-RRB-
cord-002240-38aabxh1	78	35	.	.	.
cord-002240-38aabxh1	79	1	The	the	DT
cord-002240-38aabxh1	79	2	limitation	limitation	NN
cord-002240-38aabxh1	79	3	of	of	IN
cord-002240-38aabxh1	79	4	this	this	DT
cord-002240-38aabxh1	79	5	study	study	NN
cord-002240-38aabxh1	79	6	was	be	VBD
cord-002240-38aabxh1	79	7	the	the	DT
cord-002240-38aabxh1	79	8	prolonged	prolonged	JJ
cord-002240-38aabxh1	79	9	recruitment	recruitment	NN
cord-002240-38aabxh1	79	10	period	period	NN
cord-002240-38aabxh1	79	11	.	.	.
cord-002240-38aabxh1	80	1	In	in	IN
cord-002240-38aabxh1	80	2	Fig	Fig	NNP
cord-002240-38aabxh1	80	3	.	.	.
cord-002240-38aabxh1	81	1	1	1	LS
cord-002240-38aabxh1	82	1	we	-PRON-	PRP
cord-002240-38aabxh1	82	2	propose	propose	VBP
cord-002240-38aabxh1	82	3	a	a	DT
cord-002240-38aabxh1	82	4	flowchart	flowchart	NN
cord-002240-38aabxh1	82	5	for	for	IN
cord-002240-38aabxh1	82	6	the	the	DT
cord-002240-38aabxh1	82	7	management	management	NN
cord-002240-38aabxh1	82	8	of	of	IN
cord-002240-38aabxh1	82	9	patients	patient	NNS
cord-002240-38aabxh1	82	10	with	with	IN
cord-002240-38aabxh1	82	11	severe	severe	JJ
cord-002240-38aabxh1	82	12	CAP	cap	NN
cord-002240-38aabxh1	82	13	.	.	.
cord-002240-38aabxh1	83	1	A	a	DT
cord-002240-38aabxh1	83	2	recent	recent	JJ
cord-002240-38aabxh1	83	3	meta	meta	JJ
cord-002240-38aabxh1	83	4	-	-	HYPH
cord-002240-38aabxh1	83	5	analysis	analysis	NN
cord-002240-38aabxh1	83	6	[	[	-LRB-
cord-002240-38aabxh1	83	7	26	26	CD
cord-002240-38aabxh1	83	8	]	]	-RRB-
cord-002240-38aabxh1	83	9	including	include	VBG
cord-002240-38aabxh1	83	10	nine	nine	CD
cord-002240-38aabxh1	83	11	RCTs	RCTs	NNPS
cord-002240-38aabxh1	83	12	(	(	-LRB-
cord-002240-38aabxh1	83	13	1667	1667	CD
cord-002240-38aabxh1	83	14	patients	patient	NNS
cord-002240-38aabxh1	83	15	)	)	-RRB-
cord-002240-38aabxh1	83	16	and	and	CC
cord-002240-38aabxh1	83	17	six	six	CD
cord-002240-38aabxh1	83	18	cohort	cohort	NN
cord-002240-38aabxh1	83	19	studies	study	NNS
cord-002240-38aabxh1	83	20	(	(	-LRB-
cord-002240-38aabxh1	83	21	4095	4095	CD
cord-002240-38aabxh1	83	22	patients	patient	NNS
cord-002240-38aabxh1	83	23	)	)	-RRB-
cord-002240-38aabxh1	83	24	showed	show	VBD
cord-002240-38aabxh1	83	25	that	that	IN
cord-002240-38aabxh1	83	26	the	the	DT
cord-002240-38aabxh1	83	27	use	use	NN
cord-002240-38aabxh1	83	28	of	of	IN
cord-002240-38aabxh1	83	29	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	83	30	is	be	VBZ
cord-002240-38aabxh1	83	31	not	not	RB
cord-002240-38aabxh1	83	32	associated	associate	VBN
cord-002240-38aabxh1	83	33	with	with	IN
cord-002240-38aabxh1	83	34	a	a	DT
cord-002240-38aabxh1	83	35	significant	significant	JJ
cord-002240-38aabxh1	83	36	reduction	reduction	NN
cord-002240-38aabxh1	83	37	in	in	IN
cord-002240-38aabxh1	83	38	mortality	mortality	NN
cord-002240-38aabxh1	83	39	in	in	IN
cord-002240-38aabxh1	83	40	patients	patient	NNS
cord-002240-38aabxh1	83	41	with	with	IN
cord-002240-38aabxh1	83	42	CAP	cap	NN
cord-002240-38aabxh1	83	43	(	(	-LRB-
cord-002240-38aabxh1	83	44	risk	risk	NN
cord-002240-38aabxh1	83	45	ratio	ratio	NN
cord-002240-38aabxh1	83	46	(	(	-LRB-
cord-002240-38aabxh1	83	47	RR	rr	NN
cord-002240-38aabxh1	83	48	)	)	-RRB-
cord-002240-38aabxh1	83	49	0.72	0.72	CD
cord-002240-38aabxh1	83	50	;	;	:
cord-002240-38aabxh1	83	51	95	95	CD
cord-002240-38aabxh1	83	52	%	%	NN
cord-002240-38aabxh1	83	53	CI	CI	NNP
cord-002240-38aabxh1	83	54	0.43	0.43	CD
cord-002240-38aabxh1	83	55	-	-	HYPH
cord-002240-38aabxh1	83	56	1.21	1.21	CD
cord-002240-38aabxh1	83	57	;	;	:
cord-002240-38aabxh1	83	58	evidence	evidence	NN
cord-002240-38aabxh1	83	59	rank	rank	NN
cord-002240-38aabxh1	83	60	low	low	NN
cord-002240-38aabxh1	83	61	)	)	-RRB-
cord-002240-38aabxh1	83	62	or	or	CC
cord-002240-38aabxh1	83	63	in	in	IN
cord-002240-38aabxh1	83	64	the	the	DT
cord-002240-38aabxh1	83	65	subgroup	subgroup	NN
cord-002240-38aabxh1	83	66	of	of	IN
cord-002240-38aabxh1	83	67	patients	patient	NNS
cord-002240-38aabxh1	83	68	with	with	IN
cord-002240-38aabxh1	83	69	severe	severe	JJ
cord-002240-38aabxh1	83	70	CAP	cap	NN
cord-002240-38aabxh1	83	71	(	(	-LRB-
cord-002240-38aabxh1	83	72	RCT	RCT	NNP
cord-002240-38aabxh1	83	73	RR	RR	NNP
cord-002240-38aabxh1	83	74	0.72	0.72	CD
cord-002240-38aabxh1	83	75	,	,	,
cord-002240-38aabxh1	83	76	95	95	CD
cord-002240-38aabxh1	83	77	%	%	NN
cord-002240-38aabxh1	83	78	CI	CI	NNP
cord-002240-38aabxh1	83	79	0.43	0.43	CD
cord-002240-38aabxh1	83	80	-	-	HYPH
cord-002240-38aabxh1	83	81	1.21	1.21	CD
cord-002240-38aabxh1	83	82	,	,	,
cord-002240-38aabxh1	83	83	evidence	evidence	NN
cord-002240-38aabxh1	83	84	rank	rank	NN
cord-002240-38aabxh1	83	85	low	low	RB
cord-002240-38aabxh1	84	1	;	;	:
cord-002240-38aabxh1	84	2	cohort	cohort	NN
cord-002240-38aabxh1	84	3	study	study	NN
cord-002240-38aabxh1	84	4	RR	RR	NNP
cord-002240-38aabxh1	84	5	1.00	1.00	CD
cord-002240-38aabxh1	84	6	,	,	,
cord-002240-38aabxh1	85	1	95	95	CD
cord-002240-38aabxh1	85	2	%	%	NN
cord-002240-38aabxh1	85	3	CI	CI	NNP
cord-002240-38aabxh1	85	4	0.86	0.86	CD
cord-002240-38aabxh1	85	5	-	-	HYPH
cord-002240-38aabxh1	85	6	1.17	1.17	CD
cord-002240-38aabxh1	85	7	)	)	-RRB-
cord-002240-38aabxh1	85	8	.	.	.
cord-002240-38aabxh1	86	1	However	however	RB
cord-002240-38aabxh1	86	2	,	,	,
cord-002240-38aabxh1	86	3	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	86	4	produced	produce	VBD
cord-002240-38aabxh1	86	5	a	a	DT
cord-002240-38aabxh1	86	6	benefit	benefit	NN
cord-002240-38aabxh1	86	7	in	in	IN
cord-002240-38aabxh1	86	8	terms	term	NNS
cord-002240-38aabxh1	86	9	of	of	IN
cord-002240-38aabxh1	86	10	reduction	reduction	NN
cord-002240-38aabxh1	86	11	of	of	IN
cord-002240-38aabxh1	86	12	ARDS	ARDS	NNP
cord-002240-38aabxh1	86	13	(	(	-LRB-
cord-002240-38aabxh1	86	14	RR	RR	NNP
cord-002240-38aabxh1	86	15	0.21	0.21	CD
cord-002240-38aabxh1	86	16	,	,	,
cord-002240-38aabxh1	86	17	95	95	CD
cord-002240-38aabxh1	86	18	%	%	NN
cord-002240-38aabxh1	86	19	CI	CI	NNP
cord-002240-38aabxh1	86	20	0.08	0.08	CD
cord-002240-38aabxh1	86	21	-	-	HYPH
cord-002240-38aabxh1	86	22	0.59	0.59	CD
cord-002240-38aabxh1	86	23	)	)	-RRB-
cord-002240-38aabxh1	86	24	,	,	,
cord-002240-38aabxh1	86	25	length	length	NN
cord-002240-38aabxh1	86	26	of	of	IN
cord-002240-38aabxh1	86	27	hospital	hospital	NN
cord-002240-38aabxh1	86	28	and	and	CC
cord-002240-38aabxh1	86	29	ICU	ICU	NNP
cord-002240-38aabxh1	86	30	stay	stay	VBP
cord-002240-38aabxh1	86	31	,	,	,
cord-002240-38aabxh1	86	32	duration	duration	NN
cord-002240-38aabxh1	86	33	of	of	IN
cord-002240-38aabxh1	86	34	IV	IV	NNP
cord-002240-38aabxh1	86	35	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	86	36	,	,	,
cord-002240-38aabxh1	86	37	and	and	CC
cord-002240-38aabxh1	86	38	time	time	NN
cord-002240-38aabxh1	86	39	to	to	IN
cord-002240-38aabxh1	86	40	clinical	clinical	JJ
cord-002240-38aabxh1	86	41	stability	stability	NN
cord-002240-38aabxh1	86	42	without	without	IN
cord-002240-38aabxh1	86	43	a	a	DT
cord-002240-38aabxh1	86	44	significant	significant	JJ
cord-002240-38aabxh1	86	45	increase	increase	NN
cord-002240-38aabxh1	86	46	in	in	IN
cord-002240-38aabxh1	86	47	side	side	NN
cord-002240-38aabxh1	86	48	effects	effect	NNS
cord-002240-38aabxh1	86	49	.	.	.
cord-002240-38aabxh1	87	1	In	in	IN
cord-002240-38aabxh1	87	2	contrast	contrast	NN
cord-002240-38aabxh1	87	3	,	,	,
cord-002240-38aabxh1	87	4	another	another	DT
cord-002240-38aabxh1	87	5	meta	meta	JJ
cord-002240-38aabxh1	87	6	-	-	HYPH
cord-002240-38aabxh1	87	7	analysis	analysis	NN
cord-002240-38aabxh1	87	8	[	[	-LRB-
cord-002240-38aabxh1	87	9	25	25	CD
cord-002240-38aabxh1	87	10	]	]	-RRB-
cord-002240-38aabxh1	87	11	demonstrated	demonstrate	VBD
cord-002240-38aabxh1	87	12	a	a	DT
cord-002240-38aabxh1	87	13	reduction	reduction	NN
cord-002240-38aabxh1	87	14	in	in	IN
cord-002240-38aabxh1	87	15	all	all	DT
cord-002240-38aabxh1	87	16	causes	cause	NNS
cord-002240-38aabxh1	87	17	of	of	IN
cord-002240-38aabxh1	87	18	mortality	mortality	NN
cord-002240-38aabxh1	87	19	in	in	IN
cord-002240-38aabxh1	87	20	patients	patient	NNS
cord-002240-38aabxh1	87	21	receiving	receive	VBG
cord-002240-38aabxh1	87	22	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	87	23	(	(	-LRB-
cord-002240-38aabxh1	87	24	12	12	CD
cord-002240-38aabxh1	87	25	trials	trial	NNS
cord-002240-38aabxh1	87	26	,	,	,
cord-002240-38aabxh1	87	27	1974	1974	CD
cord-002240-38aabxh1	88	1	In	in	IN
cord-002240-38aabxh1	88	2	conclusion	conclusion	NN
cord-002240-38aabxh1	88	3	,	,	,
cord-002240-38aabxh1	88	4	all	all	PDT
cord-002240-38aabxh1	88	5	these	these	DT
cord-002240-38aabxh1	88	6	studies	study	NNS
cord-002240-38aabxh1	88	7	confirm	confirm	VBP
cord-002240-38aabxh1	88	8	that	that	IN
cord-002240-38aabxh1	88	9	the	the	DT
cord-002240-38aabxh1	88	10	use	use	NN
cord-002240-38aabxh1	88	11	of	of	IN
cord-002240-38aabxh1	88	12	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	88	13	in	in	IN
cord-002240-38aabxh1	88	14	CAP	CAP	NNP
cord-002240-38aabxh1	88	15	is	be	VBZ
cord-002240-38aabxh1	88	16	associated	associate	VBN
cord-002240-38aabxh1	88	17	with	with	IN
cord-002240-38aabxh1	88	18	the	the	DT
cord-002240-38aabxh1	88	19	following	follow	VBG
cord-002240-38aabxh1	88	20	benefits	benefit	NNS
cord-002240-38aabxh1	88	21	:	:	:
cord-002240-38aabxh1	88	22	reduced	reduce	VBN
cord-002240-38aabxh1	88	23	length	length	NN
cord-002240-38aabxh1	88	24	of	of	IN
cord-002240-38aabxh1	88	25	hospital	hospital	NN
cord-002240-38aabxh1	88	26	stay	stay	NN
cord-002240-38aabxh1	88	27	,	,	,
cord-002240-38aabxh1	88	28	reduced	reduce	VBN
cord-002240-38aabxh1	88	29	time	time	NN
cord-002240-38aabxh1	88	30	to	to	IN
cord-002240-38aabxh1	88	31	clinical	clinical	JJ
cord-002240-38aabxh1	88	32	stability	stability	NN
cord-002240-38aabxh1	88	33	,	,	,
cord-002240-38aabxh1	88	34	and	and	CC
cord-002240-38aabxh1	88	35	prevention	prevention	NN
cord-002240-38aabxh1	88	36	of	of	IN
cord-002240-38aabxh1	88	37	ARDS	ARDS	NNP
cord-002240-38aabxh1	88	38	.	.	.
cord-002240-38aabxh1	89	1	No	no	DT
cord-002240-38aabxh1	89	2	definitive	definitive	JJ
cord-002240-38aabxh1	89	3	answer	answer	NN
cord-002240-38aabxh1	89	4	is	be	VBZ
cord-002240-38aabxh1	89	5	available	available	JJ
cord-002240-38aabxh1	89	6	yet	yet	RB
cord-002240-38aabxh1	89	7	regarding	regard	VBG
cord-002240-38aabxh1	89	8	the	the	DT
cord-002240-38aabxh1	89	9	effect	effect	NN
cord-002240-38aabxh1	89	10	of	of	IN
cord-002240-38aabxh1	89	11	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	89	12	on	on	IN
cord-002240-38aabxh1	89	13	the	the	DT
cord-002240-38aabxh1	89	14	reduction	reduction	NN
cord-002240-38aabxh1	89	15	of	of	IN
cord-002240-38aabxh1	89	16	death	death	NN
cord-002240-38aabxh1	89	17	and	and	CC
cord-002240-38aabxh1	89	18	larger	large	JJR
cord-002240-38aabxh1	89	19	studies	study	NNS
cord-002240-38aabxh1	89	20	are	be	VBP
cord-002240-38aabxh1	89	21	needed	need	VBN
cord-002240-38aabxh1	89	22	to	to	TO
cord-002240-38aabxh1	89	23	define	define	VB
cord-002240-38aabxh1	89	24	the	the	DT
cord-002240-38aabxh1	89	25	effect	effect	NN
cord-002240-38aabxh1	89	26	on	on	IN
cord-002240-38aabxh1	89	27	mortality	mortality	NN
cord-002240-38aabxh1	89	28	.	.	.
cord-002240-38aabxh1	90	1	In	in	IN
cord-002240-38aabxh1	90	2	particular	particular	JJ
cord-002240-38aabxh1	90	3	,	,	,
cord-002240-38aabxh1	90	4	some	some	DT
cord-002240-38aabxh1	90	5	meta	meta	NNP
cord-002240-38aabxh1	90	6	-	-	HYPH
cord-002240-38aabxh1	90	7	analyses	analysis	NNS
cord-002240-38aabxh1	90	8	suggested	suggest	VBD
cord-002240-38aabxh1	90	9	that	that	IN
cord-002240-38aabxh1	90	10	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	90	11	may	may	MD
cord-002240-38aabxh1	90	12	decrease	decrease	VB
cord-002240-38aabxh1	90	13	mortality	mortality	NN
cord-002240-38aabxh1	90	14	in	in	IN
cord-002240-38aabxh1	90	15	the	the	DT
cord-002240-38aabxh1	90	16	subgroup	subgroup	NN
cord-002240-38aabxh1	90	17	of	of	IN
cord-002240-38aabxh1	90	18	patients	patient	NNS
cord-002240-38aabxh1	90	19	with	with	IN
cord-002240-38aabxh1	90	20	severe	severe	JJ
cord-002240-38aabxh1	90	21	CAP	cap	NN
cord-002240-38aabxh1	90	22	;	;	:
cord-002240-38aabxh1	90	23	however	however	RB
cord-002240-38aabxh1	90	24	,	,	,
cord-002240-38aabxh1	90	25	these	these	DT
cord-002240-38aabxh1	90	26	data	datum	NNS
cord-002240-38aabxh1	90	27	have	have	VBP
cord-002240-38aabxh1	90	28	not	not	RB
cord-002240-38aabxh1	90	29	been	be	VBN
cord-002240-38aabxh1	90	30	confirmed	confirm	VBN
cord-002240-38aabxh1	90	31	in	in	IN
cord-002240-38aabxh1	90	32	other	other	JJ
cord-002240-38aabxh1	90	33	studies	study	NNS
cord-002240-38aabxh1	90	34	.	.	.
cord-002240-38aabxh1	91	1	The	the	DT
cord-002240-38aabxh1	91	2	effects	effect	NNS
cord-002240-38aabxh1	91	3	of	of	IN
cord-002240-38aabxh1	91	4	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	91	5	in	in	IN
cord-002240-38aabxh1	91	6	some	some	DT
cord-002240-38aabxh1	91	7	specific	specific	JJ
cord-002240-38aabxh1	91	8	infections	infection	NNS
cord-002240-38aabxh1	91	9	are	be	VBP
cord-002240-38aabxh1	91	10	the	the	DT
cord-002240-38aabxh1	91	11	subject	subject	NN
cord-002240-38aabxh1	91	12	of	of	IN
cord-002240-38aabxh1	91	13	debate	debate	NN
cord-002240-38aabxh1	91	14	.	.	.
cord-002240-38aabxh1	92	1	For	for	IN
cord-002240-38aabxh1	92	2	example	example	NN
cord-002240-38aabxh1	92	3	,	,	,
cord-002240-38aabxh1	92	4	a	a	DT
cord-002240-38aabxh1	92	5	meta	meta	JJ
cord-002240-38aabxh1	92	6	-	-	HYPH
cord-002240-38aabxh1	92	7	analysis	analysis	NN
cord-002240-38aabxh1	92	8	showed	show	VBD
cord-002240-38aabxh1	92	9	a	a	DT
cord-002240-38aabxh1	92	10	benefit	benefit	NN
cord-002240-38aabxh1	92	11	in	in	IN
cord-002240-38aabxh1	92	12	Pneumocystic	pneumocystic	JJ
cord-002240-38aabxh1	92	13	jiroveci	jiroveci	NN
cord-002240-38aabxh1	92	14	pneumonia	pneumonia	NN
cord-002240-38aabxh1	92	15	[	[	-LRB-
cord-002240-38aabxh1	92	16	28	28	CD
cord-002240-38aabxh1	92	17	]	]	-RRB-
cord-002240-38aabxh1	92	18	,	,	,
cord-002240-38aabxh1	92	19	although	although	IN
cord-002240-38aabxh1	92	20	this	this	DT
cord-002240-38aabxh1	92	21	result	result	NN
cord-002240-38aabxh1	92	22	came	come	VBD
cord-002240-38aabxh1	92	23	from	from	IN
cord-002240-38aabxh1	92	24	small	small	JJ
cord-002240-38aabxh1	92	25	RCTs	rct	NNS
cord-002240-38aabxh1	92	26	.	.	.
cord-002240-38aabxh1	93	1	In	in	IN
cord-002240-38aabxh1	93	2	patients	patient	NNS
cord-002240-38aabxh1	93	3	with	with	IN
cord-002240-38aabxh1	93	4	CAP	cap	NN
cord-002240-38aabxh1	93	5	due	due	IN
cord-002240-38aabxh1	93	6	to	to	IN
cord-002240-38aabxh1	93	7	viral	viral	JJ
cord-002240-38aabxh1	93	8	infection	infection	NN
cord-002240-38aabxh1	93	9	,	,	,
cord-002240-38aabxh1	93	10	the	the	DT
cord-002240-38aabxh1	93	11	effects	effect	NNS
cord-002240-38aabxh1	93	12	of	of	IN
cord-002240-38aabxh1	93	13	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	93	14	are	be	VBP
cord-002240-38aabxh1	93	15	still	still	RB
cord-002240-38aabxh1	93	16	not	not	RB
cord-002240-38aabxh1	93	17	clear	clear	JJ
cord-002240-38aabxh1	93	18	.	.	.
cord-002240-38aabxh1	94	1	In	in	IN
cord-002240-38aabxh1	94	2	H1N1	H1N1	NNP
cord-002240-38aabxh1	94	3	infection	infection	NN
cord-002240-38aabxh1	94	4	,	,	,
cord-002240-38aabxh1	94	5	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	94	6	use	use	NN
cord-002240-38aabxh1	94	7	was	be	VBD
cord-002240-38aabxh1	94	8	associated	associate	VBN
cord-002240-38aabxh1	94	9	with	with	IN
cord-002240-38aabxh1	94	10	a	a	DT
cord-002240-38aabxh1	94	11	higher	high	JJR
cord-002240-38aabxh1	94	12	incidence	incidence	NN
cord-002240-38aabxh1	94	13	of	of	IN
cord-002240-38aabxh1	94	14	pneumonia	pneumonia	NN
cord-002240-38aabxh1	94	15	and	and	CC
cord-002240-38aabxh1	94	16	mortality	mortality	NN
cord-002240-38aabxh1	94	17	.	.	.
cord-002240-38aabxh1	95	1	In	in	IN
cord-002240-38aabxh1	95	2	a	a	DT
cord-002240-38aabxh1	95	3	Chinese	chinese	JJ
cord-002240-38aabxh1	95	4	descriptive	descriptive	JJ
cord-002240-38aabxh1	95	5	study	study	NN
cord-002240-38aabxh1	95	6	of	of	IN
cord-002240-38aabxh1	95	7	influenza	influenza	NN
cord-002240-38aabxh1	95	8	A	A	NNP
cord-002240-38aabxh1	95	9	(	(	-LRB-
cord-002240-38aabxh1	95	10	H7N9	H7N9	NNP
cord-002240-38aabxh1	95	11	)	)	-RRB-
cord-002240-38aabxh1	95	12	viral	viral	JJ
cord-002240-38aabxh1	95	13	pneumonia	pneumonia	NN
cord-002240-38aabxh1	95	14	,	,	,
cord-002240-38aabxh1	95	15	the	the	DT
cord-002240-38aabxh1	95	16	subgroup	subgroup	NN
cord-002240-38aabxh1	95	17	of	of	IN
cord-002240-38aabxh1	95	18	patients	patient	NNS
cord-002240-38aabxh1	95	19	receiving	receive	VBG
cord-002240-38aabxh1	95	20	very	very	RB
cord-002240-38aabxh1	95	21	high	high	JJ
cord-002240-38aabxh1	95	22	doses	dose	NNS
cord-002240-38aabxh1	95	23	of	of	IN
cord-002240-38aabxh1	95	24	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	95	25	(	(	-LRB-
cord-002240-38aabxh1	95	26	>	>	VBZ
cord-002240-38aabxh1	95	27	150	150	CD
cord-002240-38aabxh1	95	28	mg	mg	NNP
cord-002240-38aabxh1	95	29	/	/	SYM
cord-002240-38aabxh1	95	30	d	d	NN
cord-002240-38aabxh1	95	31	methylprednisolone	methylprednisolone	NN
cord-002240-38aabxh1	95	32	or	or	CC
cord-002240-38aabxh1	95	33	equivalent	equivalent	NN
cord-002240-38aabxh1	95	34	)	)	-RRB-
cord-002240-38aabxh1	95	35	had	have	VBD
cord-002240-38aabxh1	95	36	increased	increase	VBN
cord-002240-38aabxh1	95	37	mortality	mortality	NN
cord-002240-38aabxh1	95	38	but	but	CC
cord-002240-38aabxh1	95	39	no	no	DT
cord-002240-38aabxh1	95	40	significantly	significantly	RB
cord-002240-38aabxh1	95	41	worse	bad	JJR
cord-002240-38aabxh1	95	42	outcome	outcome	NN
cord-002240-38aabxh1	95	43	was	be	VBD
cord-002240-38aabxh1	95	44	detected	detect	VBN
cord-002240-38aabxh1	95	45	with	with	IN
cord-002240-38aabxh1	95	46	low	low	JJ
cord-002240-38aabxh1	95	47	to	to	IN
cord-002240-38aabxh1	95	48	moderate	moderate	JJ
cord-002240-38aabxh1	95	49	doses	dose	NNS
cord-002240-38aabxh1	95	50	of	of	IN
cord-002240-38aabxh1	95	51	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	95	52	(	(	-LRB-
cord-002240-38aabxh1	95	53	25	25	CD
cord-002240-38aabxh1	95	54	-	-	SYM
cord-002240-38aabxh1	95	55	150	150	CD
cord-002240-38aabxh1	95	56	mg	mg	NNP
cord-002240-38aabxh1	95	57	/	/	SYM
cord-002240-38aabxh1	95	58	d	d	NN
cord-002240-38aabxh1	95	59	methylprednisolone	methylprednisolone	NN
cord-002240-38aabxh1	95	60	or	or	CC
cord-002240-38aabxh1	95	61	equivalent	equivalent	JJ
cord-002240-38aabxh1	95	62	)	)	-RRB-
cord-002240-38aabxh1	95	63	[	[	-LRB-
cord-002240-38aabxh1	95	64	29	29	CD
cord-002240-38aabxh1	95	65	]	]	-RRB-
cord-002240-38aabxh1	95	66	.	.	.
cord-002240-38aabxh1	96	1	A	a	DT
cord-002240-38aabxh1	96	2	recent	recent	JJ
cord-002240-38aabxh1	96	3	meta	meta	JJ
cord-002240-38aabxh1	96	4	-	-	HYPH
cord-002240-38aabxh1	96	5	analysis	analysis	NN
cord-002240-38aabxh1	96	6	by	by	IN
cord-002240-38aabxh1	96	7	Cochrane	Cochrane	NNP
cord-002240-38aabxh1	96	8	[	[	-LRB-
cord-002240-38aabxh1	96	9	30	30	CD
cord-002240-38aabxh1	96	10	]	]	-RRB-
cord-002240-38aabxh1	96	11	of	of	IN
cord-002240-38aabxh1	96	12	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	96	13	as	as	IN
cord-002240-38aabxh1	96	14	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	96	15	treatment	treatment	NN
cord-002240-38aabxh1	96	16	in	in	IN
cord-002240-38aabxh1	96	17	influenza	influenza	NN
cord-002240-38aabxh1	96	18	found	find	VBD
cord-002240-38aabxh1	96	19	insufficient	insufficient	JJ
cord-002240-38aabxh1	96	20	evidence	evidence	NN
cord-002240-38aabxh1	96	21	to	to	TO
cord-002240-38aabxh1	96	22	determine	determine	VB
cord-002240-38aabxh1	96	23	the	the	DT
cord-002240-38aabxh1	96	24	efficacy	efficacy	NN
cord-002240-38aabxh1	96	25	of	of	IN
cord-002240-38aabxh1	96	26	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	96	27	in	in	IN
cord-002240-38aabxh1	96	28	these	these	DT
cord-002240-38aabxh1	96	29	patients	patient	NNS
cord-002240-38aabxh1	96	30	.	.	.
cord-002240-38aabxh1	97	1	Delaney	Delaney	NNP
cord-002240-38aabxh1	97	2	et	et	NNP
cord-002240-38aabxh1	97	3	al	al	NNP
cord-002240-38aabxh1	97	4	.	.	.
cord-002240-38aabxh1	98	1	[	[	-LRB-
cord-002240-38aabxh1	98	2	31	31	CD
cord-002240-38aabxh1	98	3	]	]	-RRB-
cord-002240-38aabxh1	98	4	recently	recently	RB
cord-002240-38aabxh1	98	5	published	publish	VBD
cord-002240-38aabxh1	98	6	an	an	DT
cord-002240-38aabxh1	98	7	observational	observational	JJ
cord-002240-38aabxh1	98	8	multicenter	multicenter	JJ
cord-002240-38aabxh1	98	9	study	study	NN
cord-002240-38aabxh1	98	10	of	of	IN
cord-002240-38aabxh1	98	11	patients	patient	NNS
cord-002240-38aabxh1	98	12	with	with	IN
cord-002240-38aabxh1	98	13	influenza	influenza	NN
cord-002240-38aabxh1	98	14	A	a	NN
cord-002240-38aabxh1	98	15	(	(	-LRB-
cord-002240-38aabxh1	98	16	H1N1pdm09)-related	H1N1pdm09)-related	NNP
cord-002240-38aabxh1	98	17	critical	critical	JJ
cord-002240-38aabxh1	98	18	illness	illness	NN
cord-002240-38aabxh1	98	19	.	.	.
cord-002240-38aabxh1	99	1	The	the	DT
cord-002240-38aabxh1	99	2	crude	crude	JJ
cord-002240-38aabxh1	99	3	hospital	hospital	NN
cord-002240-38aabxh1	99	4	mortality	mortality	NN
cord-002240-38aabxh1	99	5	was	be	VBD
cord-002240-38aabxh1	99	6	higher	high	JJR
cord-002240-38aabxh1	99	7	in	in	IN
cord-002240-38aabxh1	99	8	patients	patient	NNS
cord-002240-38aabxh1	99	9	who	who	WP
cord-002240-38aabxh1	99	10	received	receive	VBD
cord-002240-38aabxh1	99	11	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	99	12	compared	compare	VBN
cord-002240-38aabxh1	99	13	with	with	IN
cord-002240-38aabxh1	99	14	patients	patient	NNS
cord-002240-38aabxh1	99	15	without	without	IN
cord-002240-38aabxh1	99	16	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	99	17	treatment	treatment	NN
cord-002240-38aabxh1	99	18	(	(	-LRB-
cord-002240-38aabxh1	99	19	25.5	25.5	CD
cord-002240-38aabxh1	99	20	versus	versus	IN
cord-002240-38aabxh1	99	21	16.4	16.4	CD
cord-002240-38aabxh1	99	22	%	%	NN
cord-002240-38aabxh1	99	23	,	,	,
cord-002240-38aabxh1	99	24	p	p	NN
cord-002240-38aabxh1	99	25	=	=	SYM
cord-002240-38aabxh1	99	26	0.007	0.007	CD
cord-002240-38aabxh1	99	27	)	)	-RRB-
cord-002240-38aabxh1	99	28	.	.	.
cord-002240-38aabxh1	100	1	Nevertheless	nevertheless	RB
cord-002240-38aabxh1	100	2	,	,	,
cord-002240-38aabxh1	100	3	after	after	IN
cord-002240-38aabxh1	100	4	adjusting	adjust	VBG
cord-002240-38aabxh1	100	5	for	for	IN
cord-002240-38aabxh1	100	6	potential	potential	JJ
cord-002240-38aabxh1	100	7	confounders	confounder	NNS
cord-002240-38aabxh1	100	8	,	,	,
cord-002240-38aabxh1	100	9	the	the	DT
cord-002240-38aabxh1	100	10	authors	author	NNS
cord-002240-38aabxh1	100	11	did	do	VBD
cord-002240-38aabxh1	100	12	not	not	RB
cord-002240-38aabxh1	100	13	find	find	VB
cord-002240-38aabxh1	100	14	a	a	DT
cord-002240-38aabxh1	100	15	significant	significant	JJ
cord-002240-38aabxh1	100	16	association	association	NN
cord-002240-38aabxh1	100	17	between	between	IN
cord-002240-38aabxh1	100	18	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	100	19	and	and	CC
cord-002240-38aabxh1	100	20	mortality	mortality	NN
cord-002240-38aabxh1	100	21	in	in	IN
cord-002240-38aabxh1	100	22	this	this	DT
cord-002240-38aabxh1	100	23	population	population	NN
cord-002240-38aabxh1	100	24	.	.	.
cord-002240-38aabxh1	101	1	It	-PRON-	PRP
cord-002240-38aabxh1	101	2	appears	appear	VBZ
cord-002240-38aabxh1	101	3	that	that	IN
cord-002240-38aabxh1	101	4	the	the	DT
cord-002240-38aabxh1	101	5	use	use	NN
cord-002240-38aabxh1	101	6	of	of	IN
cord-002240-38aabxh1	101	7	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	101	8	was	be	VBD
cord-002240-38aabxh1	101	9	associated	associate	VBN
cord-002240-38aabxh1	101	10	with	with	IN
cord-002240-38aabxh1	101	11	a	a	DT
cord-002240-38aabxh1	101	12	higher	high	JJR
cord-002240-38aabxh1	101	13	mortality	mortality	NN
cord-002240-38aabxh1	101	14	but	but	CC
cord-002240-38aabxh1	101	15	this	this	DT
cord-002240-38aabxh1	101	16	result	result	NN
cord-002240-38aabxh1	101	17	has	have	VBZ
cord-002240-38aabxh1	101	18	to	to	TO
cord-002240-38aabxh1	101	19	be	be	VB
cord-002240-38aabxh1	101	20	carefully	carefully	RB
cord-002240-38aabxh1	101	21	interpreted	interpret	VBN
cord-002240-38aabxh1	101	22	because	because	IN
cord-002240-38aabxh1	101	23	only	only	JJ
cord-002240-38aabxh1	101	24	observational	observational	JJ
cord-002240-38aabxh1	101	25	studies	study	NNS
cord-002240-38aabxh1	101	26	of	of	IN
cord-002240-38aabxh1	101	27	low	low	JJ
cord-002240-38aabxh1	101	28	quality	quality	NN
cord-002240-38aabxh1	101	29	were	be	VBD
cord-002240-38aabxh1	101	30	included	include	VBN
cord-002240-38aabxh1	101	31	and	and	CC
cord-002240-38aabxh1	101	32	RTCs	rtc	NNS
cord-002240-38aabxh1	101	33	were	be	VBD
cord-002240-38aabxh1	101	34	not	not	RB
cord-002240-38aabxh1	101	35	identified	identify	VBN
cord-002240-38aabxh1	101	36	for	for	IN
cord-002240-38aabxh1	101	37	the	the	DT
cord-002240-38aabxh1	101	38	analysis	analysis	NN
cord-002240-38aabxh1	101	39	.	.	.
cord-002240-38aabxh1	102	1	More	More	JJR
cord-002240-38aabxh1	102	2	studies	study	NNS
cord-002240-38aabxh1	102	3	are	be	VBP
cord-002240-38aabxh1	102	4	needed	need	VBN
cord-002240-38aabxh1	102	5	to	to	TO
cord-002240-38aabxh1	102	6	clarify	clarify	VB
cord-002240-38aabxh1	102	7	this	this	DT
cord-002240-38aabxh1	102	8	point	point	NN
cord-002240-38aabxh1	102	9	.	.	.
cord-002240-38aabxh1	103	1	The	the	DT
cord-002240-38aabxh1	103	2	main	main	JJ
cord-002240-38aabxh1	103	3	side	side	NN
cord-002240-38aabxh1	103	4	effects	effect	NNS
cord-002240-38aabxh1	103	5	associated	associate	VBN
cord-002240-38aabxh1	103	6	with	with	IN
cord-002240-38aabxh1	103	7	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	103	8	,	,	,
cord-002240-38aabxh1	103	9	especially	especially	RB
cord-002240-38aabxh1	103	10	with	with	IN
cord-002240-38aabxh1	103	11	prolonged	prolong	VBN
cord-002240-38aabxh1	103	12	use	use	NN
cord-002240-38aabxh1	103	13	,	,	,
cord-002240-38aabxh1	103	14	are	be	VBP
cord-002240-38aabxh1	103	15	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	103	16	,	,	,
cord-002240-38aabxh1	103	17	myopathy	myopathy	NN
cord-002240-38aabxh1	103	18	,	,	,
cord-002240-38aabxh1	103	19	weight	weight	NN
cord-002240-38aabxh1	103	20	gain	gain	NN
cord-002240-38aabxh1	103	21	,	,	,
cord-002240-38aabxh1	103	22	brushing	brushing	NN
cord-002240-38aabxh1	103	23	,	,	,
cord-002240-38aabxh1	103	24	and	and	CC
cord-002240-38aabxh1	103	25	osteopenia	osteopenia	FW
cord-002240-38aabxh1	103	26	(	(	-LRB-
cord-002240-38aabxh1	103	27	Fig	fig	NN
cord-002240-38aabxh1	103	28	.	.	NNP
cord-002240-38aabxh1	103	29	2	2	LS
cord-002240-38aabxh1	103	30	)	)	-RRB-
cord-002240-38aabxh1	103	31	[	[	-LRB-
cord-002240-38aabxh1	103	32	32	32	CD
cord-002240-38aabxh1	103	33	]	]	-RRB-
cord-002240-38aabxh1	103	34	.	.	.
cord-002240-38aabxh1	104	1	As	as	RB
cord-002240-38aabxh1	104	2	well	well	RB
cord-002240-38aabxh1	104	3	as	as	IN
cord-002240-38aabxh1	104	4	these	these	DT
cord-002240-38aabxh1	104	5	side	side	NN
cord-002240-38aabxh1	104	6	effects	effect	NNS
cord-002240-38aabxh1	104	7	,	,	,
cord-002240-38aabxh1	104	8	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	104	9	have	have	VBP
cord-002240-38aabxh1	104	10	strong	strong	JJ
cord-002240-38aabxh1	104	11	immunosuppressive	immunosuppressive	JJ
cord-002240-38aabxh1	104	12	effects	effect	NNS
cord-002240-38aabxh1	104	13	,	,	,
cord-002240-38aabxh1	104	14	raising	raise	VBG
cord-002240-38aabxh1	104	15	concerns	concern	NNS
cord-002240-38aabxh1	104	16	regarding	regard	VBG
cord-002240-38aabxh1	104	17	their	-PRON-	PRP$
cord-002240-38aabxh1	104	18	use	use	NN
cord-002240-38aabxh1	104	19	in	in	IN
cord-002240-38aabxh1	104	20	acute	acute	JJ
cord-002240-38aabxh1	104	21	infections	infection	NNS
cord-002240-38aabxh1	104	22	,	,	,
cord-002240-38aabxh1	104	23	despite	despite	IN
cord-002240-38aabxh1	104	24	their	-PRON-	PRP$
cord-002240-38aabxh1	104	25	potential	potential	JJ
cord-002240-38aabxh1	104	26	effect	effect	NN
cord-002240-38aabxh1	104	27	in	in	IN
cord-002240-38aabxh1	104	28	controlling	control	VBG
cord-002240-38aabxh1	104	29	excessive	excessive	JJ
cord-002240-38aabxh1	104	30	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	104	31	response	response	NN
cord-002240-38aabxh1	104	32	.	.	.
cord-002240-38aabxh1	105	1	The	the	DT
cord-002240-38aabxh1	105	2	immunosuppressant	immunosuppressant	JJ
cord-002240-38aabxh1	105	3	effect	effect	NN
cord-002240-38aabxh1	105	4	of	of	IN
cord-002240-38aabxh1	105	5	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	105	6	is	be	VBZ
cord-002240-38aabxh1	105	7	related	relate	VBN
cord-002240-38aabxh1	105	8	to	to	IN
cord-002240-38aabxh1	105	9	dose	dose	NN
cord-002240-38aabxh1	105	10	and	and	CC
cord-002240-38aabxh1	105	11	treatment	treatment	NN
cord-002240-38aabxh1	105	12	duration	duration	NN
cord-002240-38aabxh1	105	13	.	.	.
cord-002240-38aabxh1	106	1	For	for	IN
cord-002240-38aabxh1	106	2	example	example	NN
cord-002240-38aabxh1	106	3	,	,	,
cord-002240-38aabxh1	106	4	the	the	DT
cord-002240-38aabxh1	106	5	use	use	NN
cord-002240-38aabxh1	106	6	of	of	IN
cord-002240-38aabxh1	106	7	40	40	CD
cord-002240-38aabxh1	106	8	mg	mg	NNS
cord-002240-38aabxh1	106	9	of	of	IN
cord-002240-38aabxh1	106	10	prednisolone	prednisolone	NN
cord-002240-38aabxh1	106	11	per	per	IN
cord-002240-38aabxh1	106	12	day	day	NN
cord-002240-38aabxh1	106	13	for	for	IN
cord-002240-38aabxh1	106	14	more	more	JJR
cord-002240-38aabxh1	106	15	than	than	IN
cord-002240-38aabxh1	106	16	1	1	CD
cord-002240-38aabxh1	106	17	week	week	NN
cord-002240-38aabxh1	106	18	or	or	CC
cord-002240-38aabxh1	106	19	20	20	CD
cord-002240-38aabxh1	106	20	mg	mg	NN
cord-002240-38aabxh1	106	21	prednisolone	prednisolone	NN
cord-002240-38aabxh1	106	22	or	or	CC
cord-002240-38aabxh1	106	23	equivalent	equivalent	JJ
cord-002240-38aabxh1	106	24	per	per	IN
cord-002240-38aabxh1	106	25	day	day	NN
cord-002240-38aabxh1	106	26	for	for	IN
cord-002240-38aabxh1	106	27	a	a	DT
cord-002240-38aabxh1	106	28	month	month	NN
cord-002240-38aabxh1	106	29	can	can	MD
cord-002240-38aabxh1	106	30	produce	produce	VB
cord-002240-38aabxh1	106	31	immunosuppression	immunosuppression	NN
cord-002240-38aabxh1	106	32	.	.	.
cord-002240-38aabxh1	107	1	In	in	IN
cord-002240-38aabxh1	107	2	acute	acute	JJ
cord-002240-38aabxh1	107	3	infection	infection	NN
cord-002240-38aabxh1	107	4	,	,	,
cord-002240-38aabxh1	107	5	a	a	DT
cord-002240-38aabxh1	107	6	low	low	JJ
cord-002240-38aabxh1	107	7	dose	dose	NN
cord-002240-38aabxh1	107	8	for	for	IN
cord-002240-38aabxh1	107	9	a	a	DT
cord-002240-38aabxh1	107	10	short	short	JJ
cord-002240-38aabxh1	107	11	period	period	NN
cord-002240-38aabxh1	107	12	(	(	-LRB-
cord-002240-38aabxh1	107	13	some	some	DT
cord-002240-38aabxh1	107	14	days	day	NNS
cord-002240-38aabxh1	107	15	)	)	-RRB-
cord-002240-38aabxh1	107	16	may	may	MD
cord-002240-38aabxh1	107	17	be	be	VB
cord-002240-38aabxh1	107	18	useful	useful	JJ
cord-002240-38aabxh1	107	19	for	for	IN
cord-002240-38aabxh1	107	20	reducing	reduce	VBG
cord-002240-38aabxh1	107	21	inflammation	inflammation	NN
cord-002240-38aabxh1	107	22	and	and	CC
cord-002240-38aabxh1	107	23	may	may	MD
cord-002240-38aabxh1	107	24	not	not	RB
cord-002240-38aabxh1	107	25	cause	cause	VB
cord-002240-38aabxh1	107	26	so	so	RB
cord-002240-38aabxh1	107	27	much	much	JJ
cord-002240-38aabxh1	107	28	harm	harm	NN
cord-002240-38aabxh1	107	29	by	by	IN
cord-002240-38aabxh1	107	30	producing	produce	VBG
cord-002240-38aabxh1	107	31	immunosuppression	immunosuppression	NN
cord-002240-38aabxh1	107	32	.	.	.
cord-002240-38aabxh1	108	1	Moreover	moreover	RB
cord-002240-38aabxh1	108	2	,	,	,
cord-002240-38aabxh1	108	3	a	a	DT
cord-002240-38aabxh1	108	4	short	short	JJ
cord-002240-38aabxh1	108	5	period	period	NN
cord-002240-38aabxh1	108	6	of	of	IN
cord-002240-38aabxh1	108	7	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	108	8	treatment	treatment	NN
cord-002240-38aabxh1	108	9	may	may	MD
cord-002240-38aabxh1	108	10	reduce	reduce	VB
cord-002240-38aabxh1	108	11	the	the	DT
cord-002240-38aabxh1	108	12	risk	risk	NN
cord-002240-38aabxh1	108	13	for	for	IN
cord-002240-38aabxh1	108	14	side	side	JJ
cord-002240-38aabxh1	108	15	effects	effect	NNS
cord-002240-38aabxh1	108	16	.	.	.
cord-002240-38aabxh1	109	1	Hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	109	2	is	be	VBZ
cord-002240-38aabxh1	109	3	a	a	DT
cord-002240-38aabxh1	109	4	frequent	frequent	JJ
cord-002240-38aabxh1	109	5	effect	effect	NN
cord-002240-38aabxh1	109	6	associated	associate	VBN
cord-002240-38aabxh1	109	7	with	with	IN
cord-002240-38aabxh1	109	8	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	109	9	use	use	NN
cord-002240-38aabxh1	109	10	.	.	.
cord-002240-38aabxh1	110	1	This	this	DT
cord-002240-38aabxh1	110	2	occurs	occur	VBZ
cord-002240-38aabxh1	110	3	in	in	IN
cord-002240-38aabxh1	110	4	about	about	RB
cord-002240-38aabxh1	110	5	50	50	CD
cord-002240-38aabxh1	110	6	%	%	NN
cord-002240-38aabxh1	110	7	of	of	IN
cord-002240-38aabxh1	110	8	hospitalized	hospitalize	VBN
cord-002240-38aabxh1	110	9	patients	patient	NNS
cord-002240-38aabxh1	110	10	receiving	receive	VBG
cord-002240-38aabxh1	110	11	high	high	JJ
cord-002240-38aabxh1	110	12	doses	dose	NNS
cord-002240-38aabxh1	110	13	of	of	IN
cord-002240-38aabxh1	110	14	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	110	15	[	[	-LRB-
cord-002240-38aabxh1	110	16	33	33	CD
cord-002240-38aabxh1	110	17	]	]	-RRB-
cord-002240-38aabxh1	110	18	and	and	CC
cord-002240-38aabxh1	110	19	patients	patient	NNS
cord-002240-38aabxh1	110	20	with	with	IN
cord-002240-38aabxh1	110	21	chronic	chronic	JJ
cord-002240-38aabxh1	110	22	obstructive	obstructive	JJ
cord-002240-38aabxh1	110	23	pulmonary	pulmonary	JJ
cord-002240-38aabxh1	110	24	disease	disease	NN
cord-002240-38aabxh1	110	25	(	(	-LRB-
cord-002240-38aabxh1	110	26	COPD	COPD	NNP
cord-002240-38aabxh1	110	27	)	)	-RRB-
cord-002240-38aabxh1	110	28	receiving	receive	VBG
cord-002240-38aabxh1	110	29	oral	oral	JJ
cord-002240-38aabxh1	110	30	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	110	31	treatment	treatment	NN
cord-002240-38aabxh1	110	32	presented	present	VBD
cord-002240-38aabxh1	110	33	a	a	DT
cord-002240-38aabxh1	110	34	more	more	RBR
cord-002240-38aabxh1	110	35	than	than	IN
cord-002240-38aabxh1	110	36	fivefold	fivefold	JJ
cord-002240-38aabxh1	110	37	risk	risk	NN
cord-002240-38aabxh1	110	38	of	of	IN
cord-002240-38aabxh1	110	39	developing	develop	VBG
cord-002240-38aabxh1	110	40	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	110	41	.	.	.
cord-002240-38aabxh1	111	1	Hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	111	2	is	be	VBZ
cord-002240-38aabxh1	111	3	associated	associate	VBN
cord-002240-38aabxh1	111	4	with	with	IN
cord-002240-38aabxh1	111	5	higher	high	JJR
cord-002240-38aabxh1	111	6	mortality	mortality	NN
cord-002240-38aabxh1	111	7	and	and	CC
cord-002240-38aabxh1	111	8	,	,	,
cord-002240-38aabxh1	111	9	in	in	IN
cord-002240-38aabxh1	111	10	particular	particular	JJ
cord-002240-38aabxh1	111	11	,	,	,
cord-002240-38aabxh1	111	12	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	111	13	secondary	secondary	JJ
cord-002240-38aabxh1	111	14	to	to	IN
cord-002240-38aabxh1	111	15	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	111	16	increased	increase	VBD
cord-002240-38aabxh1	111	17	the	the	DT
cord-002240-38aabxh1	111	18	risk	risk	NN
cord-002240-38aabxh1	111	19	of	of	IN
cord-002240-38aabxh1	111	20	death	death	NN
cord-002240-38aabxh1	111	21	by	by	IN
cord-002240-38aabxh1	111	22	10	10	CD
cord-002240-38aabxh1	111	23	%	%	NN
cord-002240-38aabxh1	111	24	for	for	IN
cord-002240-38aabxh1	111	25	each	each	DT
cord-002240-38aabxh1	111	26	18	18	CD
cord-002240-38aabxh1	111	27	mg	mg	NNP
cord-002240-38aabxh1	111	28	/	/	SYM
cord-002240-38aabxh1	111	29	dL	dl	NN
cord-002240-38aabxh1	111	30	increase	increase	NN
cord-002240-38aabxh1	111	31	in	in	IN
cord-002240-38aabxh1	111	32	blood	blood	NN
cord-002240-38aabxh1	111	33	glucose	glucose	NN
cord-002240-38aabxh1	111	34	after	after	IN
cord-002240-38aabxh1	111	35	adjusting	adjust	VBG
cord-002240-38aabxh1	111	36	for	for	IN
cord-002240-38aabxh1	111	37	age	age	NN
cord-002240-38aabxh1	111	38	,	,	,
cord-002240-38aabxh1	111	39	sex	sex	NN
cord-002240-38aabxh1	111	40	,	,	,
cord-002240-38aabxh1	111	41	and	and	CC
cord-002240-38aabxh1	111	42	diabetes	diabetes	NN
cord-002240-38aabxh1	111	43	mellitus	mellitus	NN
cord-002240-38aabxh1	111	44	[	[	-LRB-
cord-002240-38aabxh1	111	45	34	34	CD
cord-002240-38aabxh1	111	46	]	]	-RRB-
cord-002240-38aabxh1	111	47	.	.	.
cord-002240-38aabxh1	112	1	Detection	detection	NN
cord-002240-38aabxh1	112	2	of	of	IN
cord-002240-38aabxh1	112	3	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	112	4	in	in	IN
cord-002240-38aabxh1	112	5	the	the	DT
cord-002240-38aabxh1	112	6	first	first	JJ
cord-002240-38aabxh1	112	7	24	24	CD
cord-002240-38aabxh1	112	8	h	h	NN
cord-002240-38aabxh1	112	9	in	in	IN
cord-002240-38aabxh1	112	10	patients	patient	NNS
cord-002240-38aabxh1	112	11	with	with	IN
cord-002240-38aabxh1	112	12	COPD	COPD	NNP
cord-002240-38aabxh1	112	13	reactivation	reactivation	NN
cord-002240-38aabxh1	112	14	was	be	VBD
cord-002240-38aabxh1	112	15	associated	associate	VBN
cord-002240-38aabxh1	112	16	with	with	IN
cord-002240-38aabxh1	112	17	worse	bad	JJR
cord-002240-38aabxh1	112	18	outcomes	outcome	NNS
cord-002240-38aabxh1	112	19	[	[	-LRB-
cord-002240-38aabxh1	112	20	35	35	CD
cord-002240-38aabxh1	112	21	]	]	-RRB-
cord-002240-38aabxh1	112	22	.	.	.
cord-002240-38aabxh1	113	1	On	on	IN
cord-002240-38aabxh1	113	2	the	the	DT
cord-002240-38aabxh1	113	3	other	other	JJ
cord-002240-38aabxh1	113	4	hand	hand	NN
cord-002240-38aabxh1	113	5	,	,	,
cord-002240-38aabxh1	113	6	strict	strict	JJ
cord-002240-38aabxh1	113	7	management	management	NN
cord-002240-38aabxh1	113	8	of	of	IN
cord-002240-38aabxh1	113	9	glucose	glucose	NN
cord-002240-38aabxh1	113	10	levels	level	NNS
cord-002240-38aabxh1	113	11	decreased	decrease	VBD
cord-002240-38aabxh1	113	12	morbidity	morbidity	NN
cord-002240-38aabxh1	113	13	and	and	CC
cord-002240-38aabxh1	113	14	mortality	mortality	NN
cord-002240-38aabxh1	113	15	in	in	IN
cord-002240-38aabxh1	113	16	critically	critically	RB
cord-002240-38aabxh1	113	17	ill	ill	JJ
cord-002240-38aabxh1	113	18	patients	patient	NNS
cord-002240-38aabxh1	113	19	admitted	admit	VBN
cord-002240-38aabxh1	113	20	to	to	IN
cord-002240-38aabxh1	113	21	the	the	DT
cord-002240-38aabxh1	113	22	surgical	surgical	JJ
cord-002240-38aabxh1	113	23	ICU	ICU	NNP
cord-002240-38aabxh1	113	24	[	[	-LRB-
cord-002240-38aabxh1	113	25	36	36	CD
cord-002240-38aabxh1	113	26	]	]	-RRB-
cord-002240-38aabxh1	113	27	.	.	.
cord-002240-38aabxh1	114	1	For	for	IN
cord-002240-38aabxh1	114	2	patients	patient	NNS
cord-002240-38aabxh1	114	3	in	in	IN
cord-002240-38aabxh1	114	4	the	the	DT
cord-002240-38aabxh1	114	5	medical	medical	JJ
cord-002240-38aabxh1	114	6	ICU	ICU	NNP
cord-002240-38aabxh1	114	7	,	,	,
cord-002240-38aabxh1	114	8	a	a	DT
cord-002240-38aabxh1	114	9	benefit	benefit	NN
cord-002240-38aabxh1	114	10	was	be	VBD
cord-002240-38aabxh1	114	11	shown	show	VBN
cord-002240-38aabxh1	114	12	in	in	IN
cord-002240-38aabxh1	114	13	terms	term	NNS
cord-002240-38aabxh1	114	14	of	of	IN
cord-002240-38aabxh1	114	15	morbidity	morbidity	NN
cord-002240-38aabxh1	114	16	but	but	CC
cord-002240-38aabxh1	114	17	not	not	RB
cord-002240-38aabxh1	114	18	mortality	mortality	NN
cord-002240-38aabxh1	114	19	[	[	-LRB-
cord-002240-38aabxh1	114	20	37	37	CD
cord-002240-38aabxh1	114	21	]	]	-RRB-
cord-002240-38aabxh1	114	22	.	.	.
cord-002240-38aabxh1	115	1	Myopathy	Myopathy	NNP
cord-002240-38aabxh1	115	2	is	be	VBZ
cord-002240-38aabxh1	115	3	another	another	DT
cord-002240-38aabxh1	115	4	side	side	NN
cord-002240-38aabxh1	115	5	effect	effect	NN
cord-002240-38aabxh1	115	6	associated	associate	VBN
cord-002240-38aabxh1	115	7	with	with	IN
cord-002240-38aabxh1	115	8	acute	acute	JJ
cord-002240-38aabxh1	115	9	and	and	CC
cord-002240-38aabxh1	115	10	chronic	chronic	JJ
cord-002240-38aabxh1	115	11	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	115	12	treatment	treatment	NN
cord-002240-38aabxh1	115	13	,	,	,
cord-002240-38aabxh1	115	14	especially	especially	RB
cord-002240-38aabxh1	115	15	in	in	IN
cord-002240-38aabxh1	115	16	older	old	JJR
cord-002240-38aabxh1	115	17	patients	patient	NNS
cord-002240-38aabxh1	115	18	,	,	,
cord-002240-38aabxh1	115	19	patients	patient	NNS
cord-002240-38aabxh1	115	20	with	with	IN
cord-002240-38aabxh1	115	21	cancer	cancer	NN
cord-002240-38aabxh1	115	22	and	and	CC
cord-002240-38aabxh1	115	23	respiratory	respiratory	JJ
cord-002240-38aabxh1	115	24	muscle	muscle	NN
cord-002240-38aabxh1	115	25	diseases	disease	NNS
cord-002240-38aabxh1	115	26	,	,	,
cord-002240-38aabxh1	115	27	and	and	CC
cord-002240-38aabxh1	115	28	physically	physically	RB
cord-002240-38aabxh1	115	29	inactive	inactive	JJ
cord-002240-38aabxh1	115	30	patients	patient	NNS
cord-002240-38aabxh1	115	31	[	[	-LRB-
cord-002240-38aabxh1	115	32	38	38	CD
cord-002240-38aabxh1	115	33	]	]	-RRB-
cord-002240-38aabxh1	115	34	.	.	.
cord-002240-38aabxh1	116	1	Corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	116	2	induce	induce	VBP
cord-002240-38aabxh1	116	3	myopathy	myopathy	NN
cord-002240-38aabxh1	116	4	by	by	IN
cord-002240-38aabxh1	116	5	decreasing	decrease	VBG
cord-002240-38aabxh1	116	6	protein	protein	NN
cord-002240-38aabxh1	116	7	synthesis	synthesis	NN
cord-002240-38aabxh1	116	8	and	and	CC
cord-002240-38aabxh1	116	9	increasing	increase	VBG
cord-002240-38aabxh1	116	10	protein	protein	NN
cord-002240-38aabxh1	116	11	breakdown	breakdown	NN
cord-002240-38aabxh1	116	12	.	.	.
cord-002240-38aabxh1	117	1	This	this	DT
cord-002240-38aabxh1	117	2	mechanism	mechanism	NN
cord-002240-38aabxh1	117	3	leads	lead	VBZ
cord-002240-38aabxh1	117	4	to	to	IN
cord-002240-38aabxh1	117	5	muscle	muscle	NN
cord-002240-38aabxh1	117	6	atrophy	atrophy	NN
cord-002240-38aabxh1	117	7	with	with	IN
cord-002240-38aabxh1	117	8	a	a	DT
cord-002240-38aabxh1	117	9	reduction	reduction	NN
cord-002240-38aabxh1	117	10	of	of	IN
cord-002240-38aabxh1	117	11	myofibrillar	myofibrillar	JJ
cord-002240-38aabxh1	117	12	protein	protein	NN
cord-002240-38aabxh1	117	13	content	content	NN
cord-002240-38aabxh1	117	14	and	and	CC
cord-002240-38aabxh1	117	15	cross	cross	JJ
cord-002240-38aabxh1	117	16	-	-	JJ
cord-002240-38aabxh1	117	17	sectional	sectional	JJ
cord-002240-38aabxh1	117	18	fiber	fiber	NN
cord-002240-38aabxh1	117	19	area	area	NN
cord-002240-38aabxh1	117	20	.	.	.
cord-002240-38aabxh1	118	1	In	in	IN
cord-002240-38aabxh1	118	2	critically	critically	RB
cord-002240-38aabxh1	118	3	ill	ill	JJ
cord-002240-38aabxh1	118	4	patients	patient	NNS
cord-002240-38aabxh1	118	5	,	,	,
cord-002240-38aabxh1	118	6	the	the	DT
cord-002240-38aabxh1	118	7	development	development	NN
cord-002240-38aabxh1	118	8	of	of	IN
cord-002240-38aabxh1	118	9	myopathy	myopathy	NN
cord-002240-38aabxh1	118	10	produces	produce	VBZ
cord-002240-38aabxh1	118	11	peripheral	peripheral	JJ
cord-002240-38aabxh1	118	12	muscle	muscle	NN
cord-002240-38aabxh1	118	13	weakness	weakness	NN
cord-002240-38aabxh1	118	14	with	with	IN
cord-002240-38aabxh1	118	15	longer	long	JJR
cord-002240-38aabxh1	118	16	duration	duration	NN
cord-002240-38aabxh1	118	17	of	of	IN
cord-002240-38aabxh1	118	18	[	[	-LRB-
cord-002240-38aabxh1	118	19	39	39	CD
cord-002240-38aabxh1	118	20	,	,	,
cord-002240-38aabxh1	118	21	40	40	CD
cord-002240-38aabxh1	118	22	]	]	-RRB-
cord-002240-38aabxh1	118	23	.	.	.
cord-002240-38aabxh1	119	1	There	there	EX
cord-002240-38aabxh1	119	2	is	be	VBZ
cord-002240-38aabxh1	119	3	a	a	DT
cord-002240-38aabxh1	119	4	gap	gap	NN
cord-002240-38aabxh1	119	5	in	in	IN
cord-002240-38aabxh1	119	6	knowledge	knowledge	NN
cord-002240-38aabxh1	119	7	regarding	regard	VBG
cord-002240-38aabxh1	119	8	whether	whether	IN
cord-002240-38aabxh1	119	9	the	the	DT
cord-002240-38aabxh1	119	10	beneficial	beneficial	JJ
cord-002240-38aabxh1	119	11	anti	anti	JJ
cord-002240-38aabxh1	119	12	-	-	JJ
cord-002240-38aabxh1	119	13	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	119	14	effect	effect	NN
cord-002240-38aabxh1	119	15	of	of	IN
cord-002240-38aabxh1	119	16	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	119	17	may	may	MD
cord-002240-38aabxh1	119	18	be	be	VB
cord-002240-38aabxh1	119	19	potentiated	potentiate	VBN
cord-002240-38aabxh1	119	20	by	by	IN
cord-002240-38aabxh1	119	21	the	the	DT
cord-002240-38aabxh1	119	22	administration	administration	NN
cord-002240-38aabxh1	119	23	of	of	IN
cord-002240-38aabxh1	119	24	a	a	DT
cord-002240-38aabxh1	119	25	macrolide	macrolide	NN
cord-002240-38aabxh1	119	26	,	,	,
cord-002240-38aabxh1	119	27	which	which	WDT
cord-002240-38aabxh1	119	28	has	have	VBZ
cord-002240-38aabxh1	119	29	an	an	DT
cord-002240-38aabxh1	119	30	immunomodulatory	immunomodulatory	JJ
cord-002240-38aabxh1	119	31	effect	effect	NN
cord-002240-38aabxh1	119	32	.	.	.
cord-002240-38aabxh1	120	1	The	the	DT
cord-002240-38aabxh1	120	2	best	good	JJS
cord-002240-38aabxh1	120	3	antibiotic	antibiotic	JJ
cord-002240-38aabxh1	120	4	strategy	strategy	NN
cord-002240-38aabxh1	120	5	for	for	IN
cord-002240-38aabxh1	120	6	the	the	DT
cord-002240-38aabxh1	120	7	treatment	treatment	NN
cord-002240-38aabxh1	120	8	of	of	IN
cord-002240-38aabxh1	120	9	CAP	CAP	NNP
cord-002240-38aabxh1	120	10	is	be	VBZ
cord-002240-38aabxh1	120	11	currently	currently	RB
cord-002240-38aabxh1	120	12	a	a	DT
cord-002240-38aabxh1	120	13	subject	subject	NN
cord-002240-38aabxh1	120	14	of	of	IN
cord-002240-38aabxh1	120	15	debate	debate	NN
cord-002240-38aabxh1	120	16	.	.	.
cord-002240-38aabxh1	121	1	For	for	IN
cord-002240-38aabxh1	121	2	severe	severe	JJ
cord-002240-38aabxh1	121	3	CAP	cap	NN
cord-002240-38aabxh1	121	4	,	,	,
cord-002240-38aabxh1	121	5	international	international	JJ
cord-002240-38aabxh1	121	6	guidelines	guideline	NNS
cord-002240-38aabxh1	121	7	suggest	suggest	VBP
cord-002240-38aabxh1	121	8	the	the	DT
cord-002240-38aabxh1	121	9	use	use	NN
cord-002240-38aabxh1	121	10	of	of	IN
cord-002240-38aabxh1	121	11	two	two	CD
cord-002240-38aabxh1	121	12	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	121	13	such	such	JJ
cord-002240-38aabxh1	121	14	as	as	IN
cord-002240-38aabxh1	121	15	a	a	DT
cord-002240-38aabxh1	121	16	βlactam	βlactam	NNS
cord-002240-38aabxh1	121	17	plus	plus	CC
cord-002240-38aabxh1	121	18	a	a	DT
cord-002240-38aabxh1	121	19	macrolide	macrolide	NN
cord-002240-38aabxh1	121	20	or	or	CC
cord-002240-38aabxh1	121	21	a	a	DT
cord-002240-38aabxh1	121	22	β	β	NN
cord-002240-38aabxh1	121	23	-	-	HYPH
cord-002240-38aabxh1	121	24	lactam	lactam	NNP
cord-002240-38aabxh1	121	25	plus	plus	CC
cord-002240-38aabxh1	121	26	respiratory	respiratory	JJ
cord-002240-38aabxh1	121	27	quinolone	quinolone	NNP
cord-002240-38aabxh1	121	28	(	(	-LRB-
cord-002240-38aabxh1	121	29	levofloxacin	levofloxacin	NNP
cord-002240-38aabxh1	121	30	or	or	CC
cord-002240-38aabxh1	121	31	moxifloxacin	moxifloxacin	NNS
cord-002240-38aabxh1	121	32	)	)	-RRB-
cord-002240-38aabxh1	121	33	[	[	-LRB-
cord-002240-38aabxh1	121	34	40	40	CD
cord-002240-38aabxh1	121	35	]	]	-RRB-
cord-002240-38aabxh1	121	36	.	.	.
cord-002240-38aabxh1	122	1	However	however	RB
cord-002240-38aabxh1	122	2	,	,	,
cord-002240-38aabxh1	122	3	many	many	JJ
cord-002240-38aabxh1	122	4	observational	observational	JJ
cord-002240-38aabxh1	122	5	studies	study	NNS
cord-002240-38aabxh1	122	6	and	and	CC
cord-002240-38aabxh1	122	7	a	a	DT
cord-002240-38aabxh1	122	8	recent	recent	JJ
cord-002240-38aabxh1	122	9	meta	meta	JJ
cord-002240-38aabxh1	122	10	-	-	HYPH
cord-002240-38aabxh1	122	11	analysis	analysis	NN
cord-002240-38aabxh1	122	12	have	have	VBP
cord-002240-38aabxh1	122	13	shown	show	VBN
cord-002240-38aabxh1	122	14	that	that	IN
cord-002240-38aabxh1	122	15	the	the	DT
cord-002240-38aabxh1	122	16	use	use	NN
cord-002240-38aabxh1	122	17	of	of	IN
cord-002240-38aabxh1	122	18	a	a	DT
cord-002240-38aabxh1	122	19	β	β	NN
cord-002240-38aabxh1	122	20	-	-	HYPH
cord-002240-38aabxh1	122	21	lactam	lactam	NNP
cord-002240-38aabxh1	122	22	plus	plus	CC
cord-002240-38aabxh1	122	23	a	a	DT
cord-002240-38aabxh1	122	24	macrolide	macrolide	NN
cord-002240-38aabxh1	122	25	is	be	VBZ
cord-002240-38aabxh1	122	26	the	the	DT
cord-002240-38aabxh1	122	27	best	good	JJS
cord-002240-38aabxh1	122	28	choice	choice	NN
cord-002240-38aabxh1	122	29	because	because	IN
cord-002240-38aabxh1	122	30	it	-PRON-	PRP
cord-002240-38aabxh1	122	31	is	be	VBZ
cord-002240-38aabxh1	122	32	associated	associate	VBN
cord-002240-38aabxh1	122	33	with	with	IN
cord-002240-38aabxh1	122	34	a	a	DT
cord-002240-38aabxh1	122	35	better	well	JJR
cord-002240-38aabxh1	122	36	outcome	outcome	NN
cord-002240-38aabxh1	122	37	and	and	CC
cord-002240-38aabxh1	122	38	lower	low	JJR
cord-002240-38aabxh1	122	39	mortality	mortality	NN
cord-002240-38aabxh1	122	40	in	in	IN
cord-002240-38aabxh1	122	41	patients	patient	NNS
cord-002240-38aabxh1	122	42	with	with	IN
cord-002240-38aabxh1	122	43	severe	severe	JJ
cord-002240-38aabxh1	122	44	CAP	cap	NN
cord-002240-38aabxh1	122	45	,	,	,
cord-002240-38aabxh1	122	46	especially	especially	RB
cord-002240-38aabxh1	122	47	in	in	IN
cord-002240-38aabxh1	122	48	bacteremic	bacteremic	JJ
cord-002240-38aabxh1	122	49	pneumococcal	pneumococcal	JJ
cord-002240-38aabxh1	122	50	CAP	cap	NN
cord-002240-38aabxh1	122	51	.	.	.
cord-002240-38aabxh1	123	1	The	the	DT
cord-002240-38aabxh1	123	2	mechanisms	mechanism	NNS
cord-002240-38aabxh1	123	3	responsible	responsible	JJ
cord-002240-38aabxh1	123	4	for	for	IN
cord-002240-38aabxh1	123	5	the	the	DT
cord-002240-38aabxh1	123	6	favorable	favorable	JJ
cord-002240-38aabxh1	123	7	effects	effect	NNS
cord-002240-38aabxh1	123	8	related	relate	VBN
cord-002240-38aabxh1	123	9	to	to	IN
cord-002240-38aabxh1	123	10	the	the	DT
cord-002240-38aabxh1	123	11	use	use	NN
cord-002240-38aabxh1	123	12	of	of	IN
cord-002240-38aabxh1	123	13	macrolides	macrolide	NNS
cord-002240-38aabxh1	123	14	are	be	VBP
cord-002240-38aabxh1	123	15	not	not	RB
cord-002240-38aabxh1	123	16	clear	clear	JJ
cord-002240-38aabxh1	123	17	and	and	CC
cord-002240-38aabxh1	123	18	have	have	VBP
cord-002240-38aabxh1	123	19	been	be	VBN
cord-002240-38aabxh1	123	20	attributed	attribute	VBN
cord-002240-38aabxh1	123	21	in	in	IN
cord-002240-38aabxh1	123	22	part	part	NN
cord-002240-38aabxh1	123	23	to	to	IN
cord-002240-38aabxh1	123	24	their	-PRON-	PRP$
cord-002240-38aabxh1	123	25	immunomodulatory	immunomodulatory	JJ
cord-002240-38aabxh1	123	26	effect	effect	NN
cord-002240-38aabxh1	123	27	,	,	,
cord-002240-38aabxh1	123	28	as	as	IN
cord-002240-38aabxh1	123	29	observed	observe	VBN
cord-002240-38aabxh1	123	30	in	in	IN
cord-002240-38aabxh1	123	31	some	some	DT
cord-002240-38aabxh1	123	32	studies	study	NNS
cord-002240-38aabxh1	123	33	[	[	-LRB-
cord-002240-38aabxh1	123	34	41	41	CD
cord-002240-38aabxh1	123	35	]	]	-RRB-
cord-002240-38aabxh1	123	36	.	.	.
cord-002240-38aabxh1	124	1	In	in	IN
cord-002240-38aabxh1	124	2	vitro	vitro	FW
cord-002240-38aabxh1	124	3	and	and	CC
cord-002240-38aabxh1	124	4	in	in	IN
cord-002240-38aabxh1	124	5	vivo	vivo	NNP
cord-002240-38aabxh1	124	6	experimental	experimental	JJ
cord-002240-38aabxh1	124	7	models	model	NNS
cord-002240-38aabxh1	124	8	have	have	VBP
cord-002240-38aabxh1	124	9	shown	show	VBN
cord-002240-38aabxh1	124	10	that	that	IN
cord-002240-38aabxh1	124	11	macrolides	macrolide	NNS
cord-002240-38aabxh1	124	12	inhibit	inhibit	VB
cord-002240-38aabxh1	124	13	cytokine	cytokine	JJ
cord-002240-38aabxh1	124	14	secretion	secretion	NN
cord-002240-38aabxh1	124	15	by	by	IN
cord-002240-38aabxh1	124	16	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	124	17	and	and	CC
cord-002240-38aabxh1	124	18	structural	structural	JJ
cord-002240-38aabxh1	124	19	cells	cell	NNS
cord-002240-38aabxh1	124	20	of	of	IN
cord-002240-38aabxh1	124	21	the	the	DT
cord-002240-38aabxh1	124	22	respiratory	respiratory	JJ
cord-002240-38aabxh1	124	23	tract	tract	NN
cord-002240-38aabxh1	124	24	[	[	-LRB-
cord-002240-38aabxh1	124	25	42	42	CD
cord-002240-38aabxh1	124	26	]	]	-RRB-
cord-002240-38aabxh1	124	27	.	.	.
cord-002240-38aabxh1	125	1	In	in	IN
cord-002240-38aabxh1	125	2	patients	patient	NNS
cord-002240-38aabxh1	125	3	admitted	admit	VBN
cord-002240-38aabxh1	125	4	to	to	IN
cord-002240-38aabxh1	125	5	the	the	DT
cord-002240-38aabxh1	125	6	ward	ward	NN
cord-002240-38aabxh1	125	7	with	with	IN
cord-002240-38aabxh1	125	8	non	non	JJ
cord-002240-38aabxh1	125	9	-	-	JJ
cord-002240-38aabxh1	125	10	severe	severe	JJ
cord-002240-38aabxh1	125	11	CAP	cap	NN
cord-002240-38aabxh1	125	12	[	[	-LRB-
cord-002240-38aabxh1	125	13	43	43	CD
cord-002240-38aabxh1	125	14	]	]	-RRB-
cord-002240-38aabxh1	125	15	,	,	,
cord-002240-38aabxh1	125	16	monotherapy	monotherapy	CC
cord-002240-38aabxh1	125	17	with	with	IN
cord-002240-38aabxh1	125	18	a	a	DT
cord-002240-38aabxh1	125	19	β	β	NN
cord-002240-38aabxh1	125	20	-	-	HYPH
cord-002240-38aabxh1	125	21	lactam	lactam	NNP
cord-002240-38aabxh1	125	22	was	be	VBD
cord-002240-38aabxh1	125	23	not	not	RB
cord-002240-38aabxh1	125	24	inferior	inferior	JJ
cord-002240-38aabxh1	125	25	to	to	IN
cord-002240-38aabxh1	125	26	a	a	DT
cord-002240-38aabxh1	125	27	βlactam	βlactam	NNS
cord-002240-38aabxh1	125	28	plus	plus	CC
cord-002240-38aabxh1	125	29	a	a	DT
cord-002240-38aabxh1	125	30	macrolide	macrolide	NN
cord-002240-38aabxh1	125	31	or	or	CC
cord-002240-38aabxh1	125	32	fluoroquinolone	fluoroquinolone	NN
cord-002240-38aabxh1	125	33	in	in	IN
cord-002240-38aabxh1	125	34	terms	term	NNS
cord-002240-38aabxh1	125	35	of	of	IN
cord-002240-38aabxh1	125	36	90-day	90-day	CD
cord-002240-38aabxh1	125	37	mortality	mortality	NN
cord-002240-38aabxh1	125	38	.	.	.
cord-002240-38aabxh1	126	1	In	in	IN
cord-002240-38aabxh1	126	2	another	another	DT
cord-002240-38aabxh1	126	3	trial	trial	NN
cord-002240-38aabxh1	126	4	,	,	,
cord-002240-38aabxh1	126	5	the	the	DT
cord-002240-38aabxh1	126	6	authors	author	NNS
cord-002240-38aabxh1	126	7	found	find	VBD
cord-002240-38aabxh1	126	8	no	no	DT
cord-002240-38aabxh1	126	9	non	non	JJ
cord-002240-38aabxh1	126	10	-	-	JJ
cord-002240-38aabxh1	126	11	inferiority	inferiority	NN
cord-002240-38aabxh1	126	12	of	of	IN
cord-002240-38aabxh1	126	13	β	β	NN
cord-002240-38aabxh1	126	14	-	-	HYPH
cord-002240-38aabxh1	126	15	lactam	lactam	NNP
cord-002240-38aabxh1	126	16	monotherapy	monotherapy	NN
cord-002240-38aabxh1	126	17	in	in	IN
cord-002240-38aabxh1	126	18	comparison	comparison	NN
cord-002240-38aabxh1	126	19	with	with	IN
cord-002240-38aabxh1	126	20	a	a	DT
cord-002240-38aabxh1	126	21	β	β	NN
cord-002240-38aabxh1	126	22	-	-	HYPH
cord-002240-38aabxh1	126	23	lactam	lactam	NNP
cord-002240-38aabxh1	126	24	plus	plus	CC
cord-002240-38aabxh1	126	25	a	a	DT
cord-002240-38aabxh1	126	26	macrolide	macrolide	NN
cord-002240-38aabxh1	126	27	in	in	IN
cord-002240-38aabxh1	126	28	patients	patient	NNS
cord-002240-38aabxh1	126	29	with	with	IN
cord-002240-38aabxh1	126	30	moderate	moderate	JJ
cord-002240-38aabxh1	126	31	-	-	HYPH
cord-002240-38aabxh1	126	32	severe	severe	JJ
cord-002240-38aabxh1	126	33	CAP	cap	NN
cord-002240-38aabxh1	126	34	,	,	,
cord-002240-38aabxh1	126	35	considering	consider	VBG
cord-002240-38aabxh1	126	36	as	as	IN
cord-002240-38aabxh1	126	37	outcome	outcome	NN
cord-002240-38aabxh1	126	38	the	the	DT
cord-002240-38aabxh1	126	39	proportion	proportion	NN
cord-002240-38aabxh1	126	40	of	of	IN
cord-002240-38aabxh1	126	41	patients	patient	NNS
cord-002240-38aabxh1	126	42	who	who	WP
cord-002240-38aabxh1	126	43	did	do	VBD
cord-002240-38aabxh1	126	44	not	not	RB
cord-002240-38aabxh1	126	45	reach	reach	VB
cord-002240-38aabxh1	126	46	clinical	clinical	JJ
cord-002240-38aabxh1	126	47	stability	stability	NN
cord-002240-38aabxh1	126	48	in	in	IN
cord-002240-38aabxh1	126	49	7	7	CD
cord-002240-38aabxh1	126	50	days	day	NNS
cord-002240-38aabxh1	126	51	[	[	-LRB-
cord-002240-38aabxh1	126	52	44	44	CD
cord-002240-38aabxh1	126	53	]	]	-RRB-
cord-002240-38aabxh1	126	54	.	.	.
cord-002240-38aabxh1	127	1	In	in	IN
cord-002240-38aabxh1	127	2	an	an	DT
cord-002240-38aabxh1	127	3	experimental	experimental	JJ
cord-002240-38aabxh1	127	4	mouse	mouse	NN
cord-002240-38aabxh1	127	5	model	model	NN
cord-002240-38aabxh1	127	6	of	of	IN
cord-002240-38aabxh1	127	7	Mycoplasma	Mycoplasma	NNP
cord-002240-38aabxh1	127	8	pneumoniae	pneumoniae	NN
cord-002240-38aabxh1	127	9	respiratory	respiratory	JJ
cord-002240-38aabxh1	127	10	infection	infection	NN
cord-002240-38aabxh1	127	11	,	,	,
cord-002240-38aabxh1	127	12	the	the	DT
cord-002240-38aabxh1	127	13	use	use	NN
cord-002240-38aabxh1	127	14	of	of	IN
cord-002240-38aabxh1	127	15	clarithromycin	clarithromycin	NNS
cord-002240-38aabxh1	127	16	and	and	CC
cord-002240-38aabxh1	127	17	dexamethasone	dexamethasone	NN
cord-002240-38aabxh1	127	18	was	be	VBD
cord-002240-38aabxh1	127	19	more	more	RBR
cord-002240-38aabxh1	127	20	effective	effective	JJ
cord-002240-38aabxh1	127	21	than	than	IN
cord-002240-38aabxh1	127	22	clarithromycin	clarithromycin	NNS
cord-002240-38aabxh1	127	23	alone	alone	RB
cord-002240-38aabxh1	127	24	in	in	IN
cord-002240-38aabxh1	127	25	decreasing	decrease	VBG
cord-002240-38aabxh1	127	26	levels	level	NNS
cord-002240-38aabxh1	127	27	of	of	IN
cord-002240-38aabxh1	127	28	cytokines	cytokine	NNS
cord-002240-38aabxh1	127	29	and	and	CC
cord-002240-38aabxh1	127	30	histological	histological	JJ
cord-002240-38aabxh1	127	31	signs	sign	NNS
cord-002240-38aabxh1	127	32	of	of	IN
cord-002240-38aabxh1	127	33	lung	lung	NN
cord-002240-38aabxh1	127	34	inflammation	inflammation	NN
cord-002240-38aabxh1	127	35	[	[	-LRB-
cord-002240-38aabxh1	127	36	45	45	CD
cord-002240-38aabxh1	127	37	]	]	-RRB-
cord-002240-38aabxh1	127	38	.	.	.
cord-002240-38aabxh1	128	1	Another	another	DT
cord-002240-38aabxh1	128	2	study	study	NN
cord-002240-38aabxh1	128	3	in	in	IN
cord-002240-38aabxh1	128	4	patients	patient	NNS
cord-002240-38aabxh1	128	5	with	with	IN
cord-002240-38aabxh1	128	6	non	non	JJ
cord-002240-38aabxh1	128	7	-	-	JJ
cord-002240-38aabxh1	128	8	responding	respond	VBG
cord-002240-38aabxh1	128	9	pneumonia	pneumonia	NN
cord-002240-38aabxh1	128	10	demonstrated	demonstrate	VBD
cord-002240-38aabxh1	128	11	a	a	DT
cord-002240-38aabxh1	128	12	reduction	reduction	NN
cord-002240-38aabxh1	128	13	in	in	IN
cord-002240-38aabxh1	128	14	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	128	15	biomarkers	biomarker	NNS
cord-002240-38aabxh1	128	16	such	such	JJ
cord-002240-38aabxh1	128	17	as	as	IN
cord-002240-38aabxh1	128	18	IL-6	IL-6	NNP
cord-002240-38aabxh1	128	19	and	and	CC
cord-002240-38aabxh1	128	20	IL-8	IL-8	NNP
cord-002240-38aabxh1	128	21	in	in	IN
cord-002240-38aabxh1	128	22	bronchoalveolar	bronchoalveolar	NNP
cord-002240-38aabxh1	128	23	lavage	lavage	NN
cord-002240-38aabxh1	128	24	in	in	IN
cord-002240-38aabxh1	128	25	patients	patient	NNS
cord-002240-38aabxh1	128	26	receiving	receive	VBG
cord-002240-38aabxh1	128	27	treatment	treatment	NN
cord-002240-38aabxh1	128	28	with	with	IN
cord-002240-38aabxh1	128	29	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	128	30	plus	plus	CC
cord-002240-38aabxh1	128	31	a	a	DT
cord-002240-38aabxh1	128	32	macrolide	macrolide	NN
cord-002240-38aabxh1	128	33	[	[	-LRB-
cord-002240-38aabxh1	128	34	46	46	CD
cord-002240-38aabxh1	128	35	]	]	-RRB-
cord-002240-38aabxh1	128	36	.	.	.
cord-002240-38aabxh1	129	1	The	the	DT
cord-002240-38aabxh1	129	2	combination	combination	NN
cord-002240-38aabxh1	129	3	of	of	IN
cord-002240-38aabxh1	129	4	a	a	DT
cord-002240-38aabxh1	129	5	macrolide	macrolide	NN
cord-002240-38aabxh1	129	6	plus	plus	CC
cord-002240-38aabxh1	129	7	a	a	DT
cord-002240-38aabxh1	129	8	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	129	9	is	be	VBZ
cord-002240-38aabxh1	129	10	currently	currently	RB
cord-002240-38aabxh1	129	11	used	use	VBN
cord-002240-38aabxh1	129	12	without	without	IN
cord-002240-38aabxh1	129	13	scientific	scientific	JJ
cord-002240-38aabxh1	129	14	evaluation	evaluation	NN
cord-002240-38aabxh1	129	15	,	,	,
cord-002240-38aabxh1	129	16	although	although	IN
cord-002240-38aabxh1	129	17	we	-PRON-	PRP
cord-002240-38aabxh1	129	18	do	do	VBP
cord-002240-38aabxh1	129	19	not	not	RB
cord-002240-38aabxh1	129	20	know	know	VB
cord-002240-38aabxh1	129	21	whether	whether	IN
cord-002240-38aabxh1	129	22	this	this	DT
cord-002240-38aabxh1	129	23	combination	combination	NN
cord-002240-38aabxh1	129	24	may	may	MD
cord-002240-38aabxh1	129	25	decrease	decrease	VB
cord-002240-38aabxh1	129	26	the	the	DT
cord-002240-38aabxh1	129	27	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	129	28	response	response	NN
cord-002240-38aabxh1	129	29	to	to	IN
cord-002240-38aabxh1	129	30	a	a	DT
cord-002240-38aabxh1	129	31	very	very	RB
cord-002240-38aabxh1	129	32	low	low	JJ
cord-002240-38aabxh1	129	33	level	level	NN
cord-002240-38aabxh1	129	34	,	,	,
cord-002240-38aabxh1	129	35	thereby	thereby	RB
cord-002240-38aabxh1	129	36	increasing	increase	VBG
cord-002240-38aabxh1	129	37	the	the	DT
cord-002240-38aabxh1	129	38	risk	risk	NN
cord-002240-38aabxh1	129	39	of	of	IN
cord-002240-38aabxh1	129	40	side	side	NN
cord-002240-38aabxh1	129	41	effects	effect	NNS
cord-002240-38aabxh1	129	42	.	.	.
cord-002240-38aabxh1	130	1	We	-PRON-	PRP
cord-002240-38aabxh1	130	2	therefore	therefore	RB
cord-002240-38aabxh1	130	3	need	need	VBP
cord-002240-38aabxh1	130	4	to	to	TO
cord-002240-38aabxh1	130	5	better	better	RB
cord-002240-38aabxh1	130	6	investigate	investigate	VB
cord-002240-38aabxh1	130	7	the	the	DT
cord-002240-38aabxh1	130	8	effects	effect	NNS
cord-002240-38aabxh1	130	9	of	of	IN
cord-002240-38aabxh1	130	10	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	130	11	and	and	CC
cord-002240-38aabxh1	130	12	macrolides	macrolide	NNS
cord-002240-38aabxh1	130	13	together	together	RB
cord-002240-38aabxh1	130	14	in	in	IN
cord-002240-38aabxh1	130	15	order	order	NN
cord-002240-38aabxh1	130	16	to	to	TO
cord-002240-38aabxh1	130	17	provide	provide	VB
cord-002240-38aabxh1	130	18	data	datum	NNS
cord-002240-38aabxh1	130	19	that	that	WDT
cord-002240-38aabxh1	130	20	may	may	MD
cord-002240-38aabxh1	130	21	be	be	VB
cord-002240-38aabxh1	130	22	used	use	VBN
cord-002240-38aabxh1	130	23	to	to	TO
cord-002240-38aabxh1	130	24	support	support	VB
cord-002240-38aabxh1	130	25	clinical	clinical	JJ
cord-002240-38aabxh1	130	26	indications	indication	NNS
cord-002240-38aabxh1	130	27	for	for	IN
cord-002240-38aabxh1	130	28	this	this	DT
cord-002240-38aabxh1	130	29	combination	combination	NN
cord-002240-38aabxh1	130	30	in	in	IN
cord-002240-38aabxh1	130	31	severe	severe	JJ
cord-002240-38aabxh1	130	32	CAP	cap	NN
cord-002240-38aabxh1	130	33	.	.	.
cord-002240-38aabxh1	131	1	Corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	131	2	have	have	VBP
cord-002240-38aabxh1	131	3	proven	prove	VBN
cord-002240-38aabxh1	131	4	benefits	benefit	NNS
cord-002240-38aabxh1	131	5	in	in	IN
cord-002240-38aabxh1	131	6	the	the	DT
cord-002240-38aabxh1	131	7	treatment	treatment	NN
cord-002240-38aabxh1	131	8	of	of	IN
cord-002240-38aabxh1	131	9	acute	acute	JJ
cord-002240-38aabxh1	131	10	exacerbation	exacerbation	NN
cord-002240-38aabxh1	131	11	of	of	IN
cord-002240-38aabxh1	131	12	COPD	COPD	NNP
cord-002240-38aabxh1	131	13	and	and	CC
cord-002240-38aabxh1	131	14	the	the	DT
cord-002240-38aabxh1	131	15	presence	presence	NN
cord-002240-38aabxh1	131	16	of	of	IN
cord-002240-38aabxh1	131	17	chronic	chronic	JJ
cord-002240-38aabxh1	131	18	respiratory	respiratory	JJ
cord-002240-38aabxh1	131	19	disease	disease	NN
cord-002240-38aabxh1	131	20	is	be	VBZ
cord-002240-38aabxh1	131	21	the	the	DT
cord-002240-38aabxh1	131	22	main	main	JJ
cord-002240-38aabxh1	131	23	reason	reason	NN
cord-002240-38aabxh1	131	24	for	for	IN
cord-002240-38aabxh1	131	25	adding	add	VBG
cord-002240-38aabxh1	131	26	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	131	27	to	to	IN
cord-002240-38aabxh1	131	28	antimicrobial	antimicrobial	JJ
cord-002240-38aabxh1	131	29	treatment	treatment	NN
cord-002240-38aabxh1	131	30	in	in	IN
cord-002240-38aabxh1	131	31	pneumonia	pneumonia	NN
cord-002240-38aabxh1	131	32	[	[	-LRB-
cord-002240-38aabxh1	131	33	47	47	CD
cord-002240-38aabxh1	131	34	]	]	-RRB-
cord-002240-38aabxh1	131	35	.	.	.
cord-002240-38aabxh1	132	1	Patients	patient	NNS
cord-002240-38aabxh1	132	2	with	with	IN
cord-002240-38aabxh1	132	3	COPD	COPD	NNP
cord-002240-38aabxh1	132	4	and	and	CC
cord-002240-38aabxh1	132	5	CAP	CAP	NNP
cord-002240-38aabxh1	132	6	presented	present	VBD
cord-002240-38aabxh1	132	7	a	a	DT
cord-002240-38aabxh1	132	8	different	different	JJ
cord-002240-38aabxh1	132	9	early	early	JJ
cord-002240-38aabxh1	132	10	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	132	11	pattern	pattern	NN
cord-002240-38aabxh1	132	12	compared	compare	VBN
cord-002240-38aabxh1	132	13	with	with	IN
cord-002240-38aabxh1	132	14	patients	patient	NNS
cord-002240-38aabxh1	132	15	with	with	IN
cord-002240-38aabxh1	132	16	CAP	CAP	NNP
cord-002240-38aabxh1	132	17	only	only	RB
cord-002240-38aabxh1	132	18	.	.	.
cord-002240-38aabxh1	133	1	In	in	IN
cord-002240-38aabxh1	133	2	particular	particular	JJ
cord-002240-38aabxh1	133	3	,	,	,
cord-002240-38aabxh1	133	4	on	on	IN
cord-002240-38aabxh1	133	5	the	the	DT
cord-002240-38aabxh1	133	6	day	day	NN
cord-002240-38aabxh1	133	7	of	of	IN
cord-002240-38aabxh1	133	8	admission	admission	NN
cord-002240-38aabxh1	133	9	to	to	IN
cord-002240-38aabxh1	133	10	hospital	hospital	NN
cord-002240-38aabxh1	133	11	,	,	,
cord-002240-38aabxh1	133	12	the	the	DT
cord-002240-38aabxh1	133	13	patients	patient	NNS
cord-002240-38aabxh1	133	14	with	with	IN
cord-002240-38aabxh1	133	15	COPD	COPD	NNP
cord-002240-38aabxh1	133	16	had	have	VBD
cord-002240-38aabxh1	133	17	lower	low	JJR
cord-002240-38aabxh1	133	18	levels	level	NNS
cord-002240-38aabxh1	133	19	of	of	IN
cord-002240-38aabxh1	133	20	tumor	tumor	NN
cord-002240-38aabxh1	133	21	necrosis	necrosis	NN
cord-002240-38aabxh1	133	22	factor	factor	NN
cord-002240-38aabxh1	133	23	(	(	-LRB-
cord-002240-38aabxh1	133	24	TNF	TNF	NNP
cord-002240-38aabxh1	133	25	)	)	-RRB-
cord-002240-38aabxh1	133	26	,	,	,
cord-002240-38aabxh1	133	27	IL-1	IL-1	NNP
cord-002240-38aabxh1	133	28	,	,	,
cord-002240-38aabxh1	134	1	and	and	CC
cord-002240-38aabxh1	134	2	IL-6	IL-6	NNP
cord-002240-38aabxh1	134	3	but	but	CC
cord-002240-38aabxh1	134	4	no	no	DT
cord-002240-38aabxh1	134	5	differences	difference	NNS
cord-002240-38aabxh1	134	6	in	in	IN
cord-002240-38aabxh1	134	7	levels	level	NNS
cord-002240-38aabxh1	134	8	of	of	IN
cord-002240-38aabxh1	134	9	CRP	crp	NN
cord-002240-38aabxh1	134	10	,	,	,
cord-002240-38aabxh1	134	11	procalcitonin	procalcitonin	NNS
cord-002240-38aabxh1	134	12	,	,	,
cord-002240-38aabxh1	134	13	IL-8	IL-8	NNP
cord-002240-38aabxh1	134	14	,	,	,
cord-002240-38aabxh1	134	15	and	and	CC
cord-002240-38aabxh1	134	16	IL-10	IL-10	NNP
cord-002240-38aabxh1	134	17	.	.	.
cord-002240-38aabxh1	135	1	These	these	DT
cord-002240-38aabxh1	135	2	differences	difference	NNS
cord-002240-38aabxh1	135	3	were	be	VBD
cord-002240-38aabxh1	135	4	mediated	mediate	VBN
cord-002240-38aabxh1	135	5	in	in	IN
cord-002240-38aabxh1	135	6	part	part	NN
cord-002240-38aabxh1	135	7	by	by	IN
cord-002240-38aabxh1	135	8	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	135	9	;	;	:
cord-002240-38aabxh1	135	10	in	in	IN
cord-002240-38aabxh1	135	11	fact	fact	NN
cord-002240-38aabxh1	135	12	,	,	,
cord-002240-38aabxh1	135	13	lower	low	JJR
cord-002240-38aabxh1	135	14	levels	level	NNS
cord-002240-38aabxh1	135	15	of	of	IN
cord-002240-38aabxh1	135	16	TNF	TNF	NNP
cord-002240-38aabxh1	135	17	-	-	HYPH
cord-002240-38aabxh1	135	18	α	α	NNP
cord-002240-38aabxh1	135	19	persisted	persist	VBD
cord-002240-38aabxh1	135	20	after	after	IN
cord-002240-38aabxh1	135	21	excluding	exclude	VBG
cord-002240-38aabxh1	135	22	patients	patient	NNS
cord-002240-38aabxh1	135	23	who	who	WP
cord-002240-38aabxh1	135	24	received	receive	VBD
cord-002240-38aabxh1	135	25	inhaled	inhale	VBN
cord-002240-38aabxh1	135	26	and	and	CC
cord-002240-38aabxh1	135	27	oral	oral	JJ
cord-002240-38aabxh1	135	28	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	135	29	at	at	IN
cord-002240-38aabxh1	135	30	home	home	NN
cord-002240-38aabxh1	135	31	[	[	-LRB-
cord-002240-38aabxh1	135	32	48	48	CD
cord-002240-38aabxh1	135	33	]	]	-RRB-
cord-002240-38aabxh1	135	34	.	.	.
cord-002240-38aabxh1	136	1	In	in	IN
cord-002240-38aabxh1	136	2	contrast	contrast	NN
cord-002240-38aabxh1	136	3	with	with	IN
cord-002240-38aabxh1	136	4	this	this	DT
cord-002240-38aabxh1	136	5	result	result	NN
cord-002240-38aabxh1	136	6	,	,	,
cord-002240-38aabxh1	136	7	another	another	DT
cord-002240-38aabxh1	136	8	study	study	NN
cord-002240-38aabxh1	136	9	showed	show	VBD
cord-002240-38aabxh1	136	10	that	that	IN
cord-002240-38aabxh1	136	11	COPD	COPD	NNP
cord-002240-38aabxh1	136	12	patients	patient	NNS
cord-002240-38aabxh1	136	13	with	with	IN
cord-002240-38aabxh1	136	14	CAP	CAP	NNP
cord-002240-38aabxh1	136	15	who	who	WP
cord-002240-38aabxh1	136	16	had	have	VBD
cord-002240-38aabxh1	136	17	received	receive	VBN
cord-002240-38aabxh1	136	18	prior	prior	JJ
cord-002240-38aabxh1	136	19	treatment	treatment	NN
cord-002240-38aabxh1	136	20	with	with	IN
cord-002240-38aabxh1	136	21	inhaled	inhale	VBN
cord-002240-38aabxh1	136	22	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	136	23	had	have	VBD
cord-002240-38aabxh1	136	24	lower	low	JJR
cord-002240-38aabxh1	136	25	levels	level	NNS
cord-002240-38aabxh1	136	26	of	of	IN
cord-002240-38aabxh1	136	27	TNF	TNF	NNP
cord-002240-38aabxh1	136	28	-	-	HYPH
cord-002240-38aabxh1	136	29	α	α	NNP
cord-002240-38aabxh1	136	30	after	after	IN
cord-002240-38aabxh1	136	31	adjusting	adjust	VBG
cord-002240-38aabxh1	136	32	for	for	IN
cord-002240-38aabxh1	136	33	other	other	JJ
cord-002240-38aabxh1	136	34	confounders	confounder	NNS
cord-002240-38aabxh1	136	35	in	in	IN
cord-002240-38aabxh1	136	36	comparison	comparison	NN
cord-002240-38aabxh1	136	37	with	with	IN
cord-002240-38aabxh1	136	38	the	the	DT
cord-002240-38aabxh1	136	39	overall	overall	JJ
cord-002240-38aabxh1	136	40	population	population	NN
cord-002240-38aabxh1	136	41	[	[	-LRB-
cord-002240-38aabxh1	136	42	49	49	CD
cord-002240-38aabxh1	136	43	]	]	-RRB-
cord-002240-38aabxh1	136	44	.	.	.
cord-002240-38aabxh1	137	1	In	in	IN
cord-002240-38aabxh1	137	2	addition	addition	NN
cord-002240-38aabxh1	137	3	,	,	,
cord-002240-38aabxh1	137	4	another	another	DT
cord-002240-38aabxh1	137	5	study	study	NN
cord-002240-38aabxh1	137	6	found	find	VBD
cord-002240-38aabxh1	137	7	that	that	IN
cord-002240-38aabxh1	137	8	on	on	IN
cord-002240-38aabxh1	137	9	days	day	NNS
cord-002240-38aabxh1	137	10	1	1	CD
cord-002240-38aabxh1	137	11	and	and	CC
cord-002240-38aabxh1	137	12	3	3	CD
cord-002240-38aabxh1	137	13	,	,	,
cord-002240-38aabxh1	137	14	patients	patient	NNS
cord-002240-38aabxh1	137	15	with	with	IN
cord-002240-38aabxh1	137	16	CAP	cap	NN
cord-002240-38aabxh1	137	17	and	and	CC
cord-002240-38aabxh1	137	18	a	a	DT
cord-002240-38aabxh1	137	19	history	history	NN
cord-002240-38aabxh1	137	20	of	of	IN
cord-002240-38aabxh1	137	21	COPD	COPD	NNP
cord-002240-38aabxh1	137	22	had	have	VBD
cord-002240-38aabxh1	137	23	significantly	significantly	RB
cord-002240-38aabxh1	137	24	higher	high	JJR
cord-002240-38aabxh1	137	25	levels	level	NNS
cord-002240-38aabxh1	137	26	of	of	IN
cord-002240-38aabxh1	137	27	CRP	crp	NN
cord-002240-38aabxh1	137	28	,	,	,
cord-002240-38aabxh1	137	29	procalcitonin	procalcitonin	NNS
cord-002240-38aabxh1	137	30	,	,	,
cord-002240-38aabxh1	137	31	TNF	TNF	NNP
cord-002240-38aabxh1	137	32	-	-	HYPH
cord-002240-38aabxh1	137	33	α	α	NNP
cord-002240-38aabxh1	137	34	,	,	,
cord-002240-38aabxh1	137	35	and	and	CC
cord-002240-38aabxh1	137	36	IL-6	IL-6	NNP
cord-002240-38aabxh1	137	37	than	than	IN
cord-002240-38aabxh1	137	38	patients	patient	NNS
cord-002240-38aabxh1	137	39	admitted	admit	VBN
cord-002240-38aabxh1	137	40	with	with	IN
cord-002240-38aabxh1	137	41	acute	acute	JJ
cord-002240-38aabxh1	137	42	exacerbation	exacerbation	NN
cord-002240-38aabxh1	137	43	of	of	IN
cord-002240-38aabxh1	137	44	COPD	COPD	NNP
cord-002240-38aabxh1	137	45	[	[	-LRB-
cord-002240-38aabxh1	137	46	50	50	CD
cord-002240-38aabxh1	137	47	]	]	-RRB-
cord-002240-38aabxh1	137	48	.	.	.
cord-002240-38aabxh1	138	1	These	these	DT
cord-002240-38aabxh1	138	2	results	result	NNS
cord-002240-38aabxh1	138	3	were	be	VBD
cord-002240-38aabxh1	138	4	maintained	maintain	VBN
cord-002240-38aabxh1	138	5	after	after	IN
cord-002240-38aabxh1	138	6	adjusting	adjust	VBG
cord-002240-38aabxh1	138	7	for	for	IN
cord-002240-38aabxh1	138	8	inhaled	inhale	VBN
cord-002240-38aabxh1	138	9	pharmacotherapy	pharmacotherapy	NN
cord-002240-38aabxh1	138	10	.	.	.
cord-002240-38aabxh1	139	1	In	in	IN
cord-002240-38aabxh1	139	2	conclusion	conclusion	NN
cord-002240-38aabxh1	139	3	,	,	,
cord-002240-38aabxh1	139	4	patients	patient	NNS
cord-002240-38aabxh1	139	5	with	with	IN
cord-002240-38aabxh1	139	6	CAP	CAP	NNP
cord-002240-38aabxh1	139	7	and	and	CC
cord-002240-38aabxh1	139	8	a	a	DT
cord-002240-38aabxh1	139	9	history	history	NN
cord-002240-38aabxh1	139	10	of	of	IN
cord-002240-38aabxh1	139	11	COPD	COPD	NNP
cord-002240-38aabxh1	139	12	represent	represent	VBP
cord-002240-38aabxh1	139	13	a	a	DT
cord-002240-38aabxh1	139	14	specific	specific	JJ
cord-002240-38aabxh1	139	15	population	population	NN
cord-002240-38aabxh1	139	16	with	with	IN
cord-002240-38aabxh1	139	17	a	a	DT
cord-002240-38aabxh1	139	18	different	different	JJ
cord-002240-38aabxh1	139	19	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	139	20	pattern	pattern	NN
cord-002240-38aabxh1	139	21	and	and	CC
cord-002240-38aabxh1	139	22	further	further	JJ
cord-002240-38aabxh1	139	23	studies	study	NNS
cord-002240-38aabxh1	139	24	are	be	VBP
cord-002240-38aabxh1	139	25	needed	need	VBN
cord-002240-38aabxh1	139	26	to	to	TO
cord-002240-38aabxh1	139	27	clarify	clarify	VB
cord-002240-38aabxh1	139	28	the	the	DT
cord-002240-38aabxh1	139	29	use	use	NN
cord-002240-38aabxh1	139	30	of	of	IN
cord-002240-38aabxh1	139	31	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	139	32	in	in	IN
cord-002240-38aabxh1	139	33	these	these	DT
cord-002240-38aabxh1	139	34	patients	patient	NNS
cord-002240-38aabxh1	139	35	during	during	IN
cord-002240-38aabxh1	139	36	CAP	CAP	NNP
cord-002240-38aabxh1	139	37	episodes	episode	NNS
cord-002240-38aabxh1	139	38	,	,	,
cord-002240-38aabxh1	139	39	especially	especially	RB
cord-002240-38aabxh1	139	40	in	in	IN
cord-002240-38aabxh1	139	41	those	those	DT
cord-002240-38aabxh1	139	42	receiving	receive	VBG
cord-002240-38aabxh1	139	43	inhaled	inhale	VBN
cord-002240-38aabxh1	139	44	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	139	45	.	.	.
cord-002240-38aabxh1	140	1	Fluoroquinolones	fluoroquinolone	NNS
cord-002240-38aabxh1	140	2	have	have	VBP
cord-002240-38aabxh1	140	3	also	also	RB
cord-002240-38aabxh1	140	4	shown	show	VBN
cord-002240-38aabxh1	140	5	an	an	DT
cord-002240-38aabxh1	140	6	immunomodulatory	immunomodulatory	JJ
cord-002240-38aabxh1	140	7	effect	effect	NN
cord-002240-38aabxh1	140	8	[	[	-LRB-
cord-002240-38aabxh1	140	9	51	51	CD
cord-002240-38aabxh1	140	10	]	]	-RRB-
cord-002240-38aabxh1	140	11	.	.	.
cord-002240-38aabxh1	141	1	In	in	IN
cord-002240-38aabxh1	141	2	vitro	vitro	FW
cord-002240-38aabxh1	141	3	,	,	,
cord-002240-38aabxh1	141	4	fluoroquinolones	fluoroquinolone	NNS
cord-002240-38aabxh1	141	5	favor	favor	VBP
cord-002240-38aabxh1	141	6	the	the	DT
cord-002240-38aabxh1	141	7	synthesis	synthesis	NN
cord-002240-38aabxh1	141	8	of	of	IN
cord-002240-38aabxh1	141	9	IL-2	IL-2	NNP
cord-002240-38aabxh1	141	10	but	but	CC
cord-002240-38aabxh1	141	11	reduces	reduce	VBZ
cord-002240-38aabxh1	141	12	the	the	DT
cord-002240-38aabxh1	141	13	production	production	NN
cord-002240-38aabxh1	141	14	of	of	IN
cord-002240-38aabxh1	141	15	IL-1	IL-1	NNP
cord-002240-38aabxh1	141	16	and	and	CC
cord-002240-38aabxh1	141	17	TNF	TNF	NNP
cord-002240-38aabxh1	141	18	.	.	.
cord-002240-38aabxh1	142	1	In	in	IN
cord-002240-38aabxh1	142	2	vivo	vivo	NN
cord-002240-38aabxh1	142	3	,	,	,
cord-002240-38aabxh1	142	4	they	-PRON-	PRP
cord-002240-38aabxh1	142	5	affect	affect	VBP
cord-002240-38aabxh1	142	6	cellular	cellular	JJ
cord-002240-38aabxh1	142	7	and	and	CC
cord-002240-38aabxh1	142	8	humoral	humoral	JJ
cord-002240-38aabxh1	142	9	immunity	immunity	NN
cord-002240-38aabxh1	142	10	by	by	IN
cord-002240-38aabxh1	142	11	attenuating	attenuate	VBG
cord-002240-38aabxh1	142	12	cytokine	cytokine	NN
cord-002240-38aabxh1	142	13	responses	response	NNS
cord-002240-38aabxh1	142	14	.	.	.
cord-002240-38aabxh1	143	1	In	in	IN
cord-002240-38aabxh1	143	2	addition	addition	NN
cord-002240-38aabxh1	143	3	,	,	,
cord-002240-38aabxh1	143	4	certain	certain	JJ
cord-002240-38aabxh1	143	5	fluoroquinolones	fluoroquinolone	NNS
cord-002240-38aabxh1	143	6	enhance	enhance	VBP
cord-002240-38aabxh1	143	7	hematopoiesis	hematopoiesis	NN
cord-002240-38aabxh1	143	8	by	by	IN
cord-002240-38aabxh1	143	9	increasing	increase	VBG
cord-002240-38aabxh1	143	10	concentrations	concentration	NNS
cord-002240-38aabxh1	143	11	of	of	IN
cord-002240-38aabxh1	143	12	colony	colony	NN
cord-002240-38aabxh1	143	13	-	-	HYPH
cord-002240-38aabxh1	143	14	stimulating	stimulate	VBG
cord-002240-38aabxh1	143	15	factors	factor	NNS
cord-002240-38aabxh1	143	16	(	(	-LRB-
cord-002240-38aabxh1	143	17	CSFs	CSFs	NNP
cord-002240-38aabxh1	143	18	)	)	-RRB-
cord-002240-38aabxh1	143	19	in	in	IN
cord-002240-38aabxh1	143	20	the	the	DT
cord-002240-38aabxh1	143	21	lung	lung	NN
cord-002240-38aabxh1	143	22	and	and	CC
cord-002240-38aabxh1	143	23	in	in	IN
cord-002240-38aabxh1	143	24	the	the	DT
cord-002240-38aabxh1	143	25	bone	bone	NN
cord-002240-38aabxh1	143	26	marrow	marrow	NN
cord-002240-38aabxh1	143	27	.	.	.
cord-002240-38aabxh1	144	1	CSFs	csf	NNS
cord-002240-38aabxh1	144	2	have	have	VBP
cord-002240-38aabxh1	144	3	a	a	DT
cord-002240-38aabxh1	144	4	role	role	NN
cord-002240-38aabxh1	144	5	in	in	IN
cord-002240-38aabxh1	144	6	the	the	DT
cord-002240-38aabxh1	144	7	response	response	NN
cord-002240-38aabxh1	144	8	to	to	IN
cord-002240-38aabxh1	144	9	infections	infection	NNS
cord-002240-38aabxh1	144	10	.	.	.
cord-002240-38aabxh1	145	1	In	in	IN
cord-002240-38aabxh1	145	2	fact	fact	NN
cord-002240-38aabxh1	145	3	,	,	,
cord-002240-38aabxh1	145	4	CSF	CSF	NNP
cord-002240-38aabxh1	145	5	knockout	knockout	NN
cord-002240-38aabxh1	145	6	mice	mouse	NNS
cord-002240-38aabxh1	145	7	developed	develop	VBD
cord-002240-38aabxh1	145	8	lung	lung	NN
cord-002240-38aabxh1	145	9	infections	infection	NNS
cord-002240-38aabxh1	145	10	and	and	CC
cord-002240-38aabxh1	145	11	the	the	DT
cord-002240-38aabxh1	145	12	administration	administration	NN
cord-002240-38aabxh1	145	13	of	of	IN
cord-002240-38aabxh1	145	14	CSF	CSF	NNP
cord-002240-38aabxh1	145	15	in	in	IN
cord-002240-38aabxh1	145	16	neutropenic	neutropenic	JJ
cord-002240-38aabxh1	145	17	mice	mouse	NNS
cord-002240-38aabxh1	145	18	with	with	IN
cord-002240-38aabxh1	145	19	candida	candida	NN
cord-002240-38aabxh1	145	20	reduced	reduce	VBD
cord-002240-38aabxh1	145	21	the	the	DT
cord-002240-38aabxh1	145	22	risk	risk	NN
cord-002240-38aabxh1	145	23	of	of	IN
cord-002240-38aabxh1	145	24	mortality	mortality	NN
cord-002240-38aabxh1	145	25	and	and	CC
cord-002240-38aabxh1	145	26	lung	lung	NN
cord-002240-38aabxh1	145	27	injury	injury	NN
cord-002240-38aabxh1	145	28	.	.	.
cord-002240-38aabxh1	146	1	More	More	JJR
cord-002240-38aabxh1	146	2	studies	study	NNS
cord-002240-38aabxh1	146	3	are	be	VBP
cord-002240-38aabxh1	146	4	needed	need	VBN
cord-002240-38aabxh1	146	5	,	,	,
cord-002240-38aabxh1	146	6	especially	especially	RB
cord-002240-38aabxh1	146	7	in	in	IN
cord-002240-38aabxh1	146	8	the	the	DT
cord-002240-38aabxh1	146	9	clinical	clinical	JJ
cord-002240-38aabxh1	146	10	setting	setting	NN
cord-002240-38aabxh1	146	11	,	,	,
cord-002240-38aabxh1	146	12	to	to	TO
cord-002240-38aabxh1	146	13	assess	assess	VB
cord-002240-38aabxh1	146	14	the	the	DT
cord-002240-38aabxh1	146	15	immunomodulatory	immunomodulatory	JJ
cord-002240-38aabxh1	146	16	effects	effect	NNS
cord-002240-38aabxh1	146	17	of	of	IN
cord-002240-38aabxh1	146	18	fluoroquinolones	fluoroquinolone	NNS
cord-002240-38aabxh1	146	19	.	.	.
cord-002240-38aabxh1	147	1	Although	although	IN
cord-002240-38aabxh1	147	2	the	the	DT
cord-002240-38aabxh1	147	3	recent	recent	JJ
cord-002240-38aabxh1	147	4	RCTs	rct	NNS
cord-002240-38aabxh1	147	5	provide	provide	VBP
cord-002240-38aabxh1	147	6	data	datum	NNS
cord-002240-38aabxh1	147	7	which	which	WDT
cord-002240-38aabxh1	147	8	have	have	VBP
cord-002240-38aabxh1	147	9	increased	increase	VBN
cord-002240-38aabxh1	147	10	our	-PRON-	PRP$
cord-002240-38aabxh1	147	11	knowledge	knowledge	NN
cord-002240-38aabxh1	147	12	regarding	regard	VBG
cord-002240-38aabxh1	147	13	the	the	DT
cord-002240-38aabxh1	147	14	usefulness	usefulness	NN
cord-002240-38aabxh1	147	15	of	of	IN
cord-002240-38aabxh1	147	16	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	147	17	in	in	IN
cord-002240-38aabxh1	147	18	severe	severe	JJ
cord-002240-38aabxh1	147	19	CAP	cap	NN
cord-002240-38aabxh1	147	20	,	,	,
cord-002240-38aabxh1	147	21	more	more	JJR
cord-002240-38aabxh1	147	22	studies	study	NNS
cord-002240-38aabxh1	147	23	are	be	VBP
cord-002240-38aabxh1	147	24	needed	need	VBN
cord-002240-38aabxh1	147	25	to	to	TO
cord-002240-38aabxh1	147	26	clarify	clarify	VB
cord-002240-38aabxh1	147	27	the	the	DT
cord-002240-38aabxh1	147	28	effect	effect	NN
cord-002240-38aabxh1	147	29	of	of	IN
cord-002240-38aabxh1	147	30	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	147	31	on	on	IN
cord-002240-38aabxh1	147	32	mortality	mortality	NN
cord-002240-38aabxh1	147	33	.	.	.
cord-002240-38aabxh1	148	1	Moreover	moreover	RB
cord-002240-38aabxh1	148	2	,	,	,
cord-002240-38aabxh1	148	3	we	-PRON-	PRP
cord-002240-38aabxh1	148	4	need	need	VBP
cord-002240-38aabxh1	148	5	to	to	TO
cord-002240-38aabxh1	148	6	clarify	clarify	VB
cord-002240-38aabxh1	148	7	which	which	WDT
cord-002240-38aabxh1	148	8	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	148	9	and	and	CC
cord-002240-38aabxh1	148	10	what	what	WP
cord-002240-38aabxh1	148	11	doses	dose	NNS
cord-002240-38aabxh1	148	12	and	and	CC
cord-002240-38aabxh1	148	13	durations	duration	NNS
cord-002240-38aabxh1	148	14	of	of	IN
cord-002240-38aabxh1	148	15	therapy	therapy	NN
cord-002240-38aabxh1	148	16	are	be	VBP
cord-002240-38aabxh1	148	17	most	most	RBS
cord-002240-38aabxh1	148	18	indicated	indicate	VBN
cord-002240-38aabxh1	148	19	and	and	CC
cord-002240-38aabxh1	148	20	to	to	TO
cord-002240-38aabxh1	148	21	define	define	VB
cord-002240-38aabxh1	148	22	the	the	DT
cord-002240-38aabxh1	148	23	specific	specific	JJ
cord-002240-38aabxh1	148	24	populations	population	NNS
cord-002240-38aabxh1	148	25	that	that	WDT
cord-002240-38aabxh1	148	26	may	may	MD
cord-002240-38aabxh1	148	27	benefit	benefit	VB
cord-002240-38aabxh1	148	28	from	from	IN
cord-002240-38aabxh1	148	29	this	this	DT
cord-002240-38aabxh1	148	30	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	148	31	treatment	treatment	NN
cord-002240-38aabxh1	148	32	,	,	,
cord-002240-38aabxh1	148	33	such	such	JJ
cord-002240-38aabxh1	148	34	as	as	IN
cord-002240-38aabxh1	148	35	severe	severe	JJ
cord-002240-38aabxh1	148	36	CAP	cap	NN
cord-002240-38aabxh1	148	37	with	with	IN
cord-002240-38aabxh1	148	38	a	a	DT
cord-002240-38aabxh1	148	39	strong	strong	JJ
cord-002240-38aabxh1	148	40	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	148	41	response	response	NN
cord-002240-38aabxh1	148	42	or	or	CC
cord-002240-38aabxh1	148	43	infections	infection	NNS
cord-002240-38aabxh1	148	44	with	with	IN
cord-002240-38aabxh1	148	45	specific	specific	JJ
cord-002240-38aabxh1	148	46	pathogens	pathogen	NNS
cord-002240-38aabxh1	148	47	.	.	.
cord-002240-38aabxh1	149	1	Another	another	DT
cord-002240-38aabxh1	149	2	interesting	interesting	JJ
cord-002240-38aabxh1	149	3	topic	topic	NN
cord-002240-38aabxh1	149	4	is	be	VBZ
cord-002240-38aabxh1	149	5	the	the	DT
cord-002240-38aabxh1	149	6	effect	effect	NN
cord-002240-38aabxh1	149	7	of	of	IN
cord-002240-38aabxh1	149	8	combination	combination	NN
cord-002240-38aabxh1	149	9	therapy	therapy	NN
cord-002240-38aabxh1	149	10	with	with	IN
cord-002240-38aabxh1	149	11	macrolides	macrolide	NNS
cord-002240-38aabxh1	149	12	and	and	CC
cord-002240-38aabxh1	149	13	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	149	14	in	in	IN
cord-002240-38aabxh1	149	15	the	the	DT
cord-002240-38aabxh1	149	16	modulation	modulation	NN
cord-002240-38aabxh1	149	17	of	of	IN
cord-002240-38aabxh1	149	18	the	the	DT
cord-002240-38aabxh1	149	19	immune	immune	JJ
cord-002240-38aabxh1	149	20	response	response	NN
cord-002240-38aabxh1	149	21	.	.	.
cord-002240-38aabxh1	150	1	We	-PRON-	PRP
cord-002240-38aabxh1	150	2	have	have	VBP
cord-002240-38aabxh1	150	3	some	some	DT
cord-002240-38aabxh1	150	4	promising	promising	JJ
cord-002240-38aabxh1	150	5	data	datum	NNS
cord-002240-38aabxh1	150	6	from	from	IN
cord-002240-38aabxh1	150	7	experimental	experimental	JJ
cord-002240-38aabxh1	150	8	models	model	NNS
cord-002240-38aabxh1	150	9	but	but	CC
cord-002240-38aabxh1	150	10	more	more	JJR
cord-002240-38aabxh1	150	11	data	datum	NNS
cord-002240-38aabxh1	150	12	are	be	VBP
cord-002240-38aabxh1	150	13	needed	need	VBN
cord-002240-38aabxh1	150	14	.	.	.
cord-002240-38aabxh1	151	1	In	in	IN
cord-002240-38aabxh1	151	2	patients	patient	NNS
cord-002240-38aabxh1	151	3	with	with	IN
cord-002240-38aabxh1	151	4	sepsis	sepsis	NN
cord-002240-38aabxh1	151	5	and	and	CC
cord-002240-38aabxh1	151	6	septic	septic	JJ
cord-002240-38aabxh1	151	7	shock	shock	NN
cord-002240-38aabxh1	151	8	,	,	,
cord-002240-38aabxh1	151	9	low	low	JJ
cord-002240-38aabxh1	151	10	levels	level	NNS
cord-002240-38aabxh1	151	11	of	of	IN
cord-002240-38aabxh1	151	12	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	151	13	(	(	-LRB-
cord-002240-38aabxh1	151	14	Igs	Igs	NNP
cord-002240-38aabxh1	151	15	)	)	-RRB-
cord-002240-38aabxh1	151	16	were	be	VBD
cord-002240-38aabxh1	151	17	detected	detect	VBN
cord-002240-38aabxh1	151	18	,	,	,
cord-002240-38aabxh1	151	19	with	with	IN
cord-002240-38aabxh1	151	20	a	a	DT
cord-002240-38aabxh1	151	21	reduction	reduction	NN
cord-002240-38aabxh1	151	22	in	in	IN
cord-002240-38aabxh1	151	23	IgG	igg	NN
cord-002240-38aabxh1	151	24	of	of	IN
cord-002240-38aabxh1	151	25	between	between	IN
cord-002240-38aabxh1	151	26	25	25	CD
cord-002240-38aabxh1	151	27	and	and	CC
cord-002240-38aabxh1	151	28	61	61	CD
cord-002240-38aabxh1	151	29	%	%	NN
cord-002240-38aabxh1	151	30	and	and	CC
cord-002240-38aabxh1	151	31	a	a	DT
cord-002240-38aabxh1	151	32	reduction	reduction	NN
cord-002240-38aabxh1	151	33	in	in	IN
cord-002240-38aabxh1	151	34	IgM	IgM	NNP
cord-002240-38aabxh1	151	35	of	of	IN
cord-002240-38aabxh1	151	36	between	between	IN
cord-002240-38aabxh1	151	37	19	19	CD
cord-002240-38aabxh1	151	38	and	and	CC
cord-002240-38aabxh1	151	39	33	33	CD
cord-002240-38aabxh1	151	40	%	%	NN
cord-002240-38aabxh1	151	41	[	[	-LRB-
cord-002240-38aabxh1	151	42	52	52	CD
cord-002240-38aabxh1	151	43	]	]	-RRB-
cord-002240-38aabxh1	151	44	.	.	.
cord-002240-38aabxh1	152	1	However	however	RB
cord-002240-38aabxh1	152	2	,	,	,
cord-002240-38aabxh1	152	3	a	a	DT
cord-002240-38aabxh1	152	4	recent	recent	JJ
cord-002240-38aabxh1	152	5	metaanalysis	metaanalysis	NN
cord-002240-38aabxh1	152	6	pointed	point	VBD
cord-002240-38aabxh1	152	7	out	out	RP
cord-002240-38aabxh1	152	8	the	the	DT
cord-002240-38aabxh1	152	9	limitations	limitation	NNS
cord-002240-38aabxh1	152	10	of	of	IN
cord-002240-38aabxh1	152	11	the	the	DT
cord-002240-38aabxh1	152	12	studies	study	NNS
cord-002240-38aabxh1	152	13	on	on	IN
cord-002240-38aabxh1	152	14	this	this	DT
cord-002240-38aabxh1	152	15	topic	topic	NN
cord-002240-38aabxh1	152	16	due	due	IN
cord-002240-38aabxh1	152	17	to	to	IN
cord-002240-38aabxh1	152	18	the	the	DT
cord-002240-38aabxh1	152	19	use	use	NN
cord-002240-38aabxh1	152	20	of	of	IN
cord-002240-38aabxh1	152	21	heterogeneous	heterogeneous	JJ
cord-002240-38aabxh1	152	22	cutoffs	cutoff	NNS
cord-002240-38aabxh1	152	23	to	to	TO
cord-002240-38aabxh1	152	24	define	define	VB
cord-002240-38aabxh1	152	25	normal	normal	JJ
cord-002240-38aabxh1	152	26	levels	level	NNS
cord-002240-38aabxh1	152	27	of	of	IN
cord-002240-38aabxh1	152	28	IgG	igg	NN
cord-002240-38aabxh1	152	29	[	[	-LRB-
cord-002240-38aabxh1	152	30	53	53	CD
cord-002240-38aabxh1	152	31	]	]	-RRB-
cord-002240-38aabxh1	152	32	.	.	.
cord-002240-38aabxh1	153	1	Hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-002240-38aabxh1	153	2	and	and	CC
cord-002240-38aabxh1	153	3	low	low	JJ
cord-002240-38aabxh1	153	4	levels	level	NNS
cord-002240-38aabxh1	153	5	of	of	IN
cord-002240-38aabxh1	153	6	IgG	igg	NN
cord-002240-38aabxh1	153	7	subclasses	subclass	NNS
cord-002240-38aabxh1	153	8	were	be	VBD
cord-002240-38aabxh1	153	9	noticed	notice	VBN
cord-002240-38aabxh1	153	10	in	in	IN
cord-002240-38aabxh1	153	11	patients	patient	NNS
cord-002240-38aabxh1	153	12	with	with	IN
cord-002240-38aabxh1	153	13	recurrent	recurrent	JJ
cord-002240-38aabxh1	153	14	episodes	episode	NNS
cord-002240-38aabxh1	153	15	of	of	IN
cord-002240-38aabxh1	153	16	pneumonia	pneumonia	NN
cord-002240-38aabxh1	153	17	and	and	CC
cord-002240-38aabxh1	153	18	may	may	MD
cord-002240-38aabxh1	153	19	be	be	VB
cord-002240-38aabxh1	153	20	responsible	responsible	JJ
cord-002240-38aabxh1	153	21	for	for	IN
cord-002240-38aabxh1	153	22	the	the	DT
cord-002240-38aabxh1	153	23	predisposition	predisposition	NN
cord-002240-38aabxh1	153	24	to	to	IN
cord-002240-38aabxh1	153	25	recurrent	recurrent	JJ
cord-002240-38aabxh1	153	26	infections	infection	NNS
cord-002240-38aabxh1	153	27	[	[	-LRB-
cord-002240-38aabxh1	153	28	9	9	CD
cord-002240-38aabxh1	153	29	]	]	-RRB-
cord-002240-38aabxh1	153	30	.	.	.
cord-002240-38aabxh1	154	1	A	a	DT
cord-002240-38aabxh1	154	2	case	case	NN
cord-002240-38aabxh1	154	3	-	-	HYPH
cord-002240-38aabxh1	154	4	control	control	NN
cord-002240-38aabxh1	154	5	study	study	NN
cord-002240-38aabxh1	154	6	[	[	-LRB-
cord-002240-38aabxh1	154	7	54	54	CD
cord-002240-38aabxh1	154	8	]	]	-RRB-
cord-002240-38aabxh1	154	9	showed	show	VBD
cord-002240-38aabxh1	154	10	that	that	IN
cord-002240-38aabxh1	154	11	patients	patient	NNS
cord-002240-38aabxh1	154	12	with	with	IN
cord-002240-38aabxh1	154	13	CAP	CAP	NNP
cord-002240-38aabxh1	154	14	had	have	VBD
cord-002240-38aabxh1	154	15	significantly	significantly	RB
cord-002240-38aabxh1	154	16	lower	low	JJR
cord-002240-38aabxh1	154	17	levels	level	NNS
cord-002240-38aabxh1	154	18	of	of	IN
cord-002240-38aabxh1	154	19	IgG	igg	NN
cord-002240-38aabxh1	154	20	(	(	-LRB-
cord-002240-38aabxh1	154	21	especially	especially	RB
cord-002240-38aabxh1	154	22	IgG2	igg2	JJ
cord-002240-38aabxh1	154	23	subclass	subclass	NN
cord-002240-38aabxh1	154	24	)	)	-RRB-
cord-002240-38aabxh1	154	25	and	and	CC
cord-002240-38aabxh1	154	26	IgA	IgA	NNP
cord-002240-38aabxh1	154	27	on	on	IN
cord-002240-38aabxh1	154	28	diagnosis	diagnosis	NN
cord-002240-38aabxh1	154	29	in	in	IN
cord-002240-38aabxh1	154	30	comparison	comparison	NN
cord-002240-38aabxh1	154	31	with	with	IN
cord-002240-38aabxh1	154	32	a	a	DT
cord-002240-38aabxh1	154	33	control	control	NN
cord-002240-38aabxh1	154	34	group	group	NN
cord-002240-38aabxh1	154	35	of	of	IN
cord-002240-38aabxh1	154	36	healthy	healthy	JJ
cord-002240-38aabxh1	154	37	patients	patient	NNS
cord-002240-38aabxh1	154	38	without	without	IN
cord-002240-38aabxh1	154	39	pneumonia	pneumonia	NN
cord-002240-38aabxh1	154	40	.	.	.
cord-002240-38aabxh1	155	1	Low	low	JJ
cord-002240-38aabxh1	155	2	levels	level	NNS
cord-002240-38aabxh1	155	3	of	of	IN
cord-002240-38aabxh1	155	4	Igs	Igs	NNP
cord-002240-38aabxh1	155	5	persisted	persist	VBD
cord-002240-38aabxh1	155	6	in	in	IN
cord-002240-38aabxh1	155	7	the	the	DT
cord-002240-38aabxh1	155	8	convalescent	convalescent	JJ
cord-002240-38aabxh1	155	9	phase	phase	NN
cord-002240-38aabxh1	155	10	in	in	IN
cord-002240-38aabxh1	155	11	approximately	approximately	RB
cord-002240-38aabxh1	155	12	25	25	CD
cord-002240-38aabxh1	155	13	%	%	NN
cord-002240-38aabxh1	155	14	of	of	IN
cord-002240-38aabxh1	155	15	patients	patient	NNS
cord-002240-38aabxh1	155	16	.	.	.
cord-002240-38aabxh1	156	1	Hypogammaglobulinemia	Hypogammaglobulinemia	NNP
cord-002240-38aabxh1	156	2	was	be	VBD
cord-002240-38aabxh1	156	3	more	more	RBR
cord-002240-38aabxh1	156	4	frequently	frequently	RB
cord-002240-38aabxh1	156	5	found	find	VBN
cord-002240-38aabxh1	156	6	in	in	IN
cord-002240-38aabxh1	156	7	patients	patient	NNS
cord-002240-38aabxh1	156	8	requiring	require	VBG
cord-002240-38aabxh1	156	9	hospitalization	hospitalization	NN
cord-002240-38aabxh1	156	10	than	than	IN
cord-002240-38aabxh1	156	11	in	in	IN
cord-002240-38aabxh1	156	12	outpatients	outpatient	NNS
cord-002240-38aabxh1	156	13	and	and	CC
cord-002240-38aabxh1	156	14	in	in	IN
cord-002240-38aabxh1	156	15	patients	patient	NNS
cord-002240-38aabxh1	156	16	with	with	IN
cord-002240-38aabxh1	156	17	pneumonia	pneumonia	NN
cord-002240-38aabxh1	156	18	due	due	IN
cord-002240-38aabxh1	156	19	to	to	IN
cord-002240-38aabxh1	156	20	a	a	DT
cord-002240-38aabxh1	156	21	bacterium	bacterium	NN
cord-002240-38aabxh1	156	22	other	other	JJ
cord-002240-38aabxh1	156	23	than	than	IN
cord-002240-38aabxh1	156	24	Streptococcus	Streptococcus	NNP
cord-002240-38aabxh1	156	25	pneumoniae	pneumoniae	NN
cord-002240-38aabxh1	156	26	or	or	CC
cord-002240-38aabxh1	156	27	a	a	DT
cord-002240-38aabxh1	156	28	virus	virus	NN
cord-002240-38aabxh1	156	29	or	or	CC
cord-002240-38aabxh1	156	30	without	without	IN
cord-002240-38aabxh1	156	31	pathogen	pathogen	NN
cord-002240-38aabxh1	156	32	isolation	isolation	NN
cord-002240-38aabxh1	156	33	.	.	.
cord-002240-38aabxh1	157	1	Another	another	DT
cord-002240-38aabxh1	157	2	study	study	NN
cord-002240-38aabxh1	157	3	[	[	-LRB-
cord-002240-38aabxh1	157	4	55	55	CD
cord-002240-38aabxh1	157	5	]	]	-RRB-
cord-002240-38aabxh1	157	6	confirmed	confirm	VBD
cord-002240-38aabxh1	157	7	that	that	IN
cord-002240-38aabxh1	157	8	severe	severe	JJ
cord-002240-38aabxh1	157	9	viral	viral	JJ
cord-002240-38aabxh1	157	10	infection	infection	NN
cord-002240-38aabxh1	157	11	due	due	IN
cord-002240-38aabxh1	157	12	to	to	IN
cord-002240-38aabxh1	157	13	H1N1	H1N1	NNP
cord-002240-38aabxh1	157	14	was	be	VBD
cord-002240-38aabxh1	157	15	associated	associate	VBN
cord-002240-38aabxh1	157	16	with	with	IN
cord-002240-38aabxh1	157	17	lower	low	JJR
cord-002240-38aabxh1	157	18	levels	level	NNS
cord-002240-38aabxh1	157	19	of	of	IN
cord-002240-38aabxh1	157	20	the	the	DT
cord-002240-38aabxh1	157	21	IgG2	igg2	NN
cord-002240-38aabxh1	157	22	subclass	subclass	NN
cord-002240-38aabxh1	157	23	.	.	.
cord-002240-38aabxh1	158	1	Indeed	indeed	RB
cord-002240-38aabxh1	158	2	,	,	,
cord-002240-38aabxh1	158	3	lower	low	JJR
cord-002240-38aabxh1	158	4	levels	level	NNS
cord-002240-38aabxh1	158	5	of	of	IN
cord-002240-38aabxh1	158	6	Igs	Igs	NNP
cord-002240-38aabxh1	158	7	appeared	appear	VBD
cord-002240-38aabxh1	158	8	to	to	TO
cord-002240-38aabxh1	158	9	be	be	VB
cord-002240-38aabxh1	158	10	associated	associate	VBN
cord-002240-38aabxh1	158	11	with	with	IN
cord-002240-38aabxh1	158	12	more	more	RBR
cord-002240-38aabxh1	158	13	severe	severe	JJ
cord-002240-38aabxh1	158	14	disease	disease	NN
cord-002240-38aabxh1	158	15	,	,	,
cord-002240-38aabxh1	158	16	viral	viral	JJ
cord-002240-38aabxh1	158	17	infection	infection	NN
cord-002240-38aabxh1	158	18	,	,	,
cord-002240-38aabxh1	158	19	or	or	CC
cord-002240-38aabxh1	158	20	bacterial	bacterial	JJ
cord-002240-38aabxh1	158	21	infection	infection	NN
cord-002240-38aabxh1	158	22	other	other	JJ
cord-002240-38aabxh1	158	23	than	than	IN
cord-002240-38aabxh1	158	24	Streptococcus	Streptococcus	NNP
cord-002240-38aabxh1	158	25	pneumoniae	pneumoniae	NN
cord-002240-38aabxh1	158	26	.	.	.
cord-002240-38aabxh1	159	1	The	the	DT
cord-002240-38aabxh1	159	2	reason	reason	NN
cord-002240-38aabxh1	159	3	why	why	WRB
cord-002240-38aabxh1	159	4	patients	patient	NNS
cord-002240-38aabxh1	159	5	with	with	IN
cord-002240-38aabxh1	159	6	pneumonia	pneumonia	NN
cord-002240-38aabxh1	159	7	and	and	CC
cord-002240-38aabxh1	159	8	sepsis	sepsis	NN
cord-002240-38aabxh1	159	9	can	can	MD
cord-002240-38aabxh1	159	10	have	have	VB
cord-002240-38aabxh1	159	11	low	low	JJ
cord-002240-38aabxh1	159	12	levels	level	NNS
cord-002240-38aabxh1	159	13	of	of	IN
cord-002240-38aabxh1	159	14	Igs	Igs	NNP
cord-002240-38aabxh1	159	15	is	be	VBZ
cord-002240-38aabxh1	159	16	still	still	RB
cord-002240-38aabxh1	159	17	not	not	RB
cord-002240-38aabxh1	159	18	clear	clear	JJ
cord-002240-38aabxh1	159	19	.	.	.
cord-002240-38aabxh1	160	1	Two	two	CD
cord-002240-38aabxh1	160	2	different	different	JJ
cord-002240-38aabxh1	160	3	mechanisms	mechanism	NNS
cord-002240-38aabxh1	160	4	may	may	MD
cord-002240-38aabxh1	160	5	be	be	VB
cord-002240-38aabxh1	160	6	involved	involve	VBN
cord-002240-38aabxh1	160	7	:	:	:
cord-002240-38aabxh1	160	8	the	the	DT
cord-002240-38aabxh1	160	9	infection	infection	NN
cord-002240-38aabxh1	160	10	may	may	MD
cord-002240-38aabxh1	160	11	be	be	VB
cord-002240-38aabxh1	160	12	responsible	responsible	JJ
cord-002240-38aabxh1	160	13	for	for	IN
cord-002240-38aabxh1	160	14	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-002240-38aabxh1	160	15	by	by	IN
cord-002240-38aabxh1	160	16	consuming	consume	VBG
cord-002240-38aabxh1	160	17	the	the	DT
cord-002240-38aabxh1	160	18	Igs	Igs	NNP
cord-002240-38aabxh1	160	19	or	or	CC
cord-002240-38aabxh1	160	20	the	the	DT
cord-002240-38aabxh1	160	21	presence	presence	NN
cord-002240-38aabxh1	160	22	of	of	IN
cord-002240-38aabxh1	160	23	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-002240-38aabxh1	160	24	may	may	MD
cord-002240-38aabxh1	160	25	be	be	VB
cord-002240-38aabxh1	160	26	the	the	DT
cord-002240-38aabxh1	160	27	cause	cause	NN
cord-002240-38aabxh1	160	28	of	of	IN
cord-002240-38aabxh1	160	29	the	the	DT
cord-002240-38aabxh1	160	30	infection	infection	NN
cord-002240-38aabxh1	160	31	because	because	IN
cord-002240-38aabxh1	160	32	it	-PRON-	PRP
cord-002240-38aabxh1	160	33	contributes	contribute	VBZ
cord-002240-38aabxh1	160	34	to	to	IN
cord-002240-38aabxh1	160	35	an	an	DT
cord-002240-38aabxh1	160	36	inadequate	inadequate	JJ
cord-002240-38aabxh1	160	37	defense	defense	NN
cord-002240-38aabxh1	160	38	response	response	NN
cord-002240-38aabxh1	160	39	.	.	.
cord-002240-38aabxh1	161	1	For	for	IN
cord-002240-38aabxh1	161	2	these	these	DT
cord-002240-38aabxh1	161	3	reasons	reason	NNS
cord-002240-38aabxh1	161	4	,	,	,
cord-002240-38aabxh1	161	5	in	in	IN
cord-002240-38aabxh1	161	6	recent	recent	JJ
cord-002240-38aabxh1	161	7	years	year	NNS
cord-002240-38aabxh1	161	8	,	,	,
cord-002240-38aabxh1	161	9	it	-PRON-	PRP
cord-002240-38aabxh1	161	10	has	have	VBZ
cord-002240-38aabxh1	161	11	been	be	VBN
cord-002240-38aabxh1	161	12	suggested	suggest	VBN
cord-002240-38aabxh1	161	13	that	that	IN
cord-002240-38aabxh1	161	14	the	the	DT
cord-002240-38aabxh1	161	15	administration	administration	NN
cord-002240-38aabxh1	161	16	of	of	IN
cord-002240-38aabxh1	161	17	intravenous	intravenous	JJ
cord-002240-38aabxh1	161	18	Igs	Igs	NNP
cord-002240-38aabxh1	161	19	may	may	MD
cord-002240-38aabxh1	161	20	be	be	VB
cord-002240-38aabxh1	161	21	an	an	DT
cord-002240-38aabxh1	161	22	effective	effective	JJ
cord-002240-38aabxh1	161	23	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	161	24	treatment	treatment	NN
cord-002240-38aabxh1	161	25	to	to	TO
cord-002240-38aabxh1	161	26	modulate	modulate	VB
cord-002240-38aabxh1	161	27	the	the	DT
cord-002240-38aabxh1	161	28	immune	immune	JJ
cord-002240-38aabxh1	161	29	response	response	NN
cord-002240-38aabxh1	161	30	in	in	IN
cord-002240-38aabxh1	161	31	these	these	DT
cord-002240-38aabxh1	161	32	patients	patient	NNS
cord-002240-38aabxh1	161	33	.	.	.
cord-002240-38aabxh1	162	1	Some	some	DT
cord-002240-38aabxh1	162	2	trials	trial	NNS
cord-002240-38aabxh1	162	3	have	have	VBP
cord-002240-38aabxh1	162	4	evaluated	evaluate	VBN
cord-002240-38aabxh1	162	5	the	the	DT
cord-002240-38aabxh1	162	6	effects	effect	NNS
cord-002240-38aabxh1	162	7	of	of	IN
cord-002240-38aabxh1	162	8	exogenous	exogenous	JJ
cord-002240-38aabxh1	162	9	Igs	Igs	NNP
cord-002240-38aabxh1	162	10	as	as	IN
cord-002240-38aabxh1	162	11	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	162	12	treatment	treatment	NN
cord-002240-38aabxh1	162	13	in	in	IN
cord-002240-38aabxh1	162	14	patients	patient	NNS
cord-002240-38aabxh1	162	15	with	with	IN
cord-002240-38aabxh1	162	16	sepsis	sepsis	NN
cord-002240-38aabxh1	162	17	and	and	CC
cord-002240-38aabxh1	162	18	,	,	,
cord-002240-38aabxh1	162	19	in	in	IN
cord-002240-38aabxh1	162	20	particular	particular	JJ
cord-002240-38aabxh1	162	21	,	,	,
cord-002240-38aabxh1	162	22	in	in	IN
cord-002240-38aabxh1	162	23	patients	patient	NNS
cord-002240-38aabxh1	162	24	with	with	IN
cord-002240-38aabxh1	162	25	CAP	CAP	NNP
cord-002240-38aabxh1	162	26	.	.	.
cord-002240-38aabxh1	163	1	However	however	RB
cord-002240-38aabxh1	163	2	,	,	,
cord-002240-38aabxh1	163	3	the	the	DT
cord-002240-38aabxh1	163	4	results	result	NNS
cord-002240-38aabxh1	163	5	of	of	IN
cord-002240-38aabxh1	163	6	these	these	DT
cord-002240-38aabxh1	163	7	studies	study	NNS
cord-002240-38aabxh1	163	8	are	be	VBP
cord-002240-38aabxh1	163	9	still	still	RB
cord-002240-38aabxh1	163	10	the	the	DT
cord-002240-38aabxh1	163	11	subject	subject	NN
cord-002240-38aabxh1	163	12	of	of	IN
cord-002240-38aabxh1	163	13	debate	debate	NN
cord-002240-38aabxh1	163	14	[	[	-LRB-
cord-002240-38aabxh1	163	15	56	56	CD
cord-002240-38aabxh1	163	16	]	]	-RRB-
cord-002240-38aabxh1	163	17	.	.	.
cord-002240-38aabxh1	164	1	A	a	DT
cord-002240-38aabxh1	164	2	meta	meta	JJ
cord-002240-38aabxh1	164	3	-	-	HYPH
cord-002240-38aabxh1	164	4	analysis	analysis	NN
cord-002240-38aabxh1	164	5	[	[	-LRB-
cord-002240-38aabxh1	164	6	57	57	CD
cord-002240-38aabxh1	164	7	]	]	-RRB-
cord-002240-38aabxh1	164	8	reported	report	VBD
cord-002240-38aabxh1	164	9	a	a	DT
cord-002240-38aabxh1	164	10	general	general	JJ
cord-002240-38aabxh1	164	11	reduction	reduction	NN
cord-002240-38aabxh1	164	12	in	in	IN
cord-002240-38aabxh1	164	13	mortality	mortality	NN
cord-002240-38aabxh1	164	14	(	(	-LRB-
cord-002240-38aabxh1	164	15	approximately	approximately	RB
cord-002240-38aabxh1	164	16	21	21	CD
cord-002240-38aabxh1	164	17	%	%	NN
cord-002240-38aabxh1	164	18	)	)	-RRB-
cord-002240-38aabxh1	164	19	in	in	IN
cord-002240-38aabxh1	164	20	adult	adult	NN
cord-002240-38aabxh1	164	21	patients	patient	NNS
cord-002240-38aabxh1	164	22	with	with	IN
cord-002240-38aabxh1	164	23	sepsis	sepsis	NN
cord-002240-38aabxh1	164	24	and	and	CC
cord-002240-38aabxh1	164	25	septic	septic	JJ
cord-002240-38aabxh1	164	26	shock	shock	NN
cord-002240-38aabxh1	164	27	who	who	WP
cord-002240-38aabxh1	164	28	received	receive	VBD
cord-002240-38aabxh1	164	29	polyclonal	polyclonal	JJ
cord-002240-38aabxh1	164	30	Igs	Igs	NNP
cord-002240-38aabxh1	164	31	and	and	CC
cord-002240-38aabxh1	164	32	a	a	DT
cord-002240-38aabxh1	164	33	more	more	RBR
cord-002240-38aabxh1	164	34	evident	evident	JJ
cord-002240-38aabxh1	164	35	effect	effect	NN
cord-002240-38aabxh1	164	36	on	on	IN
cord-002240-38aabxh1	164	37	mortality	mortality	NN
cord-002240-38aabxh1	164	38	in	in	IN
cord-002240-38aabxh1	164	39	the	the	DT
cord-002240-38aabxh1	164	40	subgroup	subgroup	NN
cord-002240-38aabxh1	164	41	receiving	receive	VBG
cord-002240-38aabxh1	164	42	IgM	IgM	NNP
cord-002240-38aabxh1	164	43	-	-	HYPH
cord-002240-38aabxh1	164	44	enriched	enrich	VBN
cord-002240-38aabxh1	164	45	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	164	46	.	.	.
cord-002240-38aabxh1	165	1	A	a	DT
cord-002240-38aabxh1	165	2	more	more	RBR
cord-002240-38aabxh1	165	3	recent	recent	JJ
cord-002240-38aabxh1	165	4	meta	meta	JJ
cord-002240-38aabxh1	165	5	-	-	HYPH
cord-002240-38aabxh1	165	6	analysis	analysis	NN
cord-002240-38aabxh1	165	7	by	by	IN
cord-002240-38aabxh1	165	8	Cochrane	Cochrane	NNP
cord-002240-38aabxh1	165	9	published	publish	VBN
cord-002240-38aabxh1	165	10	in	in	IN
cord-002240-38aabxh1	165	11	2013	2013	CD
cord-002240-38aabxh1	165	12	[	[	-LRB-
cord-002240-38aabxh1	165	13	56	56	CD
cord-002240-38aabxh1	165	14	]	]	-RRB-
cord-002240-38aabxh1	165	15	showed	show	VBD
cord-002240-38aabxh1	165	16	a	a	DT
cord-002240-38aabxh1	165	17	reduction	reduction	NN
cord-002240-38aabxh1	165	18	in	in	IN
cord-002240-38aabxh1	165	19	mortality	mortality	NN
cord-002240-38aabxh1	165	20	in	in	IN
cord-002240-38aabxh1	165	21	patients	patient	NNS
cord-002240-38aabxh1	165	22	who	who	WP
cord-002240-38aabxh1	165	23	received	receive	VBD
cord-002240-38aabxh1	165	24	polyclonal	polyclonal	JJ
cord-002240-38aabxh1	165	25	intravenous	intravenous	JJ
cord-002240-38aabxh1	165	26	Igs	Igs	NNP
cord-002240-38aabxh1	165	27	,	,	,
cord-002240-38aabxh1	165	28	although	although	IN
cord-002240-38aabxh1	165	29	this	this	DT
cord-002240-38aabxh1	165	30	positive	positive	JJ
cord-002240-38aabxh1	165	31	effect	effect	NN
cord-002240-38aabxh1	165	32	disappeared	disappear	VBD
cord-002240-38aabxh1	165	33	on	on	IN
cord-002240-38aabxh1	165	34	analyzing	analyze	VBG
cord-002240-38aabxh1	165	35	only	only	RB
cord-002240-38aabxh1	165	36	trials	trial	NNS
cord-002240-38aabxh1	165	37	with	with	IN
cord-002240-38aabxh1	165	38	low	low	JJ
cord-002240-38aabxh1	165	39	bias	bias	NN
cord-002240-38aabxh1	165	40	.	.	.
cord-002240-38aabxh1	166	1	A	a	DT
cord-002240-38aabxh1	166	2	large	large	JJ
cord-002240-38aabxh1	166	3	retrospective	retrospective	JJ
cord-002240-38aabxh1	166	4	study	study	NN
cord-002240-38aabxh1	166	5	in	in	IN
cord-002240-38aabxh1	166	6	Japan	Japan	NNP
cord-002240-38aabxh1	166	7	[	[	-LRB-
cord-002240-38aabxh1	166	8	58	58	CD
cord-002240-38aabxh1	166	9	]	]	-RRB-
cord-002240-38aabxh1	166	10	evaluated	evaluate	VBD
cord-002240-38aabxh1	166	11	the	the	DT
cord-002240-38aabxh1	166	12	effect	effect	NN
cord-002240-38aabxh1	166	13	of	of	IN
cord-002240-38aabxh1	166	14	intravenous	intravenous	JJ
cord-002240-38aabxh1	166	15	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	166	16	as	as	IN
cord-002240-38aabxh1	166	17	an	an	DT
cord-002240-38aabxh1	166	18	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	166	19	treatment	treatment	NN
cord-002240-38aabxh1	166	20	in	in	IN
cord-002240-38aabxh1	166	21	patients	patient	NNS
cord-002240-38aabxh1	166	22	with	with	IN
cord-002240-38aabxh1	166	23	septic	septic	JJ
cord-002240-38aabxh1	166	24	shock	shock	NN
cord-002240-38aabxh1	166	25	due	due	IN
cord-002240-38aabxh1	166	26	to	to	IN
cord-002240-38aabxh1	166	27	pneumonia	pneumonia	NN
cord-002240-38aabxh1	166	28	.	.	.
cord-002240-38aabxh1	167	1	A	a	DT
cord-002240-38aabxh1	167	2	total	total	NN
cord-002240-38aabxh1	167	3	of	of	IN
cord-002240-38aabxh1	167	4	8264	8264	CD
cord-002240-38aabxh1	167	5	patients	patient	NNS
cord-002240-38aabxh1	167	6	were	be	VBD
cord-002240-38aabxh1	167	7	studied	study	VBN
cord-002240-38aabxh1	167	8	,	,	,
cord-002240-38aabxh1	167	9	of	of	IN
cord-002240-38aabxh1	167	10	whom	whom	WP
cord-002240-38aabxh1	167	11	1324	1324	CD
cord-002240-38aabxh1	167	12	were	be	VBD
cord-002240-38aabxh1	167	13	treated	treat	VBN
cord-002240-38aabxh1	167	14	with	with	IN
cord-002240-38aabxh1	167	15	intravenous	intravenous	JJ
cord-002240-38aabxh1	167	16	Igs	Igs	NNP
cord-002240-38aabxh1	167	17	,	,	,
cord-002240-38aabxh1	167	18	in	in	IN
cord-002240-38aabxh1	167	19	comparison	comparison	NN
cord-002240-38aabxh1	167	20	with	with	IN
cord-002240-38aabxh1	167	21	6940	6940	CD
cord-002240-38aabxh1	167	22	patients	patient	NNS
cord-002240-38aabxh1	167	23	who	who	WP
cord-002240-38aabxh1	167	24	did	do	VBD
cord-002240-38aabxh1	167	25	not	not	RB
cord-002240-38aabxh1	167	26	receive	receive	VB
cord-002240-38aabxh1	167	27	the	the	DT
cord-002240-38aabxh1	167	28	Igs	Igs	NNP
cord-002240-38aabxh1	167	29	.	.	.
cord-002240-38aabxh1	168	1	No	no	DT
cord-002240-38aabxh1	168	2	benefit	benefit	NN
cord-002240-38aabxh1	168	3	was	be	VBD
cord-002240-38aabxh1	168	4	found	find	VBN
cord-002240-38aabxh1	168	5	in	in	IN
cord-002240-38aabxh1	168	6	terms	term	NNS
cord-002240-38aabxh1	168	7	of	of	IN
cord-002240-38aabxh1	168	8	mortality	mortality	NN
cord-002240-38aabxh1	168	9	in	in	IN
cord-002240-38aabxh1	168	10	the	the	DT
cord-002240-38aabxh1	168	11	group	group	NN
cord-002240-38aabxh1	168	12	of	of	IN
cord-002240-38aabxh1	168	13	patients	patient	NNS
cord-002240-38aabxh1	168	14	receiving	receive	VBG
cord-002240-38aabxh1	168	15	the	the	DT
cord-002240-38aabxh1	168	16	Igs	Igs	NNP
cord-002240-38aabxh1	168	17	.	.	.
cord-002240-38aabxh1	169	1	A	a	DT
cord-002240-38aabxh1	169	2	multicentre	multicentre	NN
cord-002240-38aabxh1	169	3	,	,	,
cord-002240-38aabxh1	169	4	randomized	randomized	JJ
cord-002240-38aabxh1	169	5	,	,	,
cord-002240-38aabxh1	169	6	placebo	placebo	NN
cord-002240-38aabxh1	169	7	-	-	HYPH
cord-002240-38aabxh1	169	8	controlled	control	VBN
cord-002240-38aabxh1	169	9	phase	phase	NN
cord-002240-38aabxh1	169	10	II	ii	CD
cord-002240-38aabxh1	169	11	trial	trial	NN
cord-002240-38aabxh1	169	12	[	[	-LRB-
cord-002240-38aabxh1	169	13	59	59	CD
cord-002240-38aabxh1	169	14	]	]	-RRB-
cord-002240-38aabxh1	169	15	is	be	VBZ
cord-002240-38aabxh1	169	16	ongoing	ongoing	JJ
cord-002240-38aabxh1	169	17	with	with	IN
cord-002240-38aabxh1	169	18	the	the	DT
cord-002240-38aabxh1	169	19	aim	aim	NN
cord-002240-38aabxh1	169	20	of	of	IN
cord-002240-38aabxh1	169	21	evaluating	evaluate	VBG
cord-002240-38aabxh1	169	22	the	the	DT
cord-002240-38aabxh1	169	23	efficacy	efficacy	NN
cord-002240-38aabxh1	169	24	and	and	CC
cord-002240-38aabxh1	169	25	safety	safety	NN
cord-002240-38aabxh1	169	26	of	of	IN
cord-002240-38aabxh1	169	27	IgM	IgM	NNP
cord-002240-38aabxh1	169	28	-	-	HYPH
cord-002240-38aabxh1	169	29	enriched	enrich	VBN
cord-002240-38aabxh1	169	30	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	169	31	preparations	preparation	NNS
cord-002240-38aabxh1	169	32	(	(	-LRB-
cord-002240-38aabxh1	169	33	pentaglobin	pentaglobin	NNP
cord-002240-38aabxh1	169	34	™	™	NNP
cord-002240-38aabxh1	169	35	,	,	,
cord-002240-38aabxh1	169	36	12	12	CD
cord-002240-38aabxh1	169	37	%	%	NN
cord-002240-38aabxh1	169	38	IgM	IgM	NNP
cord-002240-38aabxh1	169	39	,	,	,
cord-002240-38aabxh1	169	40	12	12	CD
cord-002240-38aabxh1	169	41	%	%	NN
cord-002240-38aabxh1	169	42	IgA	IgA	NNP
cord-002240-38aabxh1	169	43	,	,	,
cord-002240-38aabxh1	169	44	and	and	CC
cord-002240-38aabxh1	169	45	76	76	CD
cord-002240-38aabxh1	169	46	%	%	NN
cord-002240-38aabxh1	169	47	IgG	IgG	NNP
cord-002240-38aabxh1	169	48	)	)	-RRB-
cord-002240-38aabxh1	169	49	as	as	IN
cord-002240-38aabxh1	169	50	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	169	51	treatment	treatment	NN
cord-002240-38aabxh1	169	52	in	in	IN
cord-002240-38aabxh1	169	53	patients	patient	NNS
cord-002240-38aabxh1	169	54	with	with	IN
cord-002240-38aabxh1	169	55	mechanical	mechanical	JJ
cord-002240-38aabxh1	169	56	ventilation	ventilation	NN
cord-002240-38aabxh1	169	57	for	for	IN
cord-002240-38aabxh1	169	58	CAP	CAP	NNP
cord-002240-38aabxh1	169	59	.	.	.
cord-002240-38aabxh1	170	1	The	the	DT
cord-002240-38aabxh1	170	2	primary	primary	JJ
cord-002240-38aabxh1	170	3	outcome	outcome	NN
cord-002240-38aabxh1	170	4	is	be	VBZ
cord-002240-38aabxh1	170	5	the	the	DT
cord-002240-38aabxh1	170	6	number	number	NN
cord-002240-38aabxh1	170	7	of	of	IN
cord-002240-38aabxh1	170	8	ventilator	ventilator	NN
cord-002240-38aabxh1	170	9	-	-	HYPH
cord-002240-38aabxh1	170	10	free	free	JJ
cord-002240-38aabxh1	170	11	days	day	NNS
cord-002240-38aabxh1	170	12	.	.	.
cord-002240-38aabxh1	171	1	The	the	DT
cord-002240-38aabxh1	171	2	use	use	NN
cord-002240-38aabxh1	171	3	of	of	IN
cord-002240-38aabxh1	171	4	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	171	5	in	in	IN
cord-002240-38aabxh1	171	6	patients	patient	NNS
cord-002240-38aabxh1	171	7	with	with	IN
cord-002240-38aabxh1	171	8	severe	severe	JJ
cord-002240-38aabxh1	171	9	CAP	cap	NN
cord-002240-38aabxh1	171	10	and	and	CC
cord-002240-38aabxh1	171	11	a	a	DT
cord-002240-38aabxh1	171	12	strong	strong	JJ
cord-002240-38aabxh1	171	13	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	171	14	reaction	reaction	NN
cord-002240-38aabxh1	171	15	can	can	MD
cord-002240-38aabxh1	171	16	reduce	reduce	VB
cord-002240-38aabxh1	171	17	the	the	DT
cord-002240-38aabxh1	171	18	time	time	NN
cord-002240-38aabxh1	171	19	to	to	IN
cord-002240-38aabxh1	171	20	clinical	clinical	JJ
cord-002240-38aabxh1	171	21	stability	stability	NN
cord-002240-38aabxh1	171	22	and	and	CC
cord-002240-38aabxh1	171	23	the	the	DT
cord-002240-38aabxh1	171	24	risk	risk	NN
cord-002240-38aabxh1	171	25	of	of	IN
cord-002240-38aabxh1	171	26	treatment	treatment	NN
cord-002240-38aabxh1	171	27	failure	failure	NN
cord-002240-38aabxh1	171	28	,	,	,
cord-002240-38aabxh1	171	29	especially	especially	RB
cord-002240-38aabxh1	171	30	radiological	radiological	JJ
cord-002240-38aabxh1	171	31	progression	progression	NN
cord-002240-38aabxh1	171	32	.	.	.
cord-002240-38aabxh1	172	1	The	the	DT
cord-002240-38aabxh1	172	2	administration	administration	NN
cord-002240-38aabxh1	172	3	of	of	IN
cord-002240-38aabxh1	172	4	intravenous	intravenous	JJ
cord-002240-38aabxh1	172	5	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	172	6	can	can	MD
cord-002240-38aabxh1	172	7	reinforce	reinforce	VB
cord-002240-38aabxh1	172	8	the	the	DT
cord-002240-38aabxh1	172	9	immune	immune	JJ
cord-002240-38aabxh1	172	10	response	response	NN
cord-002240-38aabxh1	172	11	to	to	IN
cord-002240-38aabxh1	172	12	infection	infection	NN
cord-002240-38aabxh1	172	13	,	,	,
cord-002240-38aabxh1	172	14	particularly	particularly	RB
cord-002240-38aabxh1	172	15	in	in	IN
cord-002240-38aabxh1	172	16	patients	patient	NNS
cord-002240-38aabxh1	172	17	with	with	IN
cord-002240-38aabxh1	172	18	inadequate	inadequate	JJ
cord-002240-38aabxh1	172	19	levels	level	NNS
cord-002240-38aabxh1	172	20	of	of	IN
cord-002240-38aabxh1	172	21	antibodies	antibody	NNS
cord-002240-38aabxh1	172	22	and	and	CC
cord-002240-38aabxh1	172	23	when	when	WRB
cord-002240-38aabxh1	172	24	an	an	DT
cord-002240-38aabxh1	172	25	enriched	enriched	JJ
cord-002240-38aabxh1	172	26	IgM	igm	NN
cord-002240-38aabxh1	172	27	preparation	preparation	NN
cord-002240-38aabxh1	172	28	is	be	VBZ
cord-002240-38aabxh1	172	29	used	use	VBN
cord-002240-38aabxh1	172	30	.	.	.
cord-002240-38aabxh1	173	1	However	however	RB
cord-002240-38aabxh1	173	2	,	,	,
cord-002240-38aabxh1	173	3	more	more	JJR
cord-002240-38aabxh1	173	4	studies	study	NNS
cord-002240-38aabxh1	173	5	are	be	VBP
cord-002240-38aabxh1	173	6	needed	need	VBN
cord-002240-38aabxh1	173	7	to	to	TO
cord-002240-38aabxh1	173	8	evaluate	evaluate	VB
cord-002240-38aabxh1	173	9	their	-PRON-	PRP$
cord-002240-38aabxh1	173	10	effects	effect	NNS
cord-002240-38aabxh1	173	11	in	in	IN
cord-002240-38aabxh1	173	12	patients	patient	NNS
cord-002240-38aabxh1	173	13	with	with	IN
cord-002240-38aabxh1	173	14	CAP	CAP	NNP
cord-002240-38aabxh1	173	15	.	.	.
cord-002240-38aabxh1	174	1	Abbreviations	Abbreviations	NNPS
cord-002240-38aabxh1	174	2	ARDS	ARDS	NNP
cord-002240-38aabxh1	174	3	,	,	,
cord-002240-38aabxh1	174	4	acute	acute	JJ
cord-002240-38aabxh1	174	5	respiratory	respiratory	JJ
cord-002240-38aabxh1	174	6	distress	distress	NN
cord-002240-38aabxh1	174	7	syndrome	syndrome	NN
cord-002240-38aabxh1	174	8	;	;	:
cord-002240-38aabxh1	174	9	CAP	CAP	NNP
cord-002240-38aabxh1	174	10	,	,	,
cord-002240-38aabxh1	174	11	community	community	NN
cord-002240-38aabxh1	174	12	acquired	acquire	VBD
cord-002240-38aabxh1	174	13	pneumonia	pneumonia	NN
cord-002240-38aabxh1	174	14	;	;	:
cord-002240-38aabxh1	174	15	CI	CI	NNP
cord-002240-38aabxh1	174	16	,	,	,
cord-002240-38aabxh1	174	17	confidence	confidence	NN
cord-002240-38aabxh1	174	18	interval	interval	NN
cord-002240-38aabxh1	174	19	;	;	:
cord-002240-38aabxh1	174	20	COPD	COPD	NNP
cord-002240-38aabxh1	174	21	,	,	,
cord-002240-38aabxh1	174	22	chronic	chronic	JJ
cord-002240-38aabxh1	174	23	obstructive	obstructive	JJ
cord-002240-38aabxh1	174	24	pulmonary	pulmonary	JJ
cord-002240-38aabxh1	174	25	disease	disease	NN
cord-002240-38aabxh1	174	26	;	;	:
cord-002240-38aabxh1	174	27	CRP	CRP	NNP
cord-002240-38aabxh1	174	28	,	,	,
cord-002240-38aabxh1	174	29	C	C	NNP
cord-002240-38aabxh1	174	30	-	-	HYPH
cord-002240-38aabxh1	174	31	reactive	reactive	JJ
cord-002240-38aabxh1	174	32	protein	protein	NN
cord-002240-38aabxh1	174	33	;	;	:
cord-002240-38aabxh1	174	34	CSF	CSF	NNP
cord-002240-38aabxh1	174	35	,	,	,
cord-002240-38aabxh1	174	36	colony	colony	NN
cord-002240-38aabxh1	174	37	-	-	HYPH
cord-002240-38aabxh1	174	38	stimulating	stimulate	VBG
cord-002240-38aabxh1	174	39	factor	factor	NN
cord-002240-38aabxh1	174	40	;	;	:
cord-002240-38aabxh1	174	41	ICU	ICU	NNP
cord-002240-38aabxh1	174	42	,	,	,
cord-002240-38aabxh1	174	43	intensive	intensive	JJ
cord-002240-38aabxh1	174	44	care	care	NN
cord-002240-38aabxh1	174	45	unit	unit	NN
cord-002240-38aabxh1	174	46	;	;	:
cord-002240-38aabxh1	175	1	Ig	Ig	NNP
cord-002240-38aabxh1	175	2	,	,	,
cord-002240-38aabxh1	175	3	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	175	4	;	;	:
cord-002240-38aabxh1	175	5	IL	IL	NNP
cord-002240-38aabxh1	175	6	,	,	,
cord-002240-38aabxh1	175	7	interleukin	interleukin	NN
cord-002240-38aabxh1	175	8	;	;	:
cord-002240-38aabxh1	175	9	OR	or	CC
cord-002240-38aabxh1	175	10	,	,	,
cord-002240-38aabxh1	175	11	odds	odd	NNS
cord-002240-38aabxh1	175	12	ratio	ratio	NN
cord-002240-38aabxh1	175	13	;	;	:
cord-002240-38aabxh1	175	14	RCT	RCT	NNP
cord-002240-38aabxh1	175	15	,	,	,
cord-002240-38aabxh1	175	16	randomized	randomized	JJ
cord-002240-38aabxh1	175	17	controlled	control	VBN
cord-002240-38aabxh1	175	18	trial	trial	NN
cord-002240-38aabxh1	175	19	;	;	:
cord-002240-38aabxh1	175	20	RR	rr	NN
cord-002240-38aabxh1	175	21	,	,	,
cord-002240-38aabxh1	175	22	risk	risk	NN
cord-002240-38aabxh1	175	23	ratio	ratio	NN
cord-002240-38aabxh1	175	24	;	;	:
cord-002240-38aabxh1	175	25	TNF	TNF	NNP
cord-002240-38aabxh1	175	26	,	,	,
cord-002240-38aabxh1	175	27	tumor	tumor	NN
cord-002240-38aabxh1	175	28	necrosis	necrosis	NN
cord-002240-38aabxh1	175	29	factor	factor	NN
cord-002240-38aabxh1	175	30	 	 	_SP
cord-002240-38aabxh1	175	31	Risk	Risk	NNP
cord-002240-38aabxh1	175	32	factors	factor	NNS
cord-002240-38aabxh1	175	33	for	for	IN
cord-002240-38aabxh1	175	34	30-day	30-day	CD
cord-002240-38aabxh1	175	35	mortality	mortality	NN
cord-002240-38aabxh1	175	36	in	in	IN
cord-002240-38aabxh1	175	37	patients	patient	NNS
cord-002240-38aabxh1	175	38	with	with	IN
cord-002240-38aabxh1	175	39	pneumonia	pneumonia	NN
cord-002240-38aabxh1	175	40	who	who	WP
cord-002240-38aabxh1	175	41	receive	receive	VBP
cord-002240-38aabxh1	175	42	appropriate	appropriate	JJ
cord-002240-38aabxh1	175	43	initial	initial	JJ
cord-002240-38aabxh1	175	44	antibiotics	antibiotic	NNS
cord-002240-38aabxh1	175	45	:	:	:
cord-002240-38aabxh1	176	1	an	an	DT
cord-002240-38aabxh1	176	2	observational	observational	JJ
cord-002240-38aabxh1	176	3	cohort	cohort	NN
cord-002240-38aabxh1	176	4	study	study	NN
cord-002240-38aabxh1	176	5	Epidemiology	epidemiology	NN
cord-002240-38aabxh1	176	6	and	and	CC
cord-002240-38aabxh1	176	7	outcome	outcome	NN
cord-002240-38aabxh1	176	8	of	of	IN
cord-002240-38aabxh1	176	9	severe	severe	JJ
cord-002240-38aabxh1	176	10	pneumococcal	pneumococcal	JJ
cord-002240-38aabxh1	176	11	pneumonia	pneumonia	NN
cord-002240-38aabxh1	176	12	admitted	admit	VBN
cord-002240-38aabxh1	176	13	to	to	IN
cord-002240-38aabxh1	176	14	intensive	intensive	JJ
cord-002240-38aabxh1	176	15	care	care	NN
cord-002240-38aabxh1	176	16	unit	unit	NN
cord-002240-38aabxh1	176	17	:	:	:
cord-002240-38aabxh1	176	18	a	a	DT
cord-002240-38aabxh1	176	19	multicenter	multicenter	JJ
cord-002240-38aabxh1	176	20	study	study	NN
cord-002240-38aabxh1	176	21	Septic	Septic	NNP
cord-002240-38aabxh1	176	22	shock	shock	NN
cord-002240-38aabxh1	176	23	Systemic	systemic	JJ
cord-002240-38aabxh1	176	24	cytokine	cytokine	NN
cord-002240-38aabxh1	176	25	levels	level	NNS
cord-002240-38aabxh1	176	26	in	in	IN
cord-002240-38aabxh1	176	27	community	community	NN
cord-002240-38aabxh1	176	28	-	-	HYPH
cord-002240-38aabxh1	176	29	acquired	acquire	VBN
cord-002240-38aabxh1	176	30	pneumonia	pneumonia	NN
cord-002240-38aabxh1	176	31	and	and	CC
cord-002240-38aabxh1	176	32	their	-PRON-	PRP$
cord-002240-38aabxh1	176	33	association	association	NN
cord-002240-38aabxh1	176	34	with	with	IN
cord-002240-38aabxh1	176	35	disease	disease	NN
cord-002240-38aabxh1	176	36	severity	severity	NN
cord-002240-38aabxh1	176	37	Risk	risk	NN
cord-002240-38aabxh1	176	38	factors	factor	NNS
cord-002240-38aabxh1	176	39	of	of	IN
cord-002240-38aabxh1	176	40	treatment	treatment	NN
cord-002240-38aabxh1	176	41	failure	failure	NN
cord-002240-38aabxh1	176	42	in	in	IN
cord-002240-38aabxh1	176	43	community	community	NN
cord-002240-38aabxh1	176	44	acquired	acquire	VBD
cord-002240-38aabxh1	176	45	pneumonia	pneumonia	NN
cord-002240-38aabxh1	176	46	:	:	:
cord-002240-38aabxh1	176	47	implications	implication	NNS
cord-002240-38aabxh1	176	48	for	for	IN
cord-002240-38aabxh1	176	49	disease	disease	NN
cord-002240-38aabxh1	176	50	outcome	outcome	NN
cord-002240-38aabxh1	176	51	Markers	marker	NNS
cord-002240-38aabxh1	176	52	of	of	IN
cord-002240-38aabxh1	176	53	treatment	treatment	NN
cord-002240-38aabxh1	176	54	failure	failure	NN
cord-002240-38aabxh1	176	55	in	in	IN
cord-002240-38aabxh1	176	56	hospitalised	hospitalise	VBN
cord-002240-38aabxh1	176	57	community	community	NN
cord-002240-38aabxh1	176	58	acquired	acquire	VBD
cord-002240-38aabxh1	176	59	pneumonia	pneumonia	NN
cord-002240-38aabxh1	176	60	Severity	severity	NN
cord-002240-38aabxh1	176	61	of	of	IN
cord-002240-38aabxh1	176	62	meningococcal	meningococcal	JJ
cord-002240-38aabxh1	176	63	disease	disease	NN
cord-002240-38aabxh1	176	64	associated	associate	VBN
cord-002240-38aabxh1	176	65	with	with	IN
cord-002240-38aabxh1	176	66	genomic	genomic	JJ
cord-002240-38aabxh1	176	67	bacterial	bacterial	JJ
cord-002240-38aabxh1	176	68	load	load	NN
cord-002240-38aabxh1	176	69	Corticosteroids	Corticosteroids	NNPS
cord-002240-38aabxh1	176	70	for	for	IN
cord-002240-38aabxh1	176	71	severe	severe	JJ
cord-002240-38aabxh1	176	72	community	community	NN
cord-002240-38aabxh1	176	73	-	-	HYPH
cord-002240-38aabxh1	176	74	acquired	acquire	VBN
cord-002240-38aabxh1	176	75	pneumonia	pneumonia	NN
cord-002240-38aabxh1	176	76	:	:	:
cord-002240-38aabxh1	176	77	not	not	RB
cord-002240-38aabxh1	176	78	for	for	IN
cord-002240-38aabxh1	176	79	everyone	everyone	NN
cord-002240-38aabxh1	176	80	Primary	primary	JJ
cord-002240-38aabxh1	176	81	immunodeficiencies	immunodeficiency	NNS
cord-002240-38aabxh1	177	1	:	:	:
cord-002240-38aabxh1	177	2	2009	2009	CD
cord-002240-38aabxh1	177	3	update	update	NN
cord-002240-38aabxh1	177	4	Antiinflammatory	antiinflammatory	JJ
cord-002240-38aabxh1	177	5	action	action	NN
cord-002240-38aabxh1	177	6	of	of	IN
cord-002240-38aabxh1	177	7	glucocorticoids	glucocorticoid	NNS
cord-002240-38aabxh1	177	8	-	-	HYPH
cord-002240-38aabxh1	177	9	new	new	JJ
cord-002240-38aabxh1	177	10	mechanisms	mechanism	NNS
cord-002240-38aabxh1	177	11	for	for	IN
cord-002240-38aabxh1	177	12	old	old	JJ
cord-002240-38aabxh1	177	13	drugs	drug	NNS
cord-002240-38aabxh1	177	14	Treatment	Treatment	NNP
cord-002240-38aabxh1	177	15	with	with	IN
cord-002240-38aabxh1	177	16	antiinflammatory	antiinflammatory	JJ
cord-002240-38aabxh1	177	17	drugs	drug	NNS
cord-002240-38aabxh1	177	18	in	in	IN
cord-002240-38aabxh1	177	19	community	community	NN
cord-002240-38aabxh1	177	20	-	-	HYPH
cord-002240-38aabxh1	177	21	acquired	acquire	VBN
cord-002240-38aabxh1	177	22	pneumonia	pneumonia	NN
cord-002240-38aabxh1	177	23	Adrenal	adrenal	JJ
cord-002240-38aabxh1	177	24	insufficiency	insufficiency	NN
cord-002240-38aabxh1	177	25	in	in	IN
cord-002240-38aabxh1	177	26	septic	septic	JJ
cord-002240-38aabxh1	177	27	shock	shock	NN
cord-002240-38aabxh1	177	28	Effects	effect	NNS
cord-002240-38aabxh1	177	29	of	of	IN
cord-002240-38aabxh1	177	30	glucocorticoids	glucocorticoid	NNS
cord-002240-38aabxh1	177	31	in	in	IN
cord-002240-38aabxh1	177	32	ventilated	ventilate	VBN
cord-002240-38aabxh1	177	33	piglets	piglet	NNS
cord-002240-38aabxh1	177	34	with	with	IN
cord-002240-38aabxh1	177	35	severe	severe	JJ
cord-002240-38aabxh1	177	36	pneumonia	pneumonia	NN
cord-002240-38aabxh1	177	37	Effects	effect	NNS
cord-002240-38aabxh1	177	38	of	of	IN
cord-002240-38aabxh1	177	39	methylprednisolone	methylprednisolone	NN
cord-002240-38aabxh1	177	40	on	on	IN
cord-002240-38aabxh1	177	41	intracellular	intracellular	JJ
cord-002240-38aabxh1	177	42	bacterial	bacterial	JJ
cord-002240-38aabxh1	177	43	growth	growth	NN
cord-002240-38aabxh1	177	44	Hydrocortisone	Hydrocortisone	NNP
cord-002240-38aabxh1	177	45	infusion	infusion	NN
cord-002240-38aabxh1	177	46	for	for	IN
cord-002240-38aabxh1	177	47	severe	severe	JJ
cord-002240-38aabxh1	177	48	community	community	NN
cord-002240-38aabxh1	177	49	-	-	HYPH
cord-002240-38aabxh1	177	50	acquired	acquire	VBN
cord-002240-38aabxh1	177	51	pneumonia	pneumonia	NN
cord-002240-38aabxh1	177	52	:	:	:
cord-002240-38aabxh1	178	1	a	a	DT
cord-002240-38aabxh1	178	2	preliminary	preliminary	JJ
cord-002240-38aabxh1	178	3	randomized	randomized	JJ
cord-002240-38aabxh1	178	4	study	study	NN
cord-002240-38aabxh1	178	5	Effects	effect	NNS
cord-002240-38aabxh1	178	6	of	of	IN
cord-002240-38aabxh1	178	7	systemic	systemic	JJ
cord-002240-38aabxh1	178	8	steroids	steroid	NNS
cord-002240-38aabxh1	178	9	in	in	IN
cord-002240-38aabxh1	178	10	patients	patient	NNS
cord-002240-38aabxh1	178	11	with	with	IN
cord-002240-38aabxh1	178	12	severe	severe	JJ
cord-002240-38aabxh1	178	13	community	community	NN
cord-002240-38aabxh1	178	14	-	-	HYPH
cord-002240-38aabxh1	178	15	acquired	acquire	VBN
cord-002240-38aabxh1	178	16	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	17	Efficacy	Efficacy	NNP
cord-002240-38aabxh1	178	18	of	of	IN
cord-002240-38aabxh1	178	19	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	178	20	in	in	IN
cord-002240-38aabxh1	178	21	community	community	NN
cord-002240-38aabxh1	178	22	-	-	HYPH
cord-002240-38aabxh1	178	23	acquired	acquire	VBN
cord-002240-38aabxh1	178	24	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	25	:	:	:
cord-002240-38aabxh1	178	26	a	a	DT
cord-002240-38aabxh1	178	27	randomized	randomized	JJ
cord-002240-38aabxh1	178	28	double	double	RB
cord-002240-38aabxh1	178	29	-	-	HYPH
cord-002240-38aabxh1	178	30	blinded	blinded	JJ
cord-002240-38aabxh1	178	31	clinical	clinical	JJ
cord-002240-38aabxh1	178	32	trial	trial	NN
cord-002240-38aabxh1	178	33	Dexamethasone	Dexamethasone	NNP
cord-002240-38aabxh1	178	34	and	and	CC
cord-002240-38aabxh1	178	35	length	length	NN
cord-002240-38aabxh1	178	36	of	of	IN
cord-002240-38aabxh1	178	37	hospital	hospital	NN
cord-002240-38aabxh1	178	38	stay	stay	NN
cord-002240-38aabxh1	178	39	in	in	IN
cord-002240-38aabxh1	178	40	patients	patient	NNS
cord-002240-38aabxh1	178	41	with	with	IN
cord-002240-38aabxh1	178	42	community	community	NN
cord-002240-38aabxh1	178	43	-	-	HYPH
cord-002240-38aabxh1	178	44	acquired	acquire	VBN
cord-002240-38aabxh1	178	45	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	46	:	:	:
cord-002240-38aabxh1	178	47	a	a	DT
cord-002240-38aabxh1	178	48	randomised	randomised	JJ
cord-002240-38aabxh1	178	49	,	,	,
cord-002240-38aabxh1	178	50	double	double	JJ
cord-002240-38aabxh1	178	51	-	-	HYPH
cord-002240-38aabxh1	178	52	blind	blind	JJ
cord-002240-38aabxh1	178	53	,	,	,
cord-002240-38aabxh1	178	54	placebo	placebo	NN
cord-002240-38aabxh1	178	55	-	-	HYPH
cord-002240-38aabxh1	178	56	controlled	control	VBN
cord-002240-38aabxh1	178	57	trial	trial	NN
cord-002240-38aabxh1	178	58	Corticosteroids	Corticosteroids	NNPS
cord-002240-38aabxh1	178	59	for	for	IN
cord-002240-38aabxh1	178	60	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	61	Corticosteroids	Corticosteroids	NNPS
cord-002240-38aabxh1	178	62	in	in	IN
cord-002240-38aabxh1	178	63	the	the	DT
cord-002240-38aabxh1	178	64	treatment	treatment	NN
cord-002240-38aabxh1	178	65	of	of	IN
cord-002240-38aabxh1	178	66	communityacquired	communityacquired	JJ
cord-002240-38aabxh1	178	67	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	68	in	in	IN
cord-002240-38aabxh1	178	69	adults	adult	NNS
cord-002240-38aabxh1	178	70	:	:	:
cord-002240-38aabxh1	178	71	a	a	DT
cord-002240-38aabxh1	178	72	meta	meta	JJ
cord-002240-38aabxh1	178	73	-	-	HYPH
cord-002240-38aabxh1	178	74	analysis	analysis	NN
cord-002240-38aabxh1	178	75	Adjuvant	Adjuvant	NNP
cord-002240-38aabxh1	178	76	steroid	steroid	NN
cord-002240-38aabxh1	178	77	therapy	therapy	NN
cord-002240-38aabxh1	178	78	in	in	IN
cord-002240-38aabxh1	178	79	community	community	NN
cord-002240-38aabxh1	178	80	-	-	HYPH
cord-002240-38aabxh1	178	81	acquired	acquire	VBN
cord-002240-38aabxh1	178	82	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	83	:	:	:
cord-002240-38aabxh1	178	84	a	a	DT
cord-002240-38aabxh1	178	85	systematic	systematic	JJ
cord-002240-38aabxh1	178	86	review	review	NN
cord-002240-38aabxh1	178	87	and	and	CC
cord-002240-38aabxh1	178	88	metaanalysis	metaanalysis	NN
cord-002240-38aabxh1	178	89	Corticosteroid	Corticosteroid	NNP
cord-002240-38aabxh1	178	90	therapy	therapy	NN
cord-002240-38aabxh1	178	91	for	for	IN
cord-002240-38aabxh1	178	92	severe	severe	JJ
cord-002240-38aabxh1	178	93	community	community	NN
cord-002240-38aabxh1	178	94	-	-	HYPH
cord-002240-38aabxh1	178	95	acquired	acquire	VBN
cord-002240-38aabxh1	178	96	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	97	:	:	:
cord-002240-38aabxh1	178	98	a	a	DT
cord-002240-38aabxh1	178	99	meta	meta	JJ
cord-002240-38aabxh1	178	100	-	-	HYPH
cord-002240-38aabxh1	178	101	analysis	analysis	NN
cord-002240-38aabxh1	178	102	Effect	effect	NN
cord-002240-38aabxh1	178	103	of	of	IN
cord-002240-38aabxh1	178	104	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	178	105	on	on	IN
cord-002240-38aabxh1	178	106	treatment	treatment	NN
cord-002240-38aabxh1	178	107	failure	failure	NN
cord-002240-38aabxh1	178	108	among	among	IN
cord-002240-38aabxh1	178	109	hospitalized	hospitalize	VBN
cord-002240-38aabxh1	178	110	patients	patient	NNS
cord-002240-38aabxh1	178	111	with	with	IN
cord-002240-38aabxh1	178	112	severe	severe	JJ
cord-002240-38aabxh1	178	113	community	community	NN
cord-002240-38aabxh1	178	114	-	-	HYPH
cord-002240-38aabxh1	178	115	acquired	acquire	VBN
cord-002240-38aabxh1	178	116	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	117	and	and	CC
cord-002240-38aabxh1	178	118	high	high	JJ
cord-002240-38aabxh1	178	119	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	178	120	response	response	NN
cord-002240-38aabxh1	178	121	:	:	:
cord-002240-38aabxh1	178	122	a	a	DT
cord-002240-38aabxh1	178	123	randomized	randomized	JJ
cord-002240-38aabxh1	178	124	clinical	clinical	JJ
cord-002240-38aabxh1	178	125	trial	trial	NN
cord-002240-38aabxh1	178	126	Adjunct	Adjunct	NNP
cord-002240-38aabxh1	178	127	prednisone	prednisone	JJ
cord-002240-38aabxh1	178	128	therapy	therapy	NN
cord-002240-38aabxh1	178	129	for	for	IN
cord-002240-38aabxh1	178	130	patients	patient	NNS
cord-002240-38aabxh1	178	131	with	with	IN
cord-002240-38aabxh1	178	132	community	community	NN
cord-002240-38aabxh1	178	133	-	-	HYPH
cord-002240-38aabxh1	178	134	acquired	acquire	VBN
cord-002240-38aabxh1	178	135	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	136	:	:	:
cord-002240-38aabxh1	178	137	a	a	DT
cord-002240-38aabxh1	178	138	multicentre	multicentre	NN
cord-002240-38aabxh1	178	139	,	,	,
cord-002240-38aabxh1	178	140	double	double	JJ
cord-002240-38aabxh1	178	141	-	-	HYPH
cord-002240-38aabxh1	178	142	blind	blind	JJ
cord-002240-38aabxh1	178	143	,	,	,
cord-002240-38aabxh1	178	144	randomised	randomised	JJ
cord-002240-38aabxh1	178	145	,	,	,
cord-002240-38aabxh1	178	146	placebo	placebo	NN
cord-002240-38aabxh1	178	147	-	-	HYPH
cord-002240-38aabxh1	178	148	controlled	control	VBN
cord-002240-38aabxh1	178	149	trial	trial	NN
cord-002240-38aabxh1	178	150	Corticosteroid	Corticosteroid	NNP
cord-002240-38aabxh1	178	151	therapy	therapy	NN
cord-002240-38aabxh1	178	152	for	for	IN
cord-002240-38aabxh1	178	153	patients	patient	NNS
cord-002240-38aabxh1	178	154	hospitalized	hospitalize	VBN
cord-002240-38aabxh1	178	155	with	with	IN
cord-002240-38aabxh1	178	156	communityacquired	communityacquired	JJ
cord-002240-38aabxh1	178	157	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	158	:	:	:
cord-002240-38aabxh1	178	159	a	a	DT
cord-002240-38aabxh1	178	160	systematic	systematic	JJ
cord-002240-38aabxh1	178	161	review	review	NN
cord-002240-38aabxh1	178	162	and	and	CC
cord-002240-38aabxh1	178	163	meta	meta	NNP
cord-002240-38aabxh1	178	164	-	-	HYPH
cord-002240-38aabxh1	178	165	analysis	analysis	NN
cord-002240-38aabxh1	178	166	Efficacy	Efficacy	NNP
cord-002240-38aabxh1	178	167	and	and	CC
cord-002240-38aabxh1	178	168	safety	safety	NN
cord-002240-38aabxh1	178	169	of	of	IN
cord-002240-38aabxh1	178	170	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	178	171	for	for	IN
cord-002240-38aabxh1	178	172	community	community	NN
cord-002240-38aabxh1	178	173	-	-	HYPH
cord-002240-38aabxh1	178	174	acquired	acquire	VBN
cord-002240-38aabxh1	178	175	pneumonia	pneumonia	NN
cord-002240-38aabxh1	178	176	:	:	:
cord-002240-38aabxh1	178	177	a	a	DT
cord-002240-38aabxh1	178	178	systematic	systematic	JJ
cord-002240-38aabxh1	178	179	review	review	NN
cord-002240-38aabxh1	178	180	and	and	CC
cord-002240-38aabxh1	178	181	meta	meta	NNP
cord-002240-38aabxh1	178	182	-	-	HYPH
cord-002240-38aabxh1	178	183	analysis	analysis	NN
cord-002240-38aabxh1	179	1	A	a	DT
cord-002240-38aabxh1	179	2	prediction	prediction	NN
cord-002240-38aabxh1	179	3	rule	rule	NN
cord-002240-38aabxh1	179	4	to	to	TO
cord-002240-38aabxh1	179	5	identify	identify	VB
cord-002240-38aabxh1	179	6	low	low	JJ
cord-002240-38aabxh1	179	7	-	-	HYPH
cord-002240-38aabxh1	179	8	risk	risk	NN
cord-002240-38aabxh1	179	9	patients	patient	NNS
cord-002240-38aabxh1	179	10	with	with	IN
cord-002240-38aabxh1	179	11	community	community	NN
cord-002240-38aabxh1	179	12	-	-	HYPH
cord-002240-38aabxh1	179	13	acquired	acquire	VBN
cord-002240-38aabxh1	179	14	pneumonia	pneumonia	NN
cord-002240-38aabxh1	179	15	Adjunctive	Adjunctive	NNP
cord-002240-38aabxh1	179	16	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	179	17	for	for	IN
cord-002240-38aabxh1	179	18	Pneumocystis	Pneumocystis	NNP
cord-002240-38aabxh1	179	19	jiroveci	jiroveci	NN
cord-002240-38aabxh1	179	20	pneumonia	pneumonia	NN
cord-002240-38aabxh1	179	21	in	in	IN
cord-002240-38aabxh1	179	22	patients	patient	NNS
cord-002240-38aabxh1	179	23	with	with	IN
cord-002240-38aabxh1	179	24	HIV	HIV	NNP
cord-002240-38aabxh1	179	25	infection	infection	NN
cord-002240-38aabxh1	179	26	:	:	:
cord-002240-38aabxh1	179	27	a	a	DT
cord-002240-38aabxh1	179	28	metaanalysis	metaanalysis	NN
cord-002240-38aabxh1	179	29	of	of	IN
cord-002240-38aabxh1	179	30	randomised	randomised	JJ
cord-002240-38aabxh1	179	31	controlled	control	VBN
cord-002240-38aabxh1	179	32	trials	trial	NNS
cord-002240-38aabxh1	179	33	Adjuvant	Adjuvant	NNP
cord-002240-38aabxh1	179	34	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	179	35	treatment	treatment	NN
cord-002240-38aabxh1	179	36	in	in	IN
cord-002240-38aabxh1	179	37	adults	adult	NNS
cord-002240-38aabxh1	179	38	with	with	IN
cord-002240-38aabxh1	179	39	influenza	influenza	NN
cord-002240-38aabxh1	179	40	A	a	NN
cord-002240-38aabxh1	179	41	(	(	-LRB-
cord-002240-38aabxh1	179	42	H7N9	H7N9	NNP
cord-002240-38aabxh1	179	43	)	)	-RRB-
cord-002240-38aabxh1	179	44	viral	viral	JJ
cord-002240-38aabxh1	179	45	pneumonia	pneumonia	NN
cord-002240-38aabxh1	179	46	Corticosteroids	Corticosteroids	NNPS
cord-002240-38aabxh1	179	47	as	as	IN
cord-002240-38aabxh1	179	48	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	179	49	therapy	therapy	NN
cord-002240-38aabxh1	179	50	in	in	IN
cord-002240-38aabxh1	179	51	the	the	DT
cord-002240-38aabxh1	179	52	treatment	treatment	NN
cord-002240-38aabxh1	179	53	of	of	IN
cord-002240-38aabxh1	179	54	influenza	influenza	NN
cord-002240-38aabxh1	180	1	The	the	DT
cord-002240-38aabxh1	180	2	influence	influence	NN
cord-002240-38aabxh1	180	3	of	of	IN
cord-002240-38aabxh1	180	4	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	180	5	treatment	treatment	NN
cord-002240-38aabxh1	180	6	on	on	IN
cord-002240-38aabxh1	180	7	the	the	DT
cord-002240-38aabxh1	180	8	outcome	outcome	NN
cord-002240-38aabxh1	180	9	of	of	IN
cord-002240-38aabxh1	180	10	influenza	influenza	NN
cord-002240-38aabxh1	180	11	A(H1N1pdm09)-related	a(h1n1pdm09)-relate	VBN
cord-002240-38aabxh1	180	12	critical	critical	JJ
cord-002240-38aabxh1	180	13	illness	illness	NN
cord-002240-38aabxh1	180	14	Association	Association	NNP
cord-002240-38aabxh1	180	15	between	between	IN
cord-002240-38aabxh1	180	16	systemic	systemic	JJ
cord-002240-38aabxh1	180	17	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	180	18	and	and	CC
cord-002240-38aabxh1	180	19	outcomes	outcome	NNS
cord-002240-38aabxh1	180	20	of	of	IN
cord-002240-38aabxh1	180	21	intensive	intensive	JJ
cord-002240-38aabxh1	180	22	care	care	NN
cord-002240-38aabxh1	180	23	unit	unit	NN
cord-002240-38aabxh1	180	24	-	-	HYPH
cord-002240-38aabxh1	180	25	acquired	acquire	VBN
cord-002240-38aabxh1	180	26	pneumonia	pneumonia	NN
cord-002240-38aabxh1	180	27	Prevalence	prevalence	NN
cord-002240-38aabxh1	180	28	and	and	CC
cord-002240-38aabxh1	180	29	predictors	predictor	NNS
cord-002240-38aabxh1	180	30	of	of	IN
cord-002240-38aabxh1	180	31	corticosteroid	corticosteroid	NN
cord-002240-38aabxh1	180	32	-	-	HYPH
cord-002240-38aabxh1	180	33	related	relate	VBN
cord-002240-38aabxh1	180	34	hyperglycemia	hyperglycemia	NN
cord-002240-38aabxh1	180	35	in	in	IN
cord-002240-38aabxh1	180	36	hospitalized	hospitalize	VBN
cord-002240-38aabxh1	180	37	patients	patient	NNS
cord-002240-38aabxh1	180	38	Hyperglycaemia	Hyperglycaemia	NNP
cord-002240-38aabxh1	180	39	is	be	VBZ
cord-002240-38aabxh1	180	40	associated	associate	VBN
cord-002240-38aabxh1	180	41	with	with	IN
cord-002240-38aabxh1	180	42	poor	poor	JJ
cord-002240-38aabxh1	180	43	outcomes	outcome	NNS
cord-002240-38aabxh1	180	44	in	in	IN
cord-002240-38aabxh1	180	45	patients	patient	NNS
cord-002240-38aabxh1	180	46	admitted	admit	VBN
cord-002240-38aabxh1	180	47	to	to	IN
cord-002240-38aabxh1	180	48	hospital	hospital	NN
cord-002240-38aabxh1	180	49	with	with	IN
cord-002240-38aabxh1	180	50	acute	acute	JJ
cord-002240-38aabxh1	180	51	exacerbations	exacerbation	NNS
cord-002240-38aabxh1	180	52	of	of	IN
cord-002240-38aabxh1	180	53	chronic	chronic	JJ
cord-002240-38aabxh1	180	54	obstructive	obstructive	JJ
cord-002240-38aabxh1	180	55	pulmonary	pulmonary	JJ
cord-002240-38aabxh1	180	56	disease	disease	NN
cord-002240-38aabxh1	180	57	Hyperglycaemia	Hyperglycaemia	NNP
cord-002240-38aabxh1	180	58	as	as	IN
cord-002240-38aabxh1	180	59	a	a	DT
cord-002240-38aabxh1	180	60	predictor	predictor	NN
cord-002240-38aabxh1	180	61	of	of	IN
cord-002240-38aabxh1	180	62	outcome	outcome	NN
cord-002240-38aabxh1	180	63	during	during	IN
cord-002240-38aabxh1	180	64	non	non	JJ
cord-002240-38aabxh1	180	65	-	-	JJ
cord-002240-38aabxh1	180	66	invasive	invasive	JJ
cord-002240-38aabxh1	180	67	ventilation	ventilation	NN
cord-002240-38aabxh1	180	68	in	in	IN
cord-002240-38aabxh1	180	69	decompensated	decompensated	JJ
cord-002240-38aabxh1	180	70	COPD	COPD	NNP
cord-002240-38aabxh1	180	71	Intensive	intensive	JJ
cord-002240-38aabxh1	180	72	insulin	insulin	NN
cord-002240-38aabxh1	180	73	therapy	therapy	NN
cord-002240-38aabxh1	180	74	in	in	IN
cord-002240-38aabxh1	180	75	the	the	DT
cord-002240-38aabxh1	180	76	critically	critically	RB
cord-002240-38aabxh1	180	77	ill	ill	JJ
cord-002240-38aabxh1	180	78	patients	patient	NNS
cord-002240-38aabxh1	180	79	Intensive	intensive	JJ
cord-002240-38aabxh1	180	80	insulin	insulin	NN
cord-002240-38aabxh1	180	81	therapy	therapy	NN
cord-002240-38aabxh1	180	82	in	in	IN
cord-002240-38aabxh1	180	83	the	the	DT
cord-002240-38aabxh1	180	84	medical	medical	JJ
cord-002240-38aabxh1	180	85	ICU	ICU	NNP
cord-002240-38aabxh1	180	86	Glucocorticoid	Glucocorticoid	NNP
cord-002240-38aabxh1	180	87	-	-	HYPH
cord-002240-38aabxh1	180	88	induced	induce	VBN
cord-002240-38aabxh1	180	89	myopathy	myopathy	NN
cord-002240-38aabxh1	180	90	Paresis	Paresis	NNP
cord-002240-38aabxh1	180	91	acquired	acquire	VBD
cord-002240-38aabxh1	180	92	in	in	IN
cord-002240-38aabxh1	180	93	the	the	DT
cord-002240-38aabxh1	180	94	intensive	intensive	JJ
cord-002240-38aabxh1	180	95	care	care	NN
cord-002240-38aabxh1	180	96	unit	unit	NN
cord-002240-38aabxh1	180	97	:	:	:
cord-002240-38aabxh1	180	98	a	a	DT
cord-002240-38aabxh1	180	99	prospective	prospective	JJ
cord-002240-38aabxh1	180	100	multicenter	multicenter	JJ
cord-002240-38aabxh1	180	101	study	study	NN
cord-002240-38aabxh1	180	102	Infectious	Infectious	NNP
cord-002240-38aabxh1	180	103	Diseases	Diseases	NNPS
cord-002240-38aabxh1	180	104	Society	Society	NNP
cord-002240-38aabxh1	180	105	of	of	IN
cord-002240-38aabxh1	180	106	America	America	NNP
cord-002240-38aabxh1	180	107	/	/	SYM
cord-002240-38aabxh1	180	108	American	American	NNP
cord-002240-38aabxh1	180	109	Thoracic	Thoracic	NNP
cord-002240-38aabxh1	180	110	Society	Society	NNP
cord-002240-38aabxh1	180	111	consensus	consensus	NN
cord-002240-38aabxh1	180	112	guidelines	guideline	NNS
cord-002240-38aabxh1	180	113	on	on	IN
cord-002240-38aabxh1	180	114	the	the	DT
cord-002240-38aabxh1	180	115	management	management	NN
cord-002240-38aabxh1	180	116	of	of	IN
cord-002240-38aabxh1	180	117	community	community	NN
cord-002240-38aabxh1	180	118	-	-	HYPH
cord-002240-38aabxh1	180	119	acquired	acquire	VBN
cord-002240-38aabxh1	180	120	pneumonia	pneumonia	NN
cord-002240-38aabxh1	180	121	in	in	IN
cord-002240-38aabxh1	180	122	adults	adult	NNS
cord-002240-38aabxh1	180	123	Anti	anti	JJ
cord-002240-38aabxh1	180	124	-	-	JJ
cord-002240-38aabxh1	180	125	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	180	126	effects	effect	NNS
cord-002240-38aabxh1	180	127	of	of	IN
cord-002240-38aabxh1	180	128	macrolides	macrolide	NNS
cord-002240-38aabxh1	180	129	-	-	:
cord-002240-38aabxh1	180	130	an	an	DT
cord-002240-38aabxh1	180	131	underappreciated	underappreciated	JJ
cord-002240-38aabxh1	180	132	benefit	benefit	NN
cord-002240-38aabxh1	180	133	in	in	IN
cord-002240-38aabxh1	180	134	the	the	DT
cord-002240-38aabxh1	180	135	treatment	treatment	NN
cord-002240-38aabxh1	180	136	of	of	IN
cord-002240-38aabxh1	180	137	community	community	NN
cord-002240-38aabxh1	180	138	-	-	HYPH
cord-002240-38aabxh1	180	139	acquired	acquire	VBN
cord-002240-38aabxh1	180	140	respiratory	respiratory	JJ
cord-002240-38aabxh1	180	141	tract	tract	NN
cord-002240-38aabxh1	180	142	infections	infection	NNS
cord-002240-38aabxh1	180	143	and	and	CC
cord-002240-38aabxh1	180	144	chronic	chronic	JJ
cord-002240-38aabxh1	180	145	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	180	146	pulmonary	pulmonary	JJ
cord-002240-38aabxh1	180	147	conditions	condition	NNS
cord-002240-38aabxh1	180	148	?	?	.
cord-002240-38aabxh1	181	1	Immunomodulatory	immunomodulatory	JJ
cord-002240-38aabxh1	181	2	effects	effect	NNS
cord-002240-38aabxh1	181	3	of	of	IN
cord-002240-38aabxh1	181	4	macrolides	macrolide	NNS
cord-002240-38aabxh1	181	5	during	during	IN
cord-002240-38aabxh1	181	6	community	community	NN
cord-002240-38aabxh1	181	7	-	-	HYPH
cord-002240-38aabxh1	181	8	acquired	acquire	VBN
cord-002240-38aabxh1	181	9	pneumonia	pneumonia	NN
cord-002240-38aabxh1	181	10	:	:	:
cord-002240-38aabxh1	181	11	a	a	DT
cord-002240-38aabxh1	181	12	literature	literature	NN
cord-002240-38aabxh1	181	13	review	review	NN
cord-002240-38aabxh1	181	14	Antibiotic	antibiotic	JJ
cord-002240-38aabxh1	181	15	treatment	treatment	NN
cord-002240-38aabxh1	181	16	strategies	strategy	NNS
cord-002240-38aabxh1	181	17	for	for	IN
cord-002240-38aabxh1	181	18	community	community	NN
cord-002240-38aabxh1	181	19	-	-	HYPH
cord-002240-38aabxh1	181	20	acquired	acquire	VBN
cord-002240-38aabxh1	181	21	pneumonia	pneumonia	NN
cord-002240-38aabxh1	181	22	in	in	IN
cord-002240-38aabxh1	181	23	adults	adult	NNS
cord-002240-38aabxh1	182	1	beta	beta	NN
cord-002240-38aabxh1	182	2	-	-	HYPH
cord-002240-38aabxh1	182	3	Lactam	Lactam	NNP
cord-002240-38aabxh1	182	4	monotherapy	monotherapy	NN
cord-002240-38aabxh1	182	5	vs	vs	IN
cord-002240-38aabxh1	182	6	beta	beta	NN
cord-002240-38aabxh1	182	7	-	-	HYPH
cord-002240-38aabxh1	182	8	lactam	lactam	NN
cord-002240-38aabxh1	182	9	-	-	HYPH
cord-002240-38aabxh1	182	10	macrolide	macrolide	NN
cord-002240-38aabxh1	182	11	combination	combination	NN
cord-002240-38aabxh1	182	12	treatment	treatment	NN
cord-002240-38aabxh1	182	13	in	in	IN
cord-002240-38aabxh1	182	14	moderately	moderately	RB
cord-002240-38aabxh1	182	15	severe	severe	JJ
cord-002240-38aabxh1	182	16	community	community	NN
cord-002240-38aabxh1	182	17	-	-	HYPH
cord-002240-38aabxh1	182	18	acquired	acquire	VBN
cord-002240-38aabxh1	182	19	pneumonia	pneumonia	NN
cord-002240-38aabxh1	182	20	:	:	:
cord-002240-38aabxh1	182	21	a	a	DT
cord-002240-38aabxh1	182	22	randomized	randomized	JJ
cord-002240-38aabxh1	182	23	noninferiority	noninferiority	NN
cord-002240-38aabxh1	182	24	trial	trial	NN
cord-002240-38aabxh1	182	25	Efficacy	Efficacy	NNP
cord-002240-38aabxh1	182	26	of	of	IN
cord-002240-38aabxh1	182	27	increasing	increase	VBG
cord-002240-38aabxh1	182	28	dosages	dosage	NNS
cord-002240-38aabxh1	182	29	of	of	IN
cord-002240-38aabxh1	182	30	clarithromycin	clarithromycin	NNS
cord-002240-38aabxh1	182	31	for	for	IN
cord-002240-38aabxh1	182	32	treatment	treatment	NN
cord-002240-38aabxh1	182	33	of	of	IN
cord-002240-38aabxh1	182	34	experimental	experimental	JJ
cord-002240-38aabxh1	182	35	Mycoplasma	Mycoplasma	NNP
cord-002240-38aabxh1	182	36	pneumoniae	pneumoniae	NN
cord-002240-38aabxh1	182	37	pneumonia	pneumonia	NN
cord-002240-38aabxh1	182	38	Lung	Lung	NNP
cord-002240-38aabxh1	182	39	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	182	40	pattern	pattern	NN
cord-002240-38aabxh1	182	41	and	and	CC
cord-002240-38aabxh1	182	42	antibiotic	antibiotic	JJ
cord-002240-38aabxh1	182	43	treatment	treatment	NN
cord-002240-38aabxh1	182	44	in	in	IN
cord-002240-38aabxh1	182	45	pneumonia	pneumonia	NN
cord-002240-38aabxh1	183	1	Systemic	systemic	JJ
cord-002240-38aabxh1	183	2	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	183	3	for	for	IN
cord-002240-38aabxh1	183	4	community	community	NN
cord-002240-38aabxh1	183	5	-	-	HYPH
cord-002240-38aabxh1	183	6	acquired	acquire	VBN
cord-002240-38aabxh1	183	7	pneumonia	pneumonia	NN
cord-002240-38aabxh1	183	8	:	:	:
cord-002240-38aabxh1	184	1	reasons	reason	NNS
cord-002240-38aabxh1	184	2	for	for	IN
cord-002240-38aabxh1	184	3	use	use	NN
cord-002240-38aabxh1	184	4	and	and	CC
cord-002240-38aabxh1	184	5	lack	lack	NN
cord-002240-38aabxh1	184	6	of	of	IN
cord-002240-38aabxh1	184	7	benefit	benefit	NN
cord-002240-38aabxh1	184	8	on	on	IN
cord-002240-38aabxh1	184	9	outcome	outcome	NN
cord-002240-38aabxh1	184	10	Systemic	systemic	JJ
cord-002240-38aabxh1	184	11	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	184	12	pattern	pattern	NN
cord-002240-38aabxh1	184	13	of	of	IN
cord-002240-38aabxh1	184	14	community	community	NN
cord-002240-38aabxh1	184	15	-	-	HYPH
cord-002240-38aabxh1	184	16	acquired	acquire	VBN
cord-002240-38aabxh1	184	17	pneumonia	pneumonia	NN
cord-002240-38aabxh1	184	18	(	(	-LRB-
cord-002240-38aabxh1	184	19	CAP	cap	NN
cord-002240-38aabxh1	184	20	)	)	-RRB-
cord-002240-38aabxh1	184	21	patients	patient	NNS
cord-002240-38aabxh1	184	22	with	with	IN
cord-002240-38aabxh1	184	23	and	and	CC
cord-002240-38aabxh1	184	24	without	without	IN
cord-002240-38aabxh1	184	25	chronic	chronic	JJ
cord-002240-38aabxh1	184	26	obstructive	obstructive	JJ
cord-002240-38aabxh1	184	27	pulmonary	pulmonary	JJ
cord-002240-38aabxh1	184	28	disease	disease	NN
cord-002240-38aabxh1	184	29	(	(	-LRB-
cord-002240-38aabxh1	184	30	COPD	COPD	NNP
cord-002240-38aabxh1	184	31	)	)	-RRB-
cord-002240-38aabxh1	185	1	Inhaled	inhale	VBN
cord-002240-38aabxh1	185	2	corticosteroids	corticosteroid	NNS
cord-002240-38aabxh1	185	3	and	and	CC
cord-002240-38aabxh1	185	4	systemic	systemic	JJ
cord-002240-38aabxh1	185	5	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	185	6	response	response	NN
cord-002240-38aabxh1	185	7	in	in	IN
cord-002240-38aabxh1	185	8	community	community	NN
cord-002240-38aabxh1	185	9	-	-	HYPH
cord-002240-38aabxh1	185	10	acquired	acquire	VBN
cord-002240-38aabxh1	185	11	pneumonia	pneumonia	NN
cord-002240-38aabxh1	185	12	:	:	:
cord-002240-38aabxh1	185	13	a	a	DT
cord-002240-38aabxh1	185	14	prospective	prospective	JJ
cord-002240-38aabxh1	185	15	clinical	clinical	JJ
cord-002240-38aabxh1	185	16	study	study	NN
cord-002240-38aabxh1	185	17	Pneumonic	Pneumonic	NNP
cord-002240-38aabxh1	185	18	and	and	CC
cord-002240-38aabxh1	185	19	non	non	JJ
cord-002240-38aabxh1	185	20	-	-	JJ
cord-002240-38aabxh1	185	21	pneumonic	pneumonic	JJ
cord-002240-38aabxh1	185	22	exacerbations	exacerbation	NNS
cord-002240-38aabxh1	185	23	of	of	IN
cord-002240-38aabxh1	185	24	COPD	COPD	NNP
cord-002240-38aabxh1	185	25	:	:	:
cord-002240-38aabxh1	185	26	systemic	systemic	JJ
cord-002240-38aabxh1	185	27	inflammatory	inflammatory	JJ
cord-002240-38aabxh1	185	28	response	response	NN
cord-002240-38aabxh1	185	29	and	and	CC
cord-002240-38aabxh1	185	30	clinical	clinical	JJ
cord-002240-38aabxh1	185	31	characteristics	characteristic	NNS
cord-002240-38aabxh1	185	32	Immunomodulatory	immunomodulatory	JJ
cord-002240-38aabxh1	185	33	effects	effect	NNS
cord-002240-38aabxh1	185	34	of	of	IN
cord-002240-38aabxh1	185	35	quinolones	quinolone	NNS
cord-002240-38aabxh1	185	36	Assessment	Assessment	NNP
cord-002240-38aabxh1	185	37	of	of	IN
cord-002240-38aabxh1	185	38	plasmatic	plasmatic	JJ
cord-002240-38aabxh1	185	39	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	185	40	G	g	NN
cord-002240-38aabxh1	185	41	,	,	,
cord-002240-38aabxh1	185	42	A	A	NNP
cord-002240-38aabxh1	185	43	and	and	CC
cord-002240-38aabxh1	185	44	M	M	NNP
cord-002240-38aabxh1	185	45	levels	level	NNS
cord-002240-38aabxh1	185	46	in	in	IN
cord-002240-38aabxh1	185	47	septic	septic	JJ
cord-002240-38aabxh1	185	48	shock	shock	NN
cord-002240-38aabxh1	185	49	patients	patient	NNS
cord-002240-38aabxh1	186	1	Endogenous	endogenous	JJ
cord-002240-38aabxh1	186	2	IgG	igg	NN
cord-002240-38aabxh1	186	3	hypogammaglobulinaemia	hypogammaglobulinaemia	NN
cord-002240-38aabxh1	186	4	in	in	IN
cord-002240-38aabxh1	186	5	critically	critically	RB
cord-002240-38aabxh1	186	6	ill	ill	JJ
cord-002240-38aabxh1	186	7	adults	adult	NNS
cord-002240-38aabxh1	186	8	with	with	IN
cord-002240-38aabxh1	186	9	sepsis	sepsis	NN
cord-002240-38aabxh1	186	10	:	:	:
cord-002240-38aabxh1	186	11	systematic	systematic	JJ
cord-002240-38aabxh1	186	12	review	review	NN
cord-002240-38aabxh1	186	13	and	and	CC
cord-002240-38aabxh1	186	14	meta	meta	NNP
cord-002240-38aabxh1	186	15	-	-	HYPH
cord-002240-38aabxh1	186	16	analysis	analysis	NN
cord-002240-38aabxh1	186	17	Serum	serum	NN
cord-002240-38aabxh1	186	18	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	186	19	in	in	IN
cord-002240-38aabxh1	186	20	the	the	DT
cord-002240-38aabxh1	186	21	infected	infected	JJ
cord-002240-38aabxh1	186	22	and	and	CC
cord-002240-38aabxh1	186	23	convalescent	convalescent	JJ
cord-002240-38aabxh1	186	24	phases	phase	NNS
cord-002240-38aabxh1	186	25	in	in	IN
cord-002240-38aabxh1	186	26	community	community	NN
cord-002240-38aabxh1	186	27	-	-	HYPH
cord-002240-38aabxh1	186	28	acquired	acquire	VBN
cord-002240-38aabxh1	186	29	pneumonia	pneumonia	NN
cord-002240-38aabxh1	186	30	Pooled	pool	VBN
cord-002240-38aabxh1	186	31	human	human	JJ
cord-002240-38aabxh1	186	32	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	186	33	therapy	therapy	NN
cord-002240-38aabxh1	186	34	in	in	IN
cord-002240-38aabxh1	186	35	critically	critically	RB
cord-002240-38aabxh1	186	36	Ill	ill	JJ
cord-002240-38aabxh1	186	37	patients	patient	NNS
cord-002240-38aabxh1	186	38	with	with	IN
cord-002240-38aabxh1	186	39	pandemic	pandemic	NN
cord-002240-38aabxh1	186	40	2009	2009	CD
cord-002240-38aabxh1	186	41	influenza	influenza	NN
cord-002240-38aabxh1	186	42	A(H1N1	a(h1n1	NN
cord-002240-38aabxh1	186	43	)	)	-RRB-
cord-002240-38aabxh1	186	44	pneumonitis	pneumonitis	NN
cord-002240-38aabxh1	186	45	and	and	CC
cord-002240-38aabxh1	186	46	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	186	47	G2	G2	NNP
cord-002240-38aabxh1	186	48	subclass	subclass	NN
cord-002240-38aabxh1	186	49	(	(	-LRB-
cord-002240-38aabxh1	186	50	IgG2	igg2	NN
cord-002240-38aabxh1	186	51	)	)	-RRB-
cord-002240-38aabxh1	186	52	deficiency	deficiency	NN
cord-002240-38aabxh1	187	1	Intravenous	intravenous	JJ
cord-002240-38aabxh1	187	2	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	187	3	for	for	IN
cord-002240-38aabxh1	187	4	treating	treat	VBG
cord-002240-38aabxh1	187	5	sepsis	sepsis	NN
cord-002240-38aabxh1	187	6	,	,	,
cord-002240-38aabxh1	187	7	severe	severe	JJ
cord-002240-38aabxh1	187	8	sepsis	sepsis	NN
cord-002240-38aabxh1	187	9	and	and	CC
cord-002240-38aabxh1	187	10	septic	septic	JJ
cord-002240-38aabxh1	187	11	shock	shock	NN
cord-002240-38aabxh1	187	12	Use	use	NN
cord-002240-38aabxh1	187	13	of	of	IN
cord-002240-38aabxh1	187	14	polyclonal	polyclonal	JJ
cord-002240-38aabxh1	187	15	immunoglobulins	immunoglobulin	NNS
cord-002240-38aabxh1	187	16	as	as	IN
cord-002240-38aabxh1	187	17	adjunctive	adjunctive	JJ
cord-002240-38aabxh1	187	18	therapy	therapy	NN
cord-002240-38aabxh1	187	19	for	for	IN
cord-002240-38aabxh1	187	20	sepsis	sepsis	NN
cord-002240-38aabxh1	187	21	or	or	CC
cord-002240-38aabxh1	188	1	septic	septic	JJ
cord-002240-38aabxh1	188	2	shock	shock	NN
cord-002240-38aabxh1	189	1	Intravenous	intravenous	JJ
cord-002240-38aabxh1	189	2	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	189	3	and	and	CC
cord-002240-38aabxh1	189	4	mortality	mortality	NN
cord-002240-38aabxh1	189	5	in	in	IN
cord-002240-38aabxh1	189	6	pneumonia	pneumonia	NN
cord-002240-38aabxh1	189	7	patients	patient	NNS
cord-002240-38aabxh1	189	8	with	with	IN
cord-002240-38aabxh1	189	9	septic	septic	JJ
cord-002240-38aabxh1	189	10	shock	shock	NN
cord-002240-38aabxh1	189	11	:	:	:
cord-002240-38aabxh1	189	12	an	an	DT
cord-002240-38aabxh1	189	13	observational	observational	JJ
cord-002240-38aabxh1	189	14	nationwide	nationwide	JJ
cord-002240-38aabxh1	189	15	study	study	NN
cord-002240-38aabxh1	189	16	Concept	Concept	NNP
cord-002240-38aabxh1	189	17	for	for	IN
cord-002240-38aabxh1	189	18	a	a	DT
cord-002240-38aabxh1	189	19	study	study	NN
cord-002240-38aabxh1	189	20	design	design	NN
cord-002240-38aabxh1	189	21	in	in	IN
cord-002240-38aabxh1	189	22	patients	patient	NNS
cord-002240-38aabxh1	189	23	with	with	IN
cord-002240-38aabxh1	189	24	severe	severe	JJ
cord-002240-38aabxh1	189	25	community	community	NN
cord-002240-38aabxh1	189	26	-	-	HYPH
cord-002240-38aabxh1	189	27	acquired	acquire	VBN
cord-002240-38aabxh1	189	28	pneumonia	pneumonia	NN
cord-002240-38aabxh1	189	29	:	:	:
cord-002240-38aabxh1	189	30	a	a	DT
cord-002240-38aabxh1	189	31	randomised	randomised	JJ
cord-002240-38aabxh1	189	32	controlled	control	VBN
cord-002240-38aabxh1	189	33	trial	trial	NN
cord-002240-38aabxh1	189	34	with	with	IN
cord-002240-38aabxh1	189	35	a	a	DT
cord-002240-38aabxh1	189	36	novel	novel	JJ
cord-002240-38aabxh1	189	37	IGM	IGM	NNP
cord-002240-38aabxh1	189	38	-	-	HYPH
cord-002240-38aabxh1	189	39	enriched	enrich	VBN
cord-002240-38aabxh1	189	40	immunoglobulin	immunoglobulin	NN
cord-002240-38aabxh1	189	41	preparation	preparation	NN
cord-002240-38aabxh1	189	42	-	-	:
cord-002240-38aabxh1	189	43	The	the	DT
cord-002240-38aabxh1	189	44	CIGMA	CIGMA	NNP
cord-002240-38aabxh1	189	45	study	study	NN
cord-002240-38aabxh1	189	46	Not	not	RB
cord-002240-38aabxh1	189	47	applicable	applicable	JJ
cord-002240-38aabxh1	189	48	.	.	.
cord-002240-38aabxh1	190	1	Adrian	Adrian	NNP
cord-002240-38aabxh1	190	2	Ceccato	Ceccato	NNP
cord-002240-38aabxh1	190	3	is	be	VBZ
cord-002240-38aabxh1	190	4	a	a	DT
cord-002240-38aabxh1	190	5	recipient	recipient	NN
cord-002240-38aabxh1	190	6	of	of	IN
cord-002240-38aabxh1	190	7	an	an	DT
cord-002240-38aabxh1	190	8	ERS	ERS	NNP
cord-002240-38aabxh1	190	9	Long	Long	NNP
cord-002240-38aabxh1	190	10	Term	Term	NNP
cord-002240-38aabxh1	190	11	Fellowship	Fellowship	NNP
cord-002240-38aabxh1	190	12	.	.	.
cord-002240-38aabxh1	191	1	All	all	DT
cord-002240-38aabxh1	191	2	authors	author	NNS
cord-002240-38aabxh1	191	3	participated	participate	VBD
cord-002240-38aabxh1	191	4	in	in	IN
cord-002240-38aabxh1	191	5	the	the	DT
cord-002240-38aabxh1	191	6	design	design	NN
cord-002240-38aabxh1	191	7	and	and	CC
cord-002240-38aabxh1	191	8	writing	writing	NN
cord-002240-38aabxh1	191	9	of	of	IN
cord-002240-38aabxh1	191	10	the	the	DT
cord-002240-38aabxh1	191	11	paper	paper	NN
cord-002240-38aabxh1	191	12	.	.	.
cord-002240-38aabxh1	192	1	All	all	DT
cord-002240-38aabxh1	192	2	authors	author	NNS
cord-002240-38aabxh1	192	3	read	read	VBP
cord-002240-38aabxh1	192	4	and	and	CC
cord-002240-38aabxh1	192	5	approved	approve	VBD
cord-002240-38aabxh1	192	6	the	the	DT
cord-002240-38aabxh1	192	7	final	final	JJ
cord-002240-38aabxh1	192	8	manuscript	manuscript	NN
cord-002240-38aabxh1	192	9	.	.	.